Boron by Lumpkin, Mike et al.
TOXICOLOGICAL PROFILE FOR  
BORON
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES 
Public Health Service 




The use of company or product name(s) is for identification only and does not imply endorsement by the 
Agency for Toxic Substances and Disease Registry.
BORON
UPDATE STATEMENT
A Toxicological Profile for Boron Draft for Public Comment was released in October 2007. This edition 
supersedes any previously released draft or final profile.
Toxicological profiles are revised and republished as necessary. For information regarding the update 
status of previously released profiles, contact ATSDR at:
Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch




T h is  pag e  is  in te n t io n a l ly  b la n k .
FOREWORD
This toxicological profile is prepared in accordance with guidelines* developed by the Agency for 
Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health 
effects information for these toxic substances described therein. Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is 
also presented, but is described in less detail than the key studies. The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The focus of the profiles is on health and toxicologic information; therefore, each toxicological 
profile begins with a public health statement that describes,, in nontechnical language, a substance's 
relevant toxicological properties. Following the public health statement is information concerning levels 
of significant human exposure and, where known, significant health effects. The adequacy of information 
to determine a substance's health effects is described in a health effects summary. Data needs that are of 
significance to protection of public health are identified by ATSDR.
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels 
of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, 
and local levels; interested private sector organizations and groups; and members of the public.
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that 
has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal 
scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a 
nongovernmental panel and was made available for public review. Final responsibility for the contents 
and views expressed in this toxicological profile resides with ATSDR.
Thomas R- Frieden, M.D., M.P.H.
Administrator 
Agency for Toxic Substances and 
Disease Registry
*Legislative Background
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 
104(i)(l) directs the Administrator of ATSDR to . .effectuate and implement the health related 
authorities” of the statute. This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the 
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile 
for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for 
substances not found at sites on the National Priorities List, in an effort to ..establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA 
Section 104(i)(lXB), to respond to requests for consultation under section 104{i)(4), and as otherwise 
necessary to support the site-specific response actions conducted by ATSDR.
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance. Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions.
Primary Chapters/Sections o f Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance. It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure.
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health.
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are 
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure.
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues:
Section 1.6 How Can (Chemical X) Affect Children?
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: I-8OO-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) Fax: (770) 488-4178
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided. Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies.
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials. Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease,
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH.
The National Institute o f Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association o f Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues. Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/.
The American College o f Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 









ATSDR, Division of Toxicology and Environmental Medicine, Atlanta, GA
Mike Lumpkin, Ph.D.
Lara Chappell, Ph.D.
Peter R. McClure, Ph.D., DABT 
SRC, Inc., North Syracuse, NY
THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Applied Toxicology Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.
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PEER REVIEW
A peer review panel was assembled for boron. The panel consisted of the following members:
Draft for Public Comment:
1. Michael Dourson, Ph.D., DABT, Toxicological Excellence for Risk Assessment, Cincinnati,
Ohio;
2. Curtis Eckhert, Ph.D., University of California Los Angeles, Los Angeles, California; and
3. Joseph Landolph, Ph.D., University of Southern California, Los Angeles, California.
These experts collectively have knowledge of boron’s physical and chemical properties, toxicokinetics, 
key health end points, mechanisms of action, human and animal exposure, and quantification of risk to 
humans. All reviewers were selected in conformity with the conditions for peer review specified in 
Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as 
amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile. A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content. The responsibility for the content of this profile lies with the ATSDR.
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1. PUBLIC HEALTH STATEMENT
This public health statement tells you about boron and the effects of exposure to it.
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities. Boron and boron compounds have been found in at least 164 of the 
1,689 current or former NPL sites, respectively. Although the total number of NPL sites evaluated for 
this substance is not known, the possibility exists that the number of sites at which boron is found may 
increase in the future as more sites are evaluated. This information is important because these sites may 
be sources of exposure and exposure to this substance may be harmful.
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment. Such a release does not always lead to exposure. You 
can be exposed to a substance only when you come in contact with it. You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact.
If you are exposed to boron, many factors will determine whether you will be harmed. These factors 
include the dose (how much), the duration (how long), and how you come in contact with it. You must 
also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, and 
state of health.
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1.1 WHAT IS BORON?
Naturally
occurring
Boron is a widely occurring element in minerals found in the earth’s crust. It 
is the 51st most common element found in the earth’s crust and is found at 
an average concentration of 8 mg/kg (approximately 0.0008%).
Combines with 
oxygen to form 
borates
Boron is found in the environment primarily combined with oxygen in 
compounds called borates. Common borate compounds include:
• boric acid







Borate-containing minerals are mined and processed to produce borates for 
several industrial uses in the United States including:
• glass and ceramics
• soaps, bleaches, and detergents
• fire retardants
• pesticides
More information on the properties and uses of boron and boron compounds and how they behave in the 
environment may be found in Chapters 4, 5, and 6.
1.2 WHAT HAPPENS TO BORON WHEN IT ENTERS THE ENVIRONMENT?
Released into 
air, water, and 
soil
Boron can be released into air, water, or soil after natural weathering of soils 
and rocks.
Smaller amounts of boron can be released from:
• glass manufacturing plants
• coal-burning power plants
• copper smelters
• agricultural fertilizer and pesticide usage
Is not broken 
down
Boron cannot be destroyed in the environment. It can only change its form or 
become attached or separated from particles in soil, sediment, and water.
For more information on boron in the environment, see Chapter 6.
1.3 HOW MIGHT I BE EXPOSED TO BORON?
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Food You can be exposed to boron in food, mainly vegetables and fruits, as boron 
is an essential element in plants. The average daily intake of boron for 
adults is 1 milligram.
Water Boron is widely distributed in surface water and groundwater.
• the average surface water concentration is about 0.1 mg per liter 
(mg/L)
• boron concentrations in ground water can be as high as 300 mg/L in 
areas with natural boron-rich deposits
• concentrations up to 0.4 mg/L have been found in most drinking 
water samples
Soil Average concentrations of 26 and 33 mg per kilogram (mg/kg) have been 
reported in soil.
Air The general public is not likely to be exposed to air contaminated with boron. 
The average level of boron in air samples is 0.00005 mg boron per cubic 
meter of air (mg boron/m3).
Workplace air In workplaces that mine and process borates, boron concentrations in dusty 
air samples have been reported to range from about 0.5 to 3 mg boron/m3.
Consumer
products
Boric acid, anhydrous sodium tetraborate, and sodium tetraborate 
decahydrate (borax) are found in consumer products such as:
• laundry detergent
• pesticides
• facial creams and cleaners
• plant foods
• household cleaners
Further information on how you might be exposed to boron is given in Chapter 6.
1.4 HOW CAN BORON ENTER AND LEAVE MY BODY?
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Boron can enter your body when you eat food (fruit and vegetables), drink 
water containing it, when you breathe borate dust in the air, and when 
damaged skin comes in contact with it.
Typically leaves 
your body within 
4 days
Most of the boron leaves the body in urine.
Over half of the boron taken by mouth can be found in urine within 24 hours 
and the other half can be detected in urine for up to 4 days.
Further information on how boron enters and leaves the body is given in Chapter 3.
1.5 HOW CAN BORON AFFECT MY HEALTH?
This section looks at studies concerning potential health effects in animal and human studies.
One way to learn whether a chemical will harm people is to determine how the body absorbs, uses, and 
releases the chemical. For some chemicals, animal testing may be necessary. Animal testing may also 
help identify health effects such as cancer or birth defects. Without laboratory animals, scientists would 
lose a basic method for getting information needed to make wise decisions that protect public health. 
Scientists have the responsibility to treat research animals with care and compassion. Scientists must 
comply with strict animal care guidelines because laws today protect the welfare of research animals.
The effect of boron on human health depends on how much boron is present, how you are exposed to it, 
and the length of exposure.
Exposure in air People working in dusty workplaces where borates are mined and 
processed have reported irritation of the nose, throat, and eyes. The 
irritation does not persist for long periods after leaving the dusty area.
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Exposure by Humans: Exposure to large amounts of boron (about 30 g of boric acid)
ingestion over short periods of time can affect the stomach, intestines, liver, kidney,
and brain and can eventually lead to death.
Animals: Studies of dogs, rats, and mice indicate that the male reproductive 
organs, especially the testes, are affected if large amounts of boron are 
ingested for short or long periods of time. The doses that produced these 
effects in animals are more than 1,800 times higher than the average daily 
intake of boron in food by adults in the U.S. population.
No evidence of cancer was found in a study in which mice were given boric 
acid in the diet throughout their lifetime.
More information on the health effects of boron in humans and animals can be found in Chapters 2 and 3.
1.6 HOW CAN BORON AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age.
Children are likely 
to have similar 
effects as adults
It is likely that children would show the same health effects as adults. We 
do not know whether children differ in their susceptibility to the effects of 
boron.
Birth defects We do not know whether boron causes birth defects in people. Low birth 
weights, birth defects, and developmental delays have occurred in newborn 
animals whose mothers were orally exposed to high doses of boron (as 
boric acid). The doses that produced these effects in pregnant animals are 
more than 800 times higher than the average daily intake of boron in food 
by adult women in the U.S. population.
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO BORON?
If your doctor finds that you have been exposed to substantial amounts of boron, ask whether your 
children might also have been exposed. Your doctor might need to ask your state health department to 
investigate.
BORON
1. PUBLIC HEALTH STATEMENT




Pesticides containing boron compounds should be used according to their 
directions and should be kept away from children.
Store household 
chemicals out of 
reach of young 
children
Always store household chemicals in their original labeled containers out of 
reach of young children to prevent accidental poisonings. Never store 
household chemicals in containers children would find attractive to eat or 
drink from, such as old soda bottles.
Discourage 
children from 
eating dirt or 
putting hands in 
their mouth while 
playing with dirt
Children living near waste sites containing boron and boron compounds are 
likely to be exposed to higher than normal environmental levels of boron 
through breathing in boron-containing dust, touching soil, and eating 
contaminated soil.
Children should be encouraged to wash their hands frequently, especially 
before eating.
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 
BORON?
Can be measured 
in blood and urine
Blood and urine can be examined to determine whether excessive 
exposure to boron has occurred.
The detection of boron in the blood or urine cannot be used to predict the 
kind of health effects that might develop from that exposure.
Further information on how boron can be measured in exposed humans is presented in Chapters 3 and 7.
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health. Regulations 
can be enforced by law. The EPA, the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances. Recommendations provide valuable guidelines to protect public health, but cannot be 
enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances.
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Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value that is usually based on levels that 
affect animals; they are then adjusted to levels that will help protect humans. Sometimes these not-to- 
exceed levels differ among federal organizations because they used different exposure times (an 8-hour 
workday or a 24-hour day), different animal studies, or other factors.
Recommendations and regulations are also updated periodically as more information becomes available. 
For the most current information, check with the federal agency or organization that provides it.
Some regulations and recommendations for boron include the following:
Levels in drinking 
water set by EPA
The EPA has determined that exposure to boron in drinking water at 
concentrations of 4 mg/L for one day or 0.9 mg/L for 10 days is not 
expected to cause any adverse effects in a child.
The EPA has determined that lifetime exposure to 1 mg/L boron is not 
expected to cause any adverse effects.
Levels in 
workplace air set 
by OSHA
OSHA set a legal limit of 15 mg/m for boron oxide in air averaged over an 
8-hour work day.
Additional information on governmental regulations regarding boron can be found in Chapter 8.
1.10 WHERE CAN I GET MORE INFORMATION?
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below.
ATSDR can also tell you the location of occupational and environmental health clinics. These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances.
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Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You may 
request a copy of the ATSDR ToxProfiles™ CD-ROM by calling the toll-free information and technical 
assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing 
to:
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine




Organizations for-profit may request copies of final Toxicological Profiles from the following:
National Technical Information Service (NTIS) 
5285 Port Royal Road 
Springfield, VA 22161 
Phone: 1-800-553-6847 or 1-703-605-6000 
Web site: http://www.ntis.gov/
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2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO BORON IN THE UNITED 
STATES
Boron is a widely occurring element in minerals found in the earth’s crust. It is the 51st most common 
element found in the earth’s crust and is found at an average concentration of 8 mg/kg (approximately 
0.0008%). It is found in the environment primarily combined with oxygen in compounds called borates. 
Common borate compounds include boric acid, salts of boric acid (e.g., sodium tetraborates, which are 
also referred to as borax), and boron oxide. U.S. borate mining and production mainly occurs in Kern, 
San Bernardino, and Inyo Counties, California. Borate-containing minerals are mined and processed to 
produce borates for several industrial uses in the United States. Industrial uses include glass and ceramics 
(70%), soaps, bleaches, and detergents (4%), fire retardants (2%), and agriculture (2%). Other uses, 
including metallurgy, nuclear applications, sale to distributors, addition to enamels and glazes, and 
ingredients in cosmetics or medical preparations, make up the remaining 19%. There are 189 pesticide 
products registered in the United States that contain boric acid or one of its sodium salts as an active 
ingredient.
Human exposure to boron, typically as borates or boric acid, may occur through ingestion of food and 
water, or through use of pesticides containing boron compounds, inhalation of boron-containing powders 
or dusts, or the use of boron from cosmetics or medical preparations. The most appreciable boron 
exposure to the general population is likely to be through ingestion of food (as boron is an essential 
element in plants) and, to a lesser extent, water. Mean daily intakes of boron for male and female adults 
were reported to be 1.28 and 1.0 mg boron/day. Consumption of fruits and vegetables contribute largely 
to boron intake in the human diet. Boron levels reported in drinking water generally range from <1 to 
3 mg boron/L.
Boron concentrations in ambient non-occupational air samples have been reported to range from 
<5x10-7 to 8x10-5 mg boron/m3, with an average concentration of 2x10-5 mg boron/m3. Workers in other 
industries, including manufacture of fiberglass and other glass products, cleaning and laundry products, 
fertilizers, pesticides, and cosmetics, may also be exposed to boron compounds. Mean dust 
concentrations ranging from 3.3 to 18 mg particulates/m3 were measured in air samples from U.S. 
facilities where borax was packaged and shipped. Dust samples in these facilities were predominantly 
composed of various types of borates and ranged from 11.8 to 15.2% boron by weight. Using the 
midpoint of this range of boron percentages in the dusts (13.5% boron), boron concentrations in air from
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these workplaces are estimated to have ranged from 0.45 to 2.43 mg boron/m3. In another study of dust 
concentrations in air samples from a U.S. borax production facility, mean total dust concentrations ranged 
from 0.29 to 18.95 mg particulates/m3 (approximately 0.02-1.50 mg boron/m3, using the midpoint (7.9%) 
of the ranges of average boron content in these dusts).
The average surface water boron concentration in the United States is about 0.1 mg boron/L, but 
concentrations vary greatly, depending on boron content of local geologic formations and anthropogenic 
sources of boron. Several studies have measured boron concentrations in water in those areas of 
California with boron-rich deposits. Reported high boron concentrations in surface waters ranged from 
15 mg boron/L in coastal drainage waters to 360 mg boron/L in a boron-rich lake. Groundwater boron 
concentrations >100 mg boron/L are common in California. Average concentrations of 26 and 33 mg 
boron/kg soil have been reported in soils in the United States, with concentrations ranging up to 300 mg 
boron/kg. For a more complete discussion of possible exposures to boron, see Chapter 6 of the profile.
2.2 SUMMARY OF HEALTH EFFECTS
Most of the inhalation toxicity data for boron involves human or animal exposure to borate dusts such as 
boric acid, boron oxide, or various hydration states of sodium borate salts (anhydrous, pentahydrate, and 
decahydrate, also referred to borax) or other borate salts (e.g., calcium borate). Equivalent boron doses 
have been calculated throughout this assessment by multiplying reported doses by an adjustment factor 
relating the molar mass ratio of boron in a given compound to the total molar mass. Thus, the dose 
adjustment factors are 0.175 for boric acid, 0.113 for disodium borate decahydrate, 0.151 for disodium 
borate pentahydrate, 0.215 for anhydrous borate, and 0.155 for boron oxide.
The primary health effects associated with inhalation exposure of humans to boron are acute respiratory 
irritation. Sensations of “feel” just below the self-reported threshold for nasal irritation and significant 
increases in mass of nasal secretions have been observed in well-controlled laboratory studies of 
exercising volunteers exposed for short durations (up to 47 minutes) to 1.5 mg boron/m3 as boric acid or 
sodium borate dusts (Cain et al. 2004, 2008).
Acute-duration exposures of mining and processing workers to 0.44-3.1 mg boron/m3 (5.7-14.6 mg 
particulates/m3) as sodium borate dusts has been associated with mild irritation of the eyes, throat, and 
nose, as well as cough and breathlessness. No exposure-related changes in lung function were observed 
in nonsmoking workers; a decrease in 1 second forced expiratory volume (FEVi) was observed in
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workers who smoked and were exposed to higher concentrations of boron. However, a re-examination of 
the workers 7 years later did not result in boron-related alterations in lung function. Animal studies of 
inhalation exposure to boron are restricted to a series of studies that found no histological changes in a 
comprehensive examination of tissues (including the respiratory tract) from rats exposed to aerosols of 
boron oxide (6 hours/day, 5 days/week) at concentrations of 73 mg boron/m3 for 10 weeks, 27 mg 
boron/m3 for 12 weeks, or 12 mg boron/m3 for 24 weeks. There was some indication of local irritation of 
the external nares in rats exposed to 73 mg boron/m3 for 10 weeks. A limited examination of dogs 
exposed to 9 mg boron/m3 did not find hematological alterations or evidence of liver damage, evaluated 
using the sulfobromophthalein retention test.
In contrast, diborane gas (B2H4) is a potent respiratory tract toxicant. Exposure of mice to diborane gas at 
a concentration of 5 ppm diborane (1.7 mg boron/m3) for 2 weeks produced severe damage to the lungs 
including pulmonary congestion, bleeding, and edema. Slight changes (infiltration of polymorphous 
neutrophil in peribronchiolar region) were observed at 0.7 ppm diborane (0.2 mg boron/m3). However, 
diborane gas is expected to have a very short half-life in the environment and is not expected to be a 
significant environmental toxicant, except in workplaces where it might be used or manufactured and 
accidentally released.
Human case reports have shown that boron can be lethal following short-term oral exposure at high doses, 
although the dose estimation can be quite imprecise and variability in human responses to acute exposure 
is quite large. The minimal lethal dose of ingested boron (as boric acid) was reported to be 2-3 g in 
infants, 5-6 g in children, and 15-20 g in adults. However, a review of 784 human poisonings with boric 
acid (10-88 g) reported no fatalities, with 88% of cases being asymptomatic. Liver, kidney, central 
nervous system, and gastrointestinal effects and skin lesions have been found in lethal cases following 
ingestion of boron, but death has been attributed to respiratory failure. Surveys of Turkish and Chinese 
populations with elevated levels of borate salts in drinking water (9-25 mg boron/L) found no 
associations for chronic-duration exposure with reproductive effects. The essentiality of boron has been 
established for most plants and some animals, but not in humans. The use of boron as a dietary 
supplement has not been endorsed by the Food and Nutrition Board/Institute of Medicine and did not 
result in increased plasma testosterone or strength levels in bodybuilders.
Oral exposure animal studies have clearly identified the reproductive system and developing fetus as the 
most sensitive targets of boron toxicity. Adverse developmental effects have been identified for acute- 
and intermediate-duration exposures. Decreases in the number of live fetuses and litters, decreases in
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body weight, and increases in the occurrence of external, visceral, and cardiovascular malformations were 
observed in the fetuses of rabbits administered 44 mg boron/kg/day on gestation days 6-19; no 
developmental effects were observed at 22 mg boron/kg/day. Following intermediate-duration exposure, 
decreases in body weight and increases in the occurrence of skeletal malformations have been observed in 
the fetuses of rats exposed to 13 mg boron/kg/day on gestation days 0-20; a no-observed-adverse-effect 
level (NOAEL) of 10 mg boron/kg/day was identified. Reproductive effects have been observed at higher 
doses. Histological alterations in the testes and sperm effects have been observed in rats administered 
88 mg boron/kg/day for 2 weeks; the NOAEL was 44-53 mg boron/kg/day. Intermediate-duration 
exposure resulted in histological alterations in the testes and associated effects on spermatogenesis in rats 
exposed to doses of >26 mg boron/kg/day. No viable sperm were observed in male rats exposed to 
101 mg boron/kg/day for 14 weeks. Impaired ovulation and failure to conceive was also observed in 
female rats (mated with unexposed males) exposed to 116 mg boron/kg/day for 14 weeks prior to mating. 
A NOAEL of 30 mg boron/kg/day was identified for reproductive effects (testicular atrophy) in males in a 
3-generation rat study. Testicular atrophy has also been observed in rats exposed to 81 mg boron/kg/day 
and mice exposed to 201 mg boron/kg/day for 2 years; no testicular alterations were observed at 24 or 
79 mg boron/kg/day, respectively.
In addition to the developmental and reproductive effects, several systemic effects have been observed in 
orally exposed animals. Consistently observed effects following intermediate and chronic exposure 
include hematological alterations (decreases in hemoglobin levels and splenic hematopoeisis) and 
desquamated skin on the paw; these effects have been observed at doses of >60 mg boron/kg/day.
Chronic inflammation and coagulative necrosis have also been observed in the livers of mice exposed to 
79 mg boron/kg/day for 2 years.
The primary health effects associated with dermal exposure are irritation of the eyes and reversible skin 
changes. Case reports of human occupational exposures have suggested that acute dermal exposure to 
boron as borax may cause focal alopecia of the scalp. However, as this effect has been reported in only 
three cases with no estimate of dose and involved co-exposure to high levels of other organic solvents, 
this association is uncertain. In animals, ocular instillation of 50 mg boron oxide (7.8 mg boron) dust 
resulted in conjunctivitis, while instillation of a sodium perborate monohydrate solution containing
6.3 mg boron into the eyes of rabbits caused mild irritancy of the epithelium and superficial stroma.
No epidemiology studies have identified an association between boron exposure and development of 
cancer. However, some investigators have suggested that boron exposure in drinking water may be
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associated with lower incidences of some types of cancer in humans. Intermediate-duration oral exposure 
of boric acid to mice that had been implanted with prostate tumor cells resulted in significantly reduced 
tumor growth and reduced tumor serum antigen levels. Chronic-duration oral studies in rats, mice, and 
dogs involving dietary exposure to boric acid or borax have not found significant increases in neoplastic 
lesions. In vitro genotoxicity assays have given predominantly negative results. The International 
Agency for Research on Cancer (IARC), the National Toxicology Program (NTP), and EPA have not 
classified boron for human carcinogenicity.
2.3 MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for boron. An 
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure. MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects. MRLs can be derived for 
acute, intermediate, and chronic duration exposures for inhalation and oral routes. Appropriate 
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised.
Inhalation MRLs
• An MRL of 0.3 mg/m3 has been derived for acute-duration inhalation exposure (14 days or less) 
to boron.
The available information on the toxicity of inhaled boron comes from an occupational exposure study 
(Wegman et al. 1994) and two human experimental studies (Cain et al. 2004, 2008). These studies 
identified increases in nasal secretions as the most sensitive effect. Nasal and throat irritation were
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reported by volunteers exposed to >4.5 mg boron/m3 (>30 mg sodium borate/m3) for 20 minutes while 
exercising (Cain et al. 2004). These investigators identified a minimal lowest-observed-adverse-effect 
level (LOAEL) of 1.5 mg boron/m3 for increased nasal secretions in exercising volunteers exposed for 
47 minutes (Cain et al. 2008). Nose, eye, and throat irritation were self-reported by workers at a borax 
processing facility exposed to a 6-hour time-weighted average (TWA) concentration ranging from 0.44 to
3.1 mg boron/m3 (5.7-14.6 mg particulates/m3) (Wegman et al. 1994), although identification of a 
NOAEL or LOAEL in this study is problematic (see next paragraph). The identification of the respiratory 
tract as the most sensitive target of toxicity is supported by longer-term animal studies (Wilding et al. 
1959) that found no adverse systemic effects in rats or dogs exposed to higher concentrations (9-72 mg 
boron/m3).
The Cain et al. (2004, 2008) studies were selected over the Wegman et al. (1991, 1994) studies as the 
basis of the acute-duration inhalation MRL for boron because they identified a NOAEL based on 
observations from carefully-controlled exposures of volunteers. The Wegman et al. (1991, 1994) data are 
problematic for identifying a NOAEL or LOAEL because the average irritation intensity level reported 
prior to a work shift was very close to the average intensity level reported for all incidents of nasal 
irritation. Area dust samples taken in the areas in which workers reported respiratory irritation varied 
over 4 orders of magnitude, ranging from 0.12 to 205 mg particulate/m3 . The contribution of non-boron- 
containing dusts to the reported irritancy cannot be ascertained. Further, the best 0.25-hour TWA data 
(confirmed by worker response and simultaneous air sampling by a study technician) suggest that the 
probability of workers reporting incidences of nasal irritation occurred when estimated boron 
concentrations reached 0.8-1.2 mg boron/m3, which is very similar to the laboratory findings of Cain et 
al. (2004, 2008).
Cain et al. (2004, 2008) trained male and female volunteers to recognize the difference in chemesthetic 
feel (pungency or irritancy) of various levels of CO2 offered to the eyes, nose, and throat. Exposures of 
>17.7% CO2 resulted in a “feel” described by the volunteers as irritating. Twelve male volunteers were 
exposed to 0, 0.8, 1.5, 3.0, 4.5, or 6.0 mg boron/m3 (0, 5, 10, 20, 30, or 40 mg sodium borate 
pentahydrate/m3) for 20 minutes while performing light exercise (Cain et al. 2004). At 5-minute 
intervals, they reported the magnitude of “feel” of borate dust in terms of equivalent CO2 irritancy. They 
were also observed for changes in nasal secretions (by mass) and nasal airway resistance. In a similar 
fashion, six male and six female volunteers were exposed to 1.5 mg boron/m3 (10 mg sodium borate/m3) 
or 0.4 to 1.8 mg boron/m3 (2.5 to 10 mg boric acid/m3) for 47 minutes while exercising. They reported 
the magnitude of “feel” of boric acid and borate dusts in terms of equivalent CO2 irritancy. They were
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also observed for changes in nasal secretions (by mass), nasal airway resistance, and respiration 
frequency.
Male volunteers exposed to <3.0 mg boron/m3 (<20 mg sodium borate/m3) for 20 minutes reported 
increasingly higher magnitude of feel of the dust in eyes, nose, and throat. However, the mean reported 
level of feel, compared to equivalent CO2 levels, was not considered irritating by the study subjects. The 
mean reported perception of feel at >4.5 mg boron/m3 (>30 sodium borate/m3) was reported to feel 
irritating to the nose (Cain et al. 2004). Significantly increased nasal secretions (by mass) occurred at
1.5 mg boron/m3 (10 mg sodium borate/m3), but not 0.8 mg boron/m3 (5 mg sodium borate/m3) (Cain et 
al. 2004). Similarly, male and female volunteers exposed to 1.5 mg boron/m3 (10 mg sodium borate/m3) 
or 1.8 mg boron/m3 (10 mg boric acid/m3) for 47 minutes while exercising reported a mean sense of feel 
that initially increased and peaked at the equivalent of slightly less than 17.7% CO2. These boron 
exposures, with a mean reported feel equivalent to <17.7% CO2, were considered non-irritating by the 
study subjects, although increases in nasal secretions were observed at 1.8 mg boron/mg3 (10 mg boric 
acid/m3), but not at 0.9 mg boron/mg3 (5 mg boric acid/m3) (Cain et al. 2008). Nasal secretions increased 
above controls for the first 20 minutes (as observed by Cain et al. 2004), but did not accumulate 
thereafter. Nasal airway resistance decreased, then increased as a result of exercise, but did not change in 
a dose-related manner.
An acute-duration inhalation MRL of 0.3 mg boron/m3 was derived using the NOAEL of 0.8 mg 
boron/m3 associated with a minimal LOAEL of 1.5 mg/m3 for increased nasal secretions in exercising 
volunteers. The NOAEL of 0.8 mg/m3 was divided by an uncertainty factor of 3 (1005 for human 
variability in the pharmacodynamic response to boron).
A series of studies conducted by Wilding et al. (1959) examined the toxicity of boron following 
intermediate-duration exposure of rats. No adverse effects, as assessed by a histological examination of a 
comprehensive set of tissues, were observed in rats exposed to aerosols of boron oxide (6 hours/day,
5 days/week) at concentrations of 73 mg boron/m3 for 10 weeks, 27 mg boron/m3 for 12 weeks, or 12 mg 
boron/m3 for 24 weeks. A reddish exudate from the nose was observed in some of the rats exposed to 
73 mg boron/m3 for 10 weeks; the investigators noted that the rats were covered with dust and there 
probably was local irritation of the external nares and scratching. Another study by this group (Wilding et 
al. 1959) found no hematological alterations or alterations in sulfobromophthalein retention for liver 
damage in dogs exposed to 9 mg boron/m3 for 23 weeks. Because the NOAELs identified in the rat and 
dog studies were higher than concentrations associated with irritation in humans acutely exposed to boron
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(Cain et al. 2004, 2008; Wegman et al. 1994), the intermediate-duration inhalation database was 
considered inadequate for derivation of an MRL. However, these data do suggest that the acute-duration 
inhalation MRL of 0.01 mg boron/m3 should be health-protective for intermediate-duration exposures.
There are limited data on the chronic toxicity of boron in humans and no chronic-duration inhalation 
animal studies. Workers exposed to mean boron concentrations of 1.8 and 3.1 mg boron/m3 reported a 
higher frequency of respiratory symptoms such as dryness of the mouth, nose, or throat, dry cough, nose 
bleeds, and sore throat than in workers exposed to low levels of boron (0.9 and 0.2 mg boron/m3) 
(Garabrant et al. 1984, 1985); this is the same study population examined by Wegman et al. (1994) (see 
acute MRL discussion). No alterations in lung function, as measured by FEVj, were observed in 
nonsmoking workers; a reduced FEVi was found in a subgroup of smoking workers with estimated boron 
exposure of >9 mg boron/m3. In the Wegman et al. (1994) follow-up study, no alterations in lung 
function were observed 7 years after the initial examination of workers receiving exposures of >15 mg 
boron/m3. The cross-sectional design of the Garabrant et al. (1985) study prevents determining whether 
the elevation of respiratory symptoms was a consequence of acute or repeated exposure to sodium borate 
dusts. Tarasenko et al. (1972) reported low sperm counts, reduced sperm motility, and elevated fructose 
content of seminal fluids in workers exposed to 22-80 mg/m3 boron aerosols (boron form uncertain) for 
>10 years; however, interpretation of these results is limited by the small number of subjects and limited 
data reporting. Another study reported elevated fertility rates, as compared to U.S. national average, in 
workers employed at a borax production facility for at least 9 months (Whorton et al. 1994); no exposure 
data were reported. The uncertainty as to whether the effects observed in the Garabrant et al. (1984) 
study were due to acute or chronic exposure and the limitations in the Tarasenko et al. (1972) study 
preclude deriving a chronic-duration inhalation MRL for boron. However, the lack of chronic effects in 
workers observed by Wegman et al. (1994) 7 years after an assessment by Garabrant et al. (1985) 
suggests that the acute-duration inhalation MRL of 0.01 mg/m3 should be health-protective for chronic- 
duration exposures.
Oral MRLs
• An MRL of 0.2 mg/kg/day has been derived for acute-duration oral exposure (1-14 days) to 
boron.
Acute-duration oral exposures of humans to high levels of boron (as boric acid) have resulted in little or 
no observable toxicity, as was seen in accidental poisonings of 10-88 g, of which 88% of cases were 
asymptomatic (Litovitz et al. 1988). However, gastrointestinal, cardiovascular, hepatic, renal, and central
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nervous system effects, dermatitis, erythema, and death have been observed in children and adults 
exposed to >84 mg boron/kg (Ishii et al. 1993; Restuccio et al. 1992; Schillinger et al. 1982; Wong et al. 
1964).
Most of the available animal studies on the acute toxicity of boron have focused on developmental and 
reproductive toxicity end points. NTP (1987; Dieter 1994) reported gastric hyperplasia and dysplasia in 
mice exposed to 2,251 mg boron/kg/day as boric acid in the diet for 14 days; no gastrointestinal effects 
were observed at 926 mg boron/kg/day. Similarly, Weir and Fisher (1972) reported vomiting in dogs 
receiving a single gavage dose of 1,000 mg boron/kg/day as boric acid. Testicular and spermatogenic 
effects were observed in rats receiving gavage doses of 88 mg boron/kg/day for 2 weeks (Fukuda et al. 
2000; Kudo et al. 2000). No effects were observed at 44 or 53 mg boron/kg/day.
A series of studies conducted by Cherrington and Chernoff (2002) demonstrate the fetal toxicity of boron 
in mice. A variety of skeletal malformations (e.g., rib agenesis, fused rib, cervical rib, reduced rib length) 
were observed in the fetuses of mice receiving gavage doses of 88 mg boron/kg/day on gestation days 6­
10, 131 mg boron/kg on gestation day 8, or 70 mg boron/kg administered twice daily on gestation day 
8 or 6-8. Two gavage doses of 131 mg boron/kg on gestation day 8 resulted in multiple thoracic skeletal 
malformations. Reductions in fetal body weights were also observed in these studies and in studies of 
mice receiving two gavage doses of 70 mg boron/kg on gestation days 6, 7, 9, or 10. However, skeletal 
malformations were not observed in studies that did not include exposure on gestation day 8. No 
NOAELs for developmental effects were observed in the Cherrington and Chernoff (2002) studies. A 
study of rabbits (Price et al. 1996b) identified a lower LOAEL for developmental toxicity. At gavage 
doses of 44 mg boron/kg/day as boric acid administered on gestation days 6-19, significant increases in 
resorptions and decreases in the number of live litters and fetuses were observed. This dose was also 
associated with decreases in fetal body weight and increases (on percent fetuses per litter basis) in 
external, visceral, and cardiovascular malformations. Marked decreases in maternal body weight were 
also observed at 44 mg boron/kg/day. No adverse maternal or fetal effects were observed at 22 mg 
boron/kg/day.
The Price et al. (1996b) study was selected as the principal study for derivation of an acute-duration oral 
MRL because it identified a lower LOAEL than the Cherrington and Chernoff (2002) studies and 
involved a longer duration of exposure (14 days compared to 5 days). In the Price et al. (1996b) study, 
groups of 30 pregnant New Zealand white rabbits were given gavage doses of 0, 62.5, 125, or 250 mg 
boric acid/kg/day (0, 11, 22, or 44 mg boron/kg/day) on gestation days 6-19. Observations were made
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for clinical signs, maternal and fetal body weight, number of implantations, resorptions, number of live 
and dead fetuses, and fetal external, visceral, and skeletal defects. No adverse maternal effects were 
observed in rabbits in the 11 or 22 mg boron/kg/day groups. At 44 mg boron/kg/day, decreases in 
maternal body weight, relative kidney weight, and food consumption were observed. During the 
treatment period, the rabbits lost 137 g body weight compared to a weight gain of 93 g in controls. No 
differences in the number of implantation sites per litter were observed; however, there were significant 
increases in the percent resorptions per litter, percent of litters with one or more resorptions, and percent 
of litters with 100% resorption. The number of live litters was 18, 23, 20, and 6 in the 0, 11, 22, and 
44 mg boron/kg/day groups, respectively, and the number of live fetuses was 159, 175, 153, and 14, 
respectively. A decrease in fetal body weights (92% of controls) was observed at 44 mg boron/kg/day; 
although the body weight was not significantly different from controls, the effect was considered 
biologically significant. Significant increases in the percent of fetuses per litter with external, visceral, 
and cardiovascular malformations and cardiovascular variations were observed. Although the overall 
incidence of external malformations was increased at 44 mg boron/kg/day, there were no increases in a 
specific malformation. The visceral malformations primarily consisted of cardiovascular malformations, 
particularly interventricular septal defect, enlarged aorta, papillary muscle malformation, and double 
outlet right ventricle. The cardiovascular variations consisted of abnormal number of cardiac papillary 
muscles.
An acute-duration oral MRL of 0.2 mg boron/kg/day was derived using the NOAEL of 22 mg 
boron/kg/day associated with a LOAEL of 44 mg boron/kg/day for increased incidence of external, 
visceral, and cardiovascular malformations and reduced body weight in the fetuses of rabbits administered 
boric acid via gavage on gestation days 6-19. The NOAEL of 22 mg boron/kg/day was divided by an 
uncertainty factor of 100 (10 for interspecies extrapolation and 10 for human variability).
• An MRL of 0.2 mg/kg/day has been derived for intermediate-duration oral exposure (15­
364 days) to boron.
There are limited data on the intermediate-duration toxicity of boron in humans. Seizure disorders were 
observed in infants orally exposed to approximately 12-120 g of borax for 4-12 weeks (Gordon et al. 
1973; O'Sullivan and Taylor 1983). The possible association between boron exposure and impaired 
fertility was investigated in Turkish subpopulations expected to have intermediate- to chronic-duration 
exposures to boron (Sayli 1998a, 1998b, 2003; Sayli et al. 1998) and boron mining and processing 
workers, which may have included oral exposure to boron (Chang et al. 2006; Whorton et al. 1994).
These studies did not find significant associations.
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Animal studies have clearly identified reproductive and developmental toxicity as the most sensitive 
effects of oral boron exposure. Intermediate-duration exposure of rats, mice, and dogs to boric acid or 
borax results in histological damage to the testes and the associated impacts on spermatogenesis (sperm 
abnormalities and reduced sperm production) at doses >26 mg boron/kg/day as boric acid (Dieter 1994; 
Dixon et al. 1976, 1979; Fail et al. 1991; Fukuda et al. 2000; Harris et al. 1992; Ku et al. 1993a; Kudo et 
al. 2000; Lee et al. 1978; NTP 1987; Nusier and Bataineh 2005; Seal and Weeth 1980; Weir and Fisher 
1972; Yoshizaki et al. 1999). Complete sterility was observed in rats exposed to 101 mg boron/kg/day as 
boric acid or borax for 14 weeks prior to mating (Weir and Fisher 1972); a lack of viable sperm was 
observed at this dose level. Additionally, female rats exposed to similar doses (116 mg boron/kg/day) for 
14 weeks failed to become pregnant when mated with non-exposed males (Weir and Fisher 1972); the 
female sterility response at this dose level was associated with decreased ovulation. The Weir and Fisher 
(1972) 3-generation studies (males and females exposed to boric acid or borax) established a NOAEL of 
30 mg boron/kg/day for reproductive toxicity in rats.
The developing fetus appears to be a more sensitive target than the reproductive system. Reductions in 
fetal body weights were observed in rats following exposure to 13-13.6 mg boron/kg/day as boric acid on 
gestation days 0-20 (Heindel et al. 1992; Price et al. 1996a); an increase in the occurrence of skeletal 
abnormalities was also observed at this dose level (Price et al. 1996a). At 28.4 mg boron/kg/day, rib cage 
defects, enlargement of the lateral ventricles of the brain, and increased resorptions were observed in rats 
exposed to boric acid on gestation days 0-20 (Heindel et al. 1992). No developmental effects were 
observed in rats exposed to 10 mg boron/kg/day as boric acid on gestation days 0-20 (Price et al. 1996a). 
In mice, gestational exposure on days 0-17 resulted in reduced fetal weights at 79 mg boron/kg/day and 
increased skeletal defects and increased resorptions at 175.3 mg boron/kg/day (Heindel et al. 1992); a 
NOAEL of 43.4 mg boron/kg/day was identified.
Systemic effects are observed at somewhat higher doses. Hematological alterations (splenic 
extramedullary hematopiesis and decreased hemoglobin levels) were observed at 60.5 and 72 mg 
boron/kg/day in dogs and rats, respectively, exposed to as borax or boric acid (NTP 1987; Weir and 
Fisher 1972), desquamation of paw and tail skin and eye inflammation were observed in rats exposed to 
150 mg boron/kg/day as boric acid or borax (Weir and Fisher 1972), and hyperkeratosis and/or acanthosis 
was observed in rats at 577 mg boron/kg/day as boric acid (NTP 1987).
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The available intermediate-duration oral database clearly identifies the developing fetus as the most 
sensitive target of toxicity. Two studies in rats (Heindel et al. 1992; Price et al. 1996a) identified 
LOAELs of 13-13.6 mg boron/kg/day for decreases in fetal body weight and skeletal malformations 
(only identified in the Price et al. 1996a study). These LOAELs are lower than the NOAEL of 3O mg 
boron/kg/day identified for reproductive toxicity in a 3-generation study (Weir and Fisher 1972) and 
NOAELs of 35 or 45 mg boron/kg/day for hematological and dermal effects (Weir and Fisher 1972).
Multiple developmental end point data from the Price et al. (1996a) and Heindel et al. (1992) studies were 
pooled and subjected to multiple benchmark dose analyses (Allen et al. 1996); see Appendix A for 
summaries of these two studies and the benchmark dose analysis. The 95% lower confidence limit on the 
benchmark dose associated with a 5% reduction in fetal body weight (BMDLO5) was calculated to be
1O.3 mg boron/kg/day. This estimate was similar to the observed NOAEL of 1O mg boron/kg/day (Price 
et al. 1996a) and was used as a point of departure for derivation of the intermediate-duration oral MRL. 
The BMDLO5 of 1O.3 mg boron/kg/day was divided by a chemical-specific uncertainty factor of 
66 (3.3 for toxicokinetic extrapolation from animals to humans, 3.16 for toxicodynamic extrapolation 
from animals to humans, 2.O for variability in human toxicokinetics, and 3.16 for variability in human 
toxicodynamics) (see Appendix A for derivation of the chemical-specific uncertainty factor) resulting in 
an intermediate-duration oral MRL of O.2 mg boron/kg/day.
2.3.1 Chronic-Duration Oral Studies
As previously discussed, no significant associations between boron exposure and impaired fertility were 
observed in Turkish subpopulations expected to have intermediate- to chronic-duration exposures to 
boron (Sayli 199Sa, 199Sb; Sayli et al. 199S, 2OO3). Chronic-duration studies have been conducted in 
rats and dogs exposed to boric acid or borax in the diet (Weir and Fisher 1972) and mice exposed to boric 
acid in the diet (Dieter 1994; NTP 19S7). Systemic effects consisted of hematological alterations 
(decreases in hemoglobin in rats and splenic hematopoeisis in mice), desquamation of footpad skin and 
bloody ocular discharge in rats, decreased body weight gain in rats and mice, lung hemorrhage in mice, 
and hepatic chronic inflammation and coagulative necrosis in mice. The hematological, dermal, ocular, 
and body weight effects were observed in rats exposed to S1 mg boron/kg/day (NOAEL of 24 mg 
boron/kg/day). In mice, the hematological and liver effects were observed at 79 mg boron/kg/day and the 
body weight and lung effects were observed at 2O1 mg boron/kg/day. The highest dose tested in the dog 
studies (6.S mg boron/kg/day) was a NOAEL for systemic effects. Testicular atrophy was observed in 
rats exposed to S1 mg boron/kg/day as boric acid or borax (Weir and Fisher 1972) and mice exposed to
BORON
2. RELEVANCE TO PUBLIC HEALTH
21
2O1 mg boron/kg/day as boric acid (Dieter 1994; NTP 19S7); the NOAELs for these effects were 24 and 
79 mg boron/kg/day for the rats and mice, respectively. A chronic-duration oral MRL, based on results 
from the chronic oral toxicity studies in animals, was not derived. However, the intermediate MRL, 
which is based on developmental toxicity, should be protective for chronic exposure because the NOAEL 
(24 mg boron/kg/day) for testicular atrophy and systemic effects in chronically exposed rats (Weir and 
Fisher 1972) was higher than the intermediate-duration LOAELs of 13-13.6 mg boron/kg/day for 
developmental toxicity in rats (Heindel et al. 1992; Price et al. 1996a).
2. RELEVANCE TO PUBLIC HEALTH
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The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of boron. It contains 
descriptions and evaluations of toxicological studies and epidemiological investigations and provides 
conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15-364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest- 
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear. ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction. However, the 
Agency has established guidelines and policies that are used to classify these end points. ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear. LOAELs or NOAELs should also help in determining whether or not
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the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective. Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
A User's Guide has been provided at the end of this profile (see Appendix B). This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure
Most of the inhalation toxicity data for boron involves human or animal exposure to borate dusts such as 
boric acid, boron oxide, or various hydration states of sodium borate salts (anhydrous; pentahydrate; and 
decahydrate; also referred to as borax) or other borate salts (e.g., calcium borate). In aqueous media, 
boron oxide is rapidly transformed to boric acid and, depending on the pH of the media, to borate salts. 
Equivalent boron doses have been calculated throughout this assessment by multiplying reported doses by 
an adjustment factor relating the molar mass ratio of boron in a given compound to the total molar mass. 
Thus, the dose adjustment factors are 0.175 for boric acid, 0.113 for disodium borate decahydrate,
0.151 for disodium borate pentahydrate, 0.215 for anhydrous borate, and 0.155 for boron oxide. In 
addition, animal studies were located reporting the effects of inhaled diborane, a flammable boron- 
containing gas. Because of the differences in environmental prevalence, industrial uses, likelihood of 
exposure, and respiratory toxicity, the effects of diborane exposure are discussed separately from other 
boron compounds in Section 3.2.1.2, Respiratory Effects.
3.2.1.1 Death
No studies were located regarding death in humans after inhalation exposure to boron. The 4-hour 
LC50 for boric acid, borax, and disodium borates is >2 mg boron/m3 (Hubbard 1998). No fatalities were 
observed in rats exposed for 6 hours/day, 5 days/week, to 470 mg boron oxide/m3 (73 mg boron/m3) for 
10 weeks, 175 mg boron oxide/m3 (27 mg boron/m3) for 12 weeks, or 77 mg boron oxide/m3 (12 mg
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boron/m3) for 24 weeks, or dogs exposed to 57 mg boron oxide/m3 (9 mg boron/m3) for 23 weeks 
(Wilding et al. 1959).
3.2.1.2 Systemic Effects
No studies were located regarding cardiovascular, gastrointestinal, hematological, musculoskeletal, or 
renal effects in humans after inhalation exposure to boron. No studies were located regarding dermal 
effects after acute inhalation exposure in humans or animals for any duration category, but eye irritation 
has been reported in sodium-borate mining and processing workers. Information on respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, and renal effects in animals and 
respiratory effects and dermal/ocular effects in humans is discussed below. The highest NOAEL values 
and all reliable LOAEL values for these systemic effects for each species and duration category involving 
exposure to boric acid, borates, or boron oxide are recorded in Table 3-1 and plotted in Figure 3-1.
Results from a few mouse inhalation studies of diborane gas indicate that it is a potent respiratory 
toxicant, much more potent than borates or boron oxide. Since it is not expected to be as important an 
environmental compound as borates or boron oxide, NOAEL and LOAEL values from these mouse 
studies of diborane gas are not included in Table 3-1 or Figure 3-1.
Respiratory Effects. Occupational studies of workers exposed to dusts of sodium borates, the most 
important commercial forms of boron, have identified irritation of the respiratory tract and eyes, without 
measurable changes in pulmonary function. In an early cross-sectional surveillance of 629 U.S. workers 
in a sodium borate open-pit mining and production plant, past occurrence of symptoms of respiratory 
irritation such as dryness of the mouth, nose, or throat, dry cough, nose bleeds, and sore throat were 
reported at elevated frequencies in workers in areas with mean dust concentrations of 8.4 and 14.6 mg 
particulates/m3 (1.8 and 3.1 mg boron/m3, respectively), compared with workers in areas with lower mean 
dust levels of 4.0 and 1.1 mg particulate/m3 (0.9 and 0.2 mg boron/m3) (Garabrant et al. 1984; 1985). 
These boron concentrations are upper bound estimates, assuming that all of the sampled dust is anhydrous 
borax. A reduction in forced expiratory volume in 1 second (FEVj) was measured in a subgroup of 
smoking workers with estimated high cumulative exposure (>80 mg particulate/m3, >9 mg boron/m3) to 
sodium borate dusts, but not in groups of less-exposed smoking workers or in nonsmoking workers. 
However, a subsequent surveillance of FEVi in 303 of the original 629 borax workers, 7 years after the 
original surveillance, , some of whom were exposed to >15 mg boron/m3, found no exposure-related 
changes in FEV1 over this period, when adjustments were made for the effects of age, height, and 
smoking on FEV1 (Wegman et al. 1991, 1994). Although the prevalence of workers reporting acute
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C hem ical Form C om m ents
ACUTE EXPOSURE
S ystem ic
1 Human once 
20 min Resp 0.8 M 1.5 M (mild irritation of nose
and throat; increased 
nasal secretion)
Cain et al. 2004 
SODIUM BORATE
Human 1 x 47 min
Resp 0.9 (increased nasal 
secretions)




3 Rat 10 wk
5 d/wk
6 hr/d
Resp 73 (reddish nasal exudate) Wilding et al. 1959 
BORIC OXIDE
Negative


























Table 3-1 Levels of Significant Exposure to Boron - Inhalation (continued)
E xposure/ LOAEL
D uration /
Key  to  Spec ies Frequency NOAEL Less S erious Serious Reference
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Table 3-1 Levels of Significant Exposure to Boron - Inhalation (continued)
E xposure/ LOAEL
D uration /
Key  to  Spec ies F requency NOAEL Less S erious Serious Reference



























Wilding et al. 1959 
BORIC OXIDE
NOAELs are for 
histopathology or 
hematology.
Wilding et al. 1959 
BORIC OXIDE
Hematology and serum 
chemistry values 
comparable to controls; 











27 Wilding et al. 1959 
BORIC OXIDE
NOAEL is for lymph 







































12 Wilding et al. 1959 
BORIC OXIDE
NOAEL is for lymph 







73 Wilding et al. 1959 
BORIC OXIDE
Negative lymph node 
and spleen 
histopathology.






73 Wilding et al. 1959 
BORIC OXIDE







27 Wilding et al. 1959 
BORIC OXIDE













Wilding et al. 1959 
BORIC OXIDE
Wilding et al. 1959 
BORIC OXIDE
NOAEL is for brain 
histopathology.







12 Wilding et al. 1959 
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Table 3-1 Levels of Significant Exposure to Boron - Inhalation (continued)
Exposure/ LOAEL
Duration/ -----------------------------------------------------------
Key to' Species Frequency NOAEL Less Serious Serious Reference
Fig ure (Strain) (Route)__________System (mg/m3)_________ (mg/m3)________________________ (mg/m3)___________________ Chemical Form____________________ Comments






16 Human 11.4 yr (mean)
Resp (dryness of the mouth, 
nose, or throat, dry 
cough, nose bleeds, and 
sore throat)
Wilding et al. 1959 
BORIC OXIDE
Garabrant et al. 1984, 1985 
SODIUM BORATE
NOAEL is for testes or 
ovary histopathology.
Uncertain whether 
symptoms were from 
acute or chronic 
exposures.
a The number corresponds to entries in Figure 3-1.
b Used to derive an acute-duration inhalation MRL of 0.3 mg boron/m3 ; exposure level divided by an uncertainty factor o f 3 (1005 for human pharmacodynamic variability).
Bd W t = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; F = Female; Gastro = gastrointestinal; Hemato = hematological; hr = hour(s); Immuno/Lymphoret = 
immunological/lymphoreticular; LOAEL = lowest-observed-adverse-effect level; M = male; min = minute(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; 















Figure 3-1 Levels of Significant Exposure to Boron - Inhalation
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Figure 3-1 Levels of Significant Exposure to Boron - Inhalation (Continued)
Intermediate (15-364 days)
^  ^ / W /
mg/m3 ^  ^  ^  ^  ^  ^  ^  ^  ^  ^
100
3r 3r 3r 3r 3r 3r 3r 3r 3r 3r 9r 10r 15r
4r 4r 4r 4r 4r 4r 4r 4r 4r 4r 7r 11r 13r


















n-Mink Cancer Effect Level-Animals
o-Other LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals 
NOAEL - Animals
Cancer Effect Level-Humans 
LOAEL, More Serious-Humans 
LOAEL, Less Serious-Humans 
NOAEL - Humans
LD50/LC50 


















Figure 3-1 Levels of Significant Exposure to Boron - Inhalation (Continued)
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respiratory irritation symptoms increased with the mean dust concentrations for different job categories in 
the plant, the cross-sectional design of the Garabrant et al. (1985) study prevented the determination of 
whether the elevation of acute respiratory symptoms was a consequence of acute or repeated exposure to 
sodium borate dusts. Thus, the effect levels associated with the measured prevalence of acute respiratory 
symptoms in this study are not included in Table 3-1 or Figure 3-1.
The occurrence of acute respiratory symptoms as a possible consequence of acute exposure to dusts of 
sodium borate (the decahydrate, pentahydrate, and anhydrous tetraborates) was studied in a later study by 
interviewing workers about acute irritation symptoms before the work shift began and at regular hourly 
intervals during the work shift, and by measuring personal air concentrations of particulates at concurrent 
intervals for 4 consecutive days (Hu et al. 1992; Wegman et al. 1991, 1994). Seventy-nine exposed 
production workers and 27 nonexposed workers were included in the study. In the latest analysis of the 
collected data, the incidence rates for irritation symptoms in exposed workers were statistically 
significantly higher than those in nonexposed workers, with exposed workers 9-, 5-, and 3-fold more 
likely to report incidents of nasal, eye, and throat irritation, respectively, than comparison workers (Hu et 
al. 1992; Wegman et al. 1991, 1994). For the unexposed groups, the arithmetic means of the 6-hour 
TWA daily dust concentration was 0.45 mg particulates/m3 (0.02 mg boron/m3), with 100% of samples 
<1.0 mg particulates/m3 and about 90% of samples <0.5 mg particulates/m3. The arithmetic mean of the 
6-hour TWA daily dust concentrations for the exposed group was 5.72 mg particulates/m3 (0.44 mg 
boron/m3), with a majority of air concentrations between 1.0 and 10.0 mg particulates/m3 (Wegman et al. 
1991, 1994). Several factors make it difficult to identify a NOAEL or LOAEL for this study, precluding 
its inclusion in Table and Figure 3-1. Study participants rated their perception of individual episodes of 
eye, throat, and nasal irritancy on a scale of 0 (not at all) to 10 (very, very much), with ratings of 1, 2, and 
3 representing “very little”, “fairly little”, and “moderate” irritation, respectively. Unexposed responders 
to the pre-shift survey reported a mean rating of 1.9 for all symptoms, while the mean rating for nasal 
irritation (the most commonly reported effect) among exposed workers was just slightly higher at 2.2. 
Thus, the cutoff for boron dust-induced effects is likely to be for ratings of >3. In the exposed group,
91% of reported symptoms were rated with severity scores <3 and 96% of symptoms were rated with 
severity scores of <4 (“pretty much”). For incidences in which the workers depressed a counter button to 
record time of symptom onset, and the study surveyor recorded an occurrence of effect, the probability of 
reporting an effect did not change markedly until 0.25-hour TWA exposure levels reached 0.8-1.2 mg 
boron/m3 (Wegman et al. 1991). There was no significant difference in reporting of symptoms based on 
the type of borate dust, which differ in boron content by almost a factor of two (i.e., 4.7 mg anhydrous 
borax/m3 and 8.8 mg/m3 of the decahydrate provide 1 mg boron/m3). Finally, the data do not indicate a
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temporal increase in effect intensity, as would be expected for a local irritant. Further, since no chronic 
effects (i.e., reduced FEVi) were observed in workers assessed by Wegman et al. (1994), 7 years after 
being assessed by Garabrant et al. (1985), the acute-duration inhalation MRL of 0.3 mg/m3 should also be 
health-protective for intermediate- and chronic-duration exposures.
Acute-duration laboratory exposures of volunteers to boric acid and sodium borate (sodium borate 
pentahydrate) dust provide more precise estimates of effect levels than the occupational studies. Male 
and female volunteers were trained to recognize the difference in chemesthetic feel (pungency or 
irritancy) of various levels of CO2 offered to the eyes, nose, and throat (Cain et al. 2004, 2008).
Exposures of >17.7% CO2 resulted in a “feel” described by the volunteers as irritating. Male volunteers 
exposed to <3.0 mg boron/m3 (<20 mg sodium borate/m3) for 20 minutes reported increasingly higher 
magnitude of feel of the dust in eyes, nose, and throat. However, the mean reported level of feel, 
compared to equivalent CO2 levels, was not considered irritating by the study subjects. The mean 
reported perception of feel at >4.5 mg boron/m3 (>30 sodium borate/m3) was reported to feel irritating to 
the nose (Cain et al. 2004). Significantly increased nasal secretions (by mass) occurred at 1.5 mg 
boron/m3 (10 mg sodium borate/m3), but not 0.8 mg boron/m3 (5 mg sodium borate/m3) (Cain et al. 2004). 
In a similar experiment, male and female volunteers exposed to 1.5 mg boron/m3 (10 mg sodium 
borate/m3) or 1.8 mg boron/m3 (10 mg boric acid/m3) for 47 minutes while exercising reported a mean 
sense of feel that initially increased and peaked at the equivalent of slightly less than 17.7% CO2. These 
boron exposures, with a mean reported feel equivalent to <17.7% CO2, were considered non-irritating by 
the study subjects, although increases in nasal secretions were observed at 1.8 mg boron/mg3 (10 mg boric 
acid/m3), but not at 0.9 mg boron/mg3 (5 mg boric acid/m3) (Cain et al. 2008). The volume of nasal 
secretions increased above controls for the first 20 minutes of exposure, but did not continue to increase 
thereafter, suggesting that increased secretions resulted from possible dust-induced changes in osmolarity 
rather than an irritation response. No dose-related changes in nasal airway resistance or breathing 
patterns were observed. Together, these studies were used to identify a minimal LOAEL of 1.5 mg 
boron/m3, with an associated NOAEL of 0.8 mg/m3, for significantly increased mass of nasal secretions, 
from which an acute-duration inhalation MRL of 0.3 mg boron/m3 was derived (see Appendix A).
Corroborating evidence in animals for the respiratory irritation potential of inhaled boron compounds is 
sparse. Mild respiratory irritation, indicated by a 20% reduction in breathing rate, occurred in mice 
inhaling 53 mg boron/m3 (300 mg boric acid/m3) for 3 hours (Krystofiak and Schaper 1996). Rats were 
exposed to aerosols of boron oxide (6 hours/day, 5 days/week) at concentrations of 470 mg boron 
oxide/m3 (73 mg boron/m3) for 10 weeks, 175 mg boron oxide/m3 (27 mg boron/m3) for 12 weeks, or
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77 mg boron oxide/m3 (12 mg boron/m3) for 24 weeks, and dogs were exposed to 57 mg boron oxide/m3 
(9 mg boron/m3) for 23 weeks (Wilding et al. 1959). In rats, histological examination of a comprehensive 
set of tissues revealed no differences between the tissues of exposed and control animals. Signs of gross 
toxicity were restricted to the appearance of a reddish exudate from the nose of some of the rats exposed 
to 470 mg boron oxide/m3.
Mice (ICR) exposed to 0.7 ppm diborane gas (0.2 mg boron/m3) for 2 or 4 weeks exhibited slight 
infiltration of polymorphous neutrophil in peribronchiolar regions of the respiratory tract (Nomiyama et 
al. 1995). Mice exposed to 5 ppm diborane gas (1.7 mg boron/m3) for 2 weeks exhibited increased lung 
weight, nasal cavity changes, diffuse panbrochiolitis-like lesions, cellular infiltration of the bronchioles 
and perivascular area, appearance of alveolar macrophages, perivascular lymphoid hyperplasia, lung 
congestion, bleeding, and edema (Uemura et al. 1995).
Comparison of the results from the studies of mice exposed to diborane gas (Nomiyama et al. 1995; 
Uemura et al. 1995) and those from studies of rats and dogs exposed to boron oxide (Wilding et al. 1959) 
indicate that diborane gas is much more potent as a respiratory toxicant than boron oxide. Diborane gas is 
expected to have a very short half-life in the environment because of its reactivity. Thus, it is not 
expected to be a significant environmental toxicant, except in workplaces where it might be used and 
accidentally released.
Cardiovascular Effects. Rats exposed to aerosols of boron oxide at a concentration of 470 mg boron 
oxide/m3 (73 mg boron/m3) for 10 weeks, 175 mg boron oxide/m3 (27 mg boron/m3) for 12 weeks, or 
77 mg boron oxide/m3 (12 mg boron/m3) for 24 weeks showed no gross or microscopic effects in the 
cardiovascular system (Wilding et al. 1959).
Gastrointestinal Effects. No gross or microscopic changes were seen in the gastrointestinal tract of 
rats exposed to aerosols of boron oxide at a concentration of 470 mg boron oxide/m3 (73 mg boron/m3) 
for 10 weeks, 175 mg boron oxide/m3 (27 mg boron/m3) for 12 weeks, or 77 mg boron oxide/m3 (12 mg 
boron/m3) for 24 weeks (Wilding et al. 1959).
Hematological Effects. Rats exposed to aerosols of boron oxide at concentrations of 470 mg boron 
oxide/m3 (73 mg boron/m3) for 10 weeks, 175 mg boron oxide/m3 (27 mg boron/m3) for 12 weeks, or 
77 mg boron oxide/m3 (12 mg boron/m3) for 24 weeks, and dogs exposed to aerosols of boron oxide at
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concentrations of 57 mg boron oxide/m3 (9 mg boron/m3) for 23 weeks showed no significant changes in 
total red and white blood cell count, hemoglobin, hematocrit, or differential count (Wilding et al. 1959).
Musculoskeletal Effects. No gross or microscopic effects of exposure were observed in the femur, 
rib, and muscle of rats exposed to concentrations of 470 mg boron oxide/m3 (73 mg boron/m3) for 
10 weeks, 175 mg boron oxide/m3 (27 mg boron/m3) for 12 weeks, or 77 mg boron oxide/m3 (12 mg 
boron/m3) for 24 weeks (Wilding et al. 1959).
Hepatic Effects. No gross or microscopic hepatic effects were observed in rats exposed to aerosols of 
boron oxide at concentrations of 470 mg boron oxide/m3 (73 mg boron/m3) for 10 weeks, 175 mg boron 
oxide/m3 (27 mg boron/m3) for 12 weeks, or 77 mg boron oxide/m3 (12 mg boron/m3) for 24 weeks. No 
hepatic effects were indicated from serum chemistry of dogs exposed to aerosols of boron oxide at 
concentrations of 57 mg boron oxide/m3 (9 mg boron/m3) for 23 weeks (Wilding et al. 1959).
Renal Effects. No gross or microscopic renal effects were observed in rats exposed to aerosols of 
boron oxide at concentrations of 470 mg boron oxide/m3 (73 mg boron/m3) for 10 weeks, 175 mg boron 
oxide/m3 (27 mg boron/m3) for 12 weeks, or 77 mg boron oxide/m3 (12 mg boron/m3) for 24 weeks. No 
renal effects were indicated from serum chemistry of dogs exposed to aerosols of boron oxide at 
concentrations of 57 mg boron oxide/m3 (9 mg boron/m3) for 23 weeks (Wilding et al. 1959).
Ocular Effects. Human occupational exposure to a mean concentration of 0.44 mg boron/m3 (5.72 mg 
particulates/m3) (Hu et al. 1992; Wegman et al. 1994) and 1.8-3.1 mg boron/m3 (8.4-14.6 mg 
particulates/m3) (Garabrant et al. 1984, 1985) as sodium borate dust produced eye irritation following 
acute-duration exposures. The cross-sectional study design of Garabrant et al. (1984, 1985) made it 
difficult to determine whether the observed effects were caused by acute or repeated exposures; however, 
the design employed by Wegman et al. (1994), which included 6-hour TWA air samples and worker 
reports of irritancy before the start of the work shift and during the shift, allowed the determination that 
this acute ocular irritation was due to acute exposure. No ocular effects were observed in rats exposed to 
aerosols of boron oxide at concentrations of 470 mg boron oxide/m3 (73 mg boron/m3) for 10 weeks,
175 mg boron oxide/m3 (27 mg boron/m3) for 12 weeks, or 77 mg boron oxide/m3 (12 mg boron/m3) for 
24 weeks (Wilding et al. 1959).
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3.2.1.3 Immunological and Lymphoreticular Effects
No gross or microscopic effects on immunological or lymphoreticular tissues (lymph nodes and spleens) 
were observed in rats exposed to aerosols of boron oxide at concentrations of 470 mg boron oxide/m3 
(73 mg boron/m3) for 10 weeks, 175 mg boron oxide/m3 (27 mg boron/m3) for 12 weeks, or 77 mg boron 
oxide/m3 (12 mg boron/m3) for 24 weeks (Wilding et al. 1959).
3.2.1.4 Neurological Effects
No gross or microscopic effects on the brain were observed in rats exposed to aerosols of boron oxide at 
concentrations of 470 mg boron oxide/m3 (73 mg boron/m3) for 10 weeks, 175 mg boron oxide/m3 (27 mg 
boron/m3) for 12 weeks, or 77 mg boron oxide/m3 (12 mg boron/m3) for 24 weeks (Wilding et al. 1959).
3.2.1.5 Reproductive Effects
A study of 28 male boric acid production workers occupationally exposed to 22-80 mg/m3 boron aerosols 
(boron form uncertain) for >10 years (Tarasenko et al. 1972) revealed low sperm counts, reduced sperm 
motility, and elevated fructose content of seminal fluids, compared to controls. These effects are 
consistent with high-dose animal exposures. However, this study is limited by the small number of 
subjects and limited data reporting. Furthermore, a cross-sectional survey of 753 employees working for 
at least 9 months at a borax production facility in California found worker fertility rates to be higher than 
the U.S. national average (Whorton et al. 1994). However, this study is limited by lack of exposure data.
In animals, no gross or microscopic effects were found on the ovary or testes of rats exposed to aerosols 
of boron oxide at concentrations of 470 mg boron oxide/m3 (73 mg boron/m3) for 10 weeks, 175 mg 
boron oxide/m3 (27 mg boron/m3) for 12 weeks, or 77 mg boron oxide/m3 (12 mg boron/m3) for 24 weeks 
(Wilding et al. 1959).
3.2.1.6 Developmental Effects




No studies were located regarding cancer in humans or animals after inhalation exposure to boron.
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3.2.2 Oral Exposure
Data for boron oral toxicity in humans involves exposure to the borates or boric acid. These boron- 
containing compounds are primarily found in food and water and have been implicated in numerous 
accidental or intentional poisonings in human case reports. Similarly, the boron toxicity studies in 
animals have utilized exposures to borates or boric acid.
3.2.2.1 Death
Case reports of lethal oral exposure of humans to boron primarily involve accidental or intentional 
exposures to high levels of boric acid. Similar clinical signs have been seen in adults and children. A 
review of 784 primarily acute boric acid exposures in adults and children found that 88% of cases were 
asymptomatic. The reports did not contain information on the dose response for boric acid, as 
symptomatic cases had doses ranging from 100 mg to 55 g boric acid (18 mg-10 g boron), while 
asymptomatic cases had doses ranging from 10 mg to 89 g boric acid (2 mg-16 g boron) (Litovitz et al. 
1988). Nonetheless, death occurred in some children following oral doses in this wide dose range. Five 
infants who ingested formula accidentally prepared with 2.5% aqueous solution of boric acid became 
lethargic, developed vomiting and diarrhea, and died within 3 days after exposure (Wong et al. 1964).
The estimated boric acid consumption ranged from 4.51 to 14 g (0.8-2.5g boron). In two infants who 
ingested 9.25 g boric acid (505 mg boron/kg/day) and 14 g boric acid (765 mg boron/kg/day), 
degenerative changes were seen in the liver, kidney, and brain (Wong et al. 1964). In a food poisoning 
incident in Malaysia, 13 children died after consuming Chinese noodles contaminated with boric acid 
(Chao et al. 1991a, 1991b). The deaths were determined by the study authors to be caused by unknown 
levels of aflatoxin and boric acid in the noodles. Clinical signs included vomiting, pyrexia, diarrhea, 
abdominal pain, anorexia, giddiness, seizures, and eventual coma. Postmortem examination revealed 
coagulative necrosis of the liver, proliferative metaplasia of the hepatocytes, giant cell formation, central 
vein sclerosis, bile stasis, and steatosis, acute renal tubule necrosis, upper gastrointestinal erosion, and 
encephalopathy. However, the relative contribution of boric acid to these effects could not be determined.
A common suite of symptoms was presented in case reports of adult oral exposures that resulted in death. 
A 77-year-old man ingested a single dose of 30 g of boric acid (85 mg boron/kg) to cure hiccups (Ishii et 
al. 1993). Effects included vomiting, diarrhea, erythema, cyanotic extremities, acute renal failure, 
cardiopulmonary hypotension, and death from cardiac insufficiency. Almost identical clinical signs and
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death occurred in a 45-year-old man ingesting approximately 49 g of boron (280 g boric acid, 700 mg 
boron/kg assuming a body weight of 70 kg) (Restuccio et al. 1992).
In animals, rats appear to be more sensitive than dogs or mice to the lethal effects of acute boron 
exposures. Oral LD50 values for respective boron equivalents of boric acid or borax were 898 and 
642 mg/kg in an unspecified rat strain (Smyth et al. 1969), 600 and 510 mg/kg in Sprague-Dawley rats 
(Weir and Fisher 1972), and 550 and 690 mg/kg in Long Evans rats (Weir and Fisher 1972). No deaths 
were reported in dogs exposed to a single dose of 696 mg boron/kg (3,977 mg boric acid/kg) and 738 mg 
boron/kg (5,549 mg borax/kg) (Weir and Fisher 1972). No single-dose LD50 studies in mice were 
available; however, mortality rates of 20 and 60% were observed in males given 14 daily doses of 
2,251 and 3,671 mg boron/kg/day (12.9 or 21.0 g boric acid/kg/day) in the diet, respectively (NTP 1987), 
but not at 926 mg boron/kg/day (5.3 g boric acid/kg/day). These animals were lethargic and exhibited 
discolored spleen, liver, and renal medullae and hyperplasia and dysplasia of the forestomach (NTP 
1987).
With intermediate-duration oral exposure, rats appear to be slightly more sensitive than mice to the 
lethality of boric acid. There was 100% mortality in Sprague-Dawley rats fed 450 mg boron/kg/day 
within a 6-week period (Weir and Fisher 1972). Congestion of liver and kidneys, small gonads, and brain 
swelling were reported. Eighty percent of male and 60% of female B6C3F1 mice died in a study 
involving exposure to 577 mg boron/kg/day (3,298 mg boric acid/kg/day) in the diet for up to 90 days 
(NTP 1987). Hyperkeratosis and/or acanthosis in the stomach and extramedullary hematopoiesis of the 
spleen in both sexes of mice were observed at the same dose level.
With chronic exposure to boric acid in the diet, mortality at 103 weeks was >40 and >30% in male and 
female B6C3F1 mice, respectively, exposed to >79 mg boron/kg/day (>450 mg boric acid/kg/day), 
compared to 18 and 34% in untreated male and female controls, respectively (NTP 1987). No clinical 
signs were reported for either sex; however, boron caused an increased incidence of testicular atrophy and 




LD50 values and, in some cases, the lowest levels at which death was reported in humans and animals and 
the duration categories are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.2 Systemic Effects
No studies were located regarding respiratory effects in animals or musculoskeletal effects in humans or 
animals after oral exposure to boron.
Information on respiratory, gastrointestinal, hematological, cardiovascular, hepatic, renal, and 
dermal/ocular effects is discussed below. The highest NOAEL values and all reliable LOAEL values for 
these systemic effects for each species and duration category are recorded in Table 3-2 and plotted in 
Figure 3-2.
Respiratory Effects. Widespread vascular congestion and hemorrhages in the lungs were reported in 
one infant who ingested an estimated dose of 505 mg boron/kg/day for 3-5 days (Wong et al. 1964).
Cardiovascular Effects. Ingestion of 85 mg boron/kg (as 30 g of boric acid) by a 77-year-old man 
(Ishii et al. 1993) resulted in cardiopulmonary hypotension and death from cardiac insufficiency.
Gastrointestinal Effects. Ingestion of boron in humans can cause gastrointestinal effects. Nausea, 
persistent vomiting, diarrhea, and colicky abdominal pain in infants were associated with acute ingestion 
of a total of >184 mg boron/kg/day (based on 1.9 kg body weight) as boric acid, which was accidentally 
incorporated in infant formula (Wong et al. 1964). Vomiting and diarrhea occurred following ingestion 
of 85 mg boron/kg (as 30g of boric acid) by a 77-year-old man (Ishii et al. 1993). Vomiting was the only 
sign of boron toxicity in two adult females who ingested 14 g boron (80 g boric acid) in a fungicide and 
52 g boron (297 g boric acid) in a suicide attempt. In the absence of body weight data, doses for these 
cases could not be estimated. The subjects were hospitalized for 24-96 hours and did not develop further 
symptoms following release (Linden et al. 1986). Food poisoning of 13 children with unknown levels of 
aflatoxin and boric acid (Chao et al. 1991a, 1991b) resulted in vomiting, diarrhea, abdominal pain, 
anorexia, and upper gastrointestinal erosion.
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2251 (2G% mortality) NTP 1987, Dieter 1994 
Boric acid
Higher percentage 




















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
E xposure/ LOAEL
D uration /
Key to  Species F requency NOAEL Less S erious Serious Reference
F igure (S train) (______)__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form____________________ C om m ents
S ystem ic
8 Human 3-5 d 
(F)
Resp 5G5 (vascular congestion,
hemorrage in one infant 
who died)
Wong et al. 1964 
Boric acid
From case-reports of 
11 infants; renal, 
hepatic , and 
respiratory effects from 
post-mortem 
observations of 2 fatal 
cases.




fatty changes, congestion 
in one infant who died)
Renal 765 (parenchymatous
degeneration, reduced 
urine output, protein in 




shedding o f skin in one 
infant who died)
Mouse 14 d Gastro 926 2251 (gastric hyperplasia and NTP 1987, Dieter 1994
















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Frequency NOAEL Less S erious Serious Reference
F igure (S train) (Route) System  (m g/kg/day) (m g/kg/day) (m g/kg/day) C hem ical Form  C om m ents
10 Dog
(Mongrel)









thrombosis, and edema 
in brain of one infant)
Weir and Fisher 1972 
Boric acid
Wong et al. 1964 
Boric acid













53 M 88 M (12 and 13% reduction in 
absolute and relative 
testes weight; increase in 
residual body-like 
structures in the testes; 
increase in cellular debris 
in the epididymal ducts; 
exfoliation of round 
spermatides, retention of 
step 19 spermatids)
NTP 1987, Dieter 1994 
Boric acid
Fukuda et al. 2000 
Boric acid












44 M 88 M (decreased stage XII
spermatids and 
spermatogonia; 
increased stage X 
pacytene spermatocytes)





















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies F requency NOAEL Less S erious Serious Reference
F igure (S train) (______)__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form____________________ C om m ents






70 F (reduced fetal weight and 
increased skeletal 
e ffects- cervical rib, rib 
agenesis, reduced rib 
length, and fused ribs)

















131 F (reduced fetal weight and 
increased cervical 
ossification)
Cherrington and Chernoff 2002 
Boric acid
88 F (increased skeletal 
abnormalities)
Cherrington and Chernoff 2002 
Boric acid
70 F (reduced fetal weight and 
increased skeletal 
abnormalities)








7, 9, or 70 F (reduced fetal weight)

























NOAEL Less Serious 










131 F (reduced fetal weight and 
increased multiple 
skeletal malformations)







7G F 21G F (no littering) Harris et al. 1992 
Boric acid
Endpoints: implantation 
sites, littering, live 
pups/liter, post-natal 
pup weight. No 
examination for fetal 









22 F 44 F (increased resorptions, 
decreased number of live 
litters and fetuses, 




















45G (1GG% mortality by 6
weeks)
















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
Exposure/
D uration /
Key to  Species
F igure (Strain) (Route)
NOAEL Less Serious 





C hem ical Form C om m ents
25 Mouse 13 wk 
(B6C3F1) (F)
577 (80% males and 60% NTP 1987, Dieter 1994
females died) Boric acid
S ystem ic
26 Human 1 d/wk 
7 wk 
(C)
Endocr G.G3 M Ferrando and Green 1993 
Boron







Hepatic 43 M 86 M (11% reduction in liver
weight)
Dixon et al. 1979 
Borax
Bd Wt 172 M
2S Rat 9 wk
(Fischer- 344) (F)
Bd Wt 52 M 68 M (16% decrease in body
weight gain)
Ku et al. 1993a 
Boric acid
2S Rat 4 wk
(Fischer- 344) (F)
Endocr 61 M (approximately 60-78% 
decrease in plasma 
testosterone)
















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Freq uency NOAEL Less S erious Serious Reference
Figure  (S train) (______)__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form____________________ C om m ents
30 Rat 9G d
(Sprague- (F) 
Dawley)
Cardio 45G W eir and Fisher 1972 
Borax










45 M 150 M (16% decrease in relative 
liver weight without 
histologic changes)
Renal 450
Dermal 45 150 (desquamated skin on 
paws and tails)






























Hepatic 45 M 150 M (22% reduction in liver 




Dermal 45 150 (desquamated skin on 
paws and tail)




C hem ical Form C om m ents
31 Rat 9G d
(Sprague- (F) 
Dawley)
W eir and Fisher 1972 
Boric acid

































C hem ical Form C om m ents







288 M 577 M (hyperkeratosis and/or 
acanthosis o f the 
stomach)
NTP 1987, Dieter 1994 
Boric acid
NOAELs are for 
histopathology.











144 M 288 M (17% reduction in body 
weight)




















Key to  Species






















60.5 (decreased packed cell 
volume and hemoglobin 
values)
W eir and Fisher 1972 
Borax

















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Frequency NOAEL Less S erious Serious Reference





Resp 60.5 W eir and Fisher 1972 
Boric acid







Hepatic 6 F 60.5 F (46% increase in relative
liver weight with no 
adverse histologic 
changes)














50 F 170 F (15% increase in relative 
brain weight)
Weir and Fisher 1972 
Borax
36 Rat 9°  d 50 F 170 F (15% increase in relative Weir and Fisher 1972
DSa™ e- brain weight) Boric acid
37 Mouse 13 wk 
(B6C3F1) (F)
577 NTP 1987, Dieter 1994 
Boric acid
















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies F requency NOAEL Less S erious Serious Reference













W eir and Fisher 1972 
Borax
Dixon et al. 1976 
Borax









43 M (decreased testicular 
enzyme activities; 
increased plasma FSH)
86 M (infertility for 3 weeks 
following exposure)
Dixon et al. 1979 
Borax







41 Rat 60 d
(Sprague- (F) 
Dawley)
43 M (62% decrease in testes 
weight; 37% decrease in 
epidiymis weight; 
increased plasma FSH; 
reduced diameter of 
seminiferous tubules)
86 M (infertility for 5 weeks 
following exposure)
Dixon et al. 1979 
Borax





















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies F requency NOAEL Less S erious Serious Reference






53 M (13 and 15% reduction in 
absolute and relative 
testes weight; cellular 
debris in the testes, 
cauda and caput 
epididymis; focal atrophy 
o f the seminiferous 
tubules; decrease in the 
number o f sperm in the 
ducta lumina)






43 Rat 9 wk
(Fischer- 344) (F)
26 M (mildly inhibited
spermiation by week 5)
52 M (testicular atrophy by 
week 9; severe inhibition 
o f spermiation)












22 M 44 M (reduced sperm motility;
reduced total sperm in 
caudal epididymis)





























NOAEL Less Serious 




C hem ical Form C om m ents
45 Rat 30-60 d 
(F)
50 100 (testicular atrophy, 
decreased enzymes)







136 M (decreased weights of 
testes and associated 
tissues; decreased 
sperm motility, number of 
spermatocytes, 
spermatids, Leydig cells, 
testosterone levels, 
sexually aggressive 
behavior, number of 
females impregnated; 
increased fetal resorption 
in impregnated females)







FSH and testosterone 
levels, sexual behavior.











45 M 150 M (53% reduction in 
testicular weight)







45 M 150 M (53% decrease in 
testicular weight; 
testicular atrophy)
















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies F requency NOAEL Less S erious Serious Reference
F igure (S train) (_____ )__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form____________________ C om m ents
50 Rat 3 gen
(Sprague- (F) 
Dawley)
30 101 M (complete sterility) 
116 F (complete sterility)
W eir and Fisher 1972 
Borax
Both genders exposed. 
Sterility associated with 
testicular atrophy in 
males and decreased 
ovulation in females.
51 Rat 3 gen
(Sprague- (F) 
Dawley)
30 101 M (complete sterility) 
116 F (complete sterility)
W eir and Fisher 1972 
Boric acid
Both genders exposed. 
Sterility associated with 
testicular atrophy in 
males and decreased 
ovulation in females.
52 Rat 3 gen
(Sprague- (F) 
Dawley)







53 Rat 3 gen
(Sprague- (F) 
Dawley)





















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Frequency NOAEL Less S erious Serious Reference





9 M 26 M (increased
pre-implantation fetal 
loss; decreased sperm 
motility;
morphologically-abnormal 
sperm heads and tails)
Yoshizaki et al. 1999 
Boric acid
Exposed males mated 
with unexposed 
females; inability to 











motility, litters per mating 
pair, and live pups per 
litter)
Fail et al. 1991 
Boric acid
Treated males mated 
with untreated females. 




M: 17 d (d 3-20) 
F: 20 d (d 0-20) 
(G)
21 M 70 M (reduced testis weight,
germ cell loss)
210 M (exfoliation/disruption of 
seminiferous tubules; 
inhibited spermiation; no 
effect on % females 
pregnant)
Harris et al. 1992 
Boric acid
Mating on days 8-12; 
Endpoints: male 
reproductive organ 
weight and histology; % 
pregnant and number 
o f live implants.
57 Mouse 13 wk 2gg m (degeneration or atrophy NTP 1987, Dieter 1994















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies F requency NOAEL Less S erious Serious Reference
F igure (S train) (Route) System  (m g/kg/day) (m g/kg/day) (m g/kg/day) C hem ical Form  C om m ents
58 Dog 90 d 6 M 60.5 M (50% decrease in relative Weir and Fisher 1972
(Beagle) (F) testes weight; severe Borax
testicular atrophy)
59 Dog 90 d 6 M 60.5 M (40% decrease in testes Weir and Fisher 1972
(Beagle) (F) weight; severe testicular Boric acid
atrophy)






13.6 (reduced fetal weight) 28.4 (rib cage defects, Heindel et a l. 1992
enlargement o f the lateral Boric acid 
ventricles of the brain, 
increased resorptions)
61 Rat Gd 0-20
(Sprague- (F) 
Dawley)
10 F 13 F (reduced fetal weight,
increase in skeletal 
abnormalities observed 
on gestation day 20)
Price et al. 1996a, 1998 
Boric acid
Effects seen on 
gestation day 20 were 






43.4 79 (reduced fetal body
weight)
175.3 (increased skeletal 
effects [short rib XIII, 
fused ribs, agenesis of 
lumbar vertabra], 
increased resorptions)














































79 (40% mortality) NTP 1987, Dieter 1994 
Boric acid
W eir and Fisher 1972 
Boric acid







24 F 81 F (decreased packed cell 









24 81 (scaly tails,
desquamation o f skin on 
footpads)
Ocular 24 81 (bloody ocular discharge)
















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies F requency NOAEL Less S erious Serious Reference
F igure (S train) (______)__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form____________________ C om m ents











W eir and Fisher 1972 
Borax
NOAELs are for 
histopathology.
81 (decreased packed cell 









24 81 (scaly tails,
desquamation o f skin on 
footpads)
Ocular 24 81 (bloody ocular discharge)
































C hem ical Form C om m ents










79 M (spenic hematopoiesis)
79 (chronic inflammation; 
coagulative necrosis)
201 F (lung hemorrhage) NTP 1987, Dieter 1994 
Boric acid





























Key to  Species
F igure (Strain) (Route)
NOAEL Less Serious 




















W eir and Fisher 1972 
Boric acid




















Key to  Species Fr(equetn ‘:y








C hem ical Form C om m ents
68 Dog
(Beagle)



















24 81 (increased relative brain 
weight)
Weir and Fisher 1972 
Borax
NOAELs are for 
histopathology.







24 81 (increased relative brain
weight)
Weir and Fisher 1972 
Borax
71 Mouse 103 wk
(B6C3F1) (F)
201 NTP 1987, Dieter 1994 
Boric acid























NOAEL Less Serious 
















24 M 81 M (decreased relative
testes weight; testicular 
atrophy; atrophied 
seminiferous epithelium 
and reduced tubular size)
W eir and Fisher 1972 
Borax
74 Rat 2 yr
(Sprague- (F) 
Dawley)
24 M 81 M (decreased relative
testes weight; testicular 
atrophy; atrophied 
seminiferous epithelium 
and reduced tubular size)
W eir and Fisher 1972 
Boric acid
75 Mouse 103 wk
(B6C3F1) (F)
79 201 (testicular atrophy,
interstitial hyperplasia)
NTP 1987, Dieter 1994 
Boric acid
76 Dog 2 yr 6 8  M Weir and Fisher 1972















Table 3-2 Levels of Significant Exposure to Boron - Oral (continued)
E xposure/






NOAEL Less Serious 




C hem ical Form C om m ents
77 Dog 2 yr
(Beagle) (F)
6.s M W eir and Fisher 1972 
Boric acid
Table 3-2 Oral
a The number corresponds to entries in Figure 3-2.
b Used to derive an acute-duration oral MRL of 0.2 mg/kg/day; dose divided by an uncertainty factor of 100 (10 for interspecies extrapolation and 10 for human variability).
c Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 3-2. Where such differences exist, only the levels of effect for the 
most sensitive gender are presented.
d Used to derive an intermediate-duration oral MRL o f 0.2 mg/kg/day; a point o f departure from benchmark dose analysis o f 10.3 mg boron/kg/day was divided by a chemical-specific 
uncertainty factor of 66 (3.3 for toxicokinetic extrapolation from animals to humans, 3.16 for toxicodynamic extrapolation from animals to humans, 2.0 for variability in human 
toxicokinetics, and 3.16 for variability in human toxicodynamics).
Bd W t = body weight; (C) = capsule; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; (F) = feed; F = Female; FSH = follicle stimulating hormone; 
(G) = gavage; Gastro = gastrointestinal; Gd = gestational day; Hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male;
















Figure 3-2 Levels of Significant Exposure to Boron - Oral
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n-Mink Cancer Effect Level-Animals
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LOAEL, Less Serious-Humans 
NOAEL - Humans
LD50/LC50 





































33d 34d ® 29r 33d 34d
30r 31r
•3 2 m  37m
3 32m





Ü  38d 36r 58d 59d i j4 0 r  J 4 ? r 44 ,  45r
8 4 3 f

























n-Mink Cancer Effect Level-Animals
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Figure 3-2 Levels of Significant Exposure to Boron - Oral (Continued)
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Figure 3-2 Levels of Significant Exposure to Boron - Oral (Continued)
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Figure 3-2 Levels of Significant Exposure to Boron - Oral (Continued)
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In B6C3F1 mice, dietary exposure to >2,251 mg boron/kg/day as boric acid for 14 days resulted in gastric 
hyperplasia and dysplasia (NTP 1987). Dogs given a single dose of 1,000 mg boron/kg as boric acid 
vomited (Weir and Fisher 1972).
Hematological Effects. In animals orally exposed for intermediate or chronic durations, effects on 
hematological end points have been observed sporadically in dogs and consistently in mice; they did not 
occur in rats exposed for 90 days. Mongrel dogs fed 60.5 mg boron/kg/day for 90 days in the diet as 
borax (but not as boric acid) had decreased packed cell volume and hemoglobin values, but no 
hematological effects were seen in dogs fed 81 mg boron/kg/day as borax or boric acid for 2 years (Weir 
and Fisher 1972). Erythrocyte count and total and differential leukocyte counts were comparable to 
control levels (Weir and Fisher 1972). Splenic extramedullary hematopoiesis occurred in mice fed 72 mg 
boron/kg/day as boric acid for 90 days and 79 mg boron/kg/day for 2 years (Dieter 1994; NTP 1987), 
while no hematological effects were observed in rats fed 450 mg boron/kg/day as borax or boric acid for 
90 days (Weir and Fisher 1972). Decreased packed cell volume and hemoglobin values were seen in rats 
fed 81 mg boron/kg/day as borax for 2 years (Weir and Fisher 1972).
Hepatic Effects. Case reports in humans suggest that the liver is susceptible to boron toxicity at high 
dose levels (Wong et al. 1964). Jaundice has been reported, and there were mild alterations at histological 
examination in infants who ingested 505 or 765 mg boron/kg/day as boric acid (accidentally incorporated 
in infant formula) for 3-5 days (Wong et al. 1964). In the same incident, congestion and fatty changes 
were observed, and there was parenchymatous degeneration in newborn infants who ingested 505 or 
765 mg boron/kg as boric acid for 3-5 days (Wong et al. 1964). Coagulative necrosis of the liver, 
proliferative metaplasia of the hepatocytes, giant cell formation, central vein sclerosis, bile stasis, and 
hepatic steatosis were observed in children ingesting unknown levels of aflatoxin and boric acid in 
Chinese noodles (Chao et al. 1991a, 1991b).
In mice, the liver appears to be a toxicity target of repeated oral exposure to boric acid, but it is not a 
target in rats and dogs repeatedly exposed to boric acid or borates. Two-year dietary exposures of 
>79 mg boron/kg/day as boric acid to B6C3F1 mice resulted in chronic inflammation and coagulative 
necrosis in the liver (NTP 1987; Dieter 1994), but no exposure-related hepatic lesions were found in 
Sprague-Dawley rats fed 81 mg boron/kg/day as boric acid or borax in the diet for 2 years or in mongrel 
dogs fed 6.8 mg boron/kg/day as boric acid or borax in the diet for 2 years (Weir and Fisher 1972). No 
exposure-related liver lesions were seen in mice fed 577 mg boron/kg/day as boric acid for 13 weeks
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(Dieter 1994; NTP 1987); in Sprague-Dawley rats fed 450 mg boron/kg/day as boric acid or borax for 
90 days (Weir and Fisher 1972); or in mongrel dogs fed 60.5 mg boron/kg/day as boric acid or borax for 
90 days (Weir and Fisher 1972).
Boron-related changes in liver weights have not been consistently observed in animal studies. Reduced 
liver weights were observed in rats fed 86 mg boron/kg/day as borax for 30 days (Dixon et al. 1979) and 
fed 150 mg boron/kg/day as borax or boric acid for 90 days (Weir and Fisher 1972), while increased 
relative liver weights were seen in mongrel dogs fed 60.5 mg boron/kg/day as boric acid for 90 days 
(Weir and Fisher 1972).
In liver microsomal fractions from rats given approximately 20.8 mg boron/kg/day as borax in drinking 
water, NADPH-cytochrome C reductase activity and cytochrome b5 content decreased in the liver 
microsomal fraction after 10 and 14 weeks of exposure (Settimi et al. 1982). There was also a reduction 
in the cytochrome P-450 concentration detected at 14 weeks (Settimi et al. 1982). The toxicological 
significance of these biochemical changes is not clear, especially since intermediate- and chronic-duration 
feeding studies with Sprague-Dawley rats fed boric acid or borax did not report exposure-related hepatic 
lesions (Weir and Fisher 1972).
Renal Effects. Human case reports involving high accidental ingestion levels show that boron can 
cause injury to the kidney. Acute renal failure was observed in a 77-year-old man ingesting 85 mg 
boron/kg (as 30 g of boric acid) (Ishii et al. 1993). Degenerative changes in parenchymal cells with 
oliguria and albuminuria have been demonstrated in two newborn infants after ingestion of 505 and 
765 mg boron/kg/day as boric acid in an evaporated milk formula over a period of 3-5 days (Wong et al. 
1964). Acute renal tubule necrosis was seen in children dying from ingestion of unknown levels of 
aflatoxin and boric acid in Chinese noodles (Chao et al. 1991a, 1991b).
No exposure-related renal lesions were observed in Sprague-Dawley rats fed up to 450 mg boron/kg/day 
as borax or boric acid for 90 days (Weir and Fisher 1972), in mice fed 577 mg boron/kg/day as boric acid 
for 13 weeks (NTP 1987; Dieter 1994), or in dogs fed up to 60.5 mg boron/kg/day as borax or boric acid 
for 90 days (Weir and Fisher 1972). With 2 years of dietary exposure, no exposure-related renal lesions 
were observed in Sprague-Dawley rats fed 81 mg boron/kg/day as borax or boric acid (Weir and Fisher 
1972), in B6C3F1 mice fed up to 201 mg boron/kg/day as boric acid (Dieter 1994; NTP 1987), or in 
mongrel dogs fed 6.8 mg boron/kg/day as borax or boric acid (Weir and Fisher 1972). The available data 
indicate that the kidney is not a sensitive toxicity target of oral exposure to boric acid or borates.
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Endocrine Effects. Human data for endocrine effects from orally ingested boron are limited to 
studies of low-dose boron nutritional supplementation. Postmenopausal women ingesting 0.4 mg 
boron/day (as 3.25 mg sodium borate/day) in the diet had a 3-fold increase in plasma testosterone levels 
compared to those ingesting 0.03 mg boron/day (as 0.25 mg sodium borate/day) (Nielsen et al. 1987). 
However, bodybuilders taking daily supplements of 2.5 mg boron (approximately 0.03 mg/kg; calculated 
using mean body weights from study data) for 7 weeks did not exhibit differences from controls in free or 
total plasma testosterone levels (Ferrando and Green 1993).
Rats fed diets with 61 mg boron/kg/day as boric acid (9000 ppm) for 28 days had decreases of 
approximately 60-78% in plasma testosterone levels beginning on day 4 of exposure (Treinen and Chapin
1991). Follicle stimulating hormone (FSH) and leutenizing hormone (LH) levels in the blood of rats fed 
26-68 mg boron/kg/day as boric acid (3,000-9,000 ppm; doses estimated by study authors) in the diet 
were increased, possibly in response to testicular atrophy observed in the 52 and 68 mg boron/kg/day 
groups (Ku et al. 1993a). No histologic lesions were observed in thyroid, adrenals, or pituitary tissues of 
Sprague-Dawley rats fed 450 or 81 mg boron/kg/day as boric acid or borax in the diet for 90 days or 
2 years, respectively, or in mongrel dogs fed 60.5 or 6.8 mg boron/kg/day as boric acid or borax in the 
diet for 90 days or 2 years, respectively (Weir and Fisher 1972) or in pituitary tissues of mice fed 577 or 
201 mg boron/kg day as boric acid for 90 days or 2 years, respectively (Dieter 1994; NTP 1987).
Dermal Effects. Skin effects can occur following ingestion of boron (as boric acid) in humans. 
Extensive exfoliative dermatitis began in infants as an erythema involving palms, soles, and buttocks. It 
eventually became generalized with subsequent bulbous formation, massive desquamation, and sloughing 
(Wong et al. 1964). These changes were associated with ingestion of 505 mg boron/kg/day; however, 
skin lesions were lacking following ingestion of 765 mg boron/kg/day. Similarly, extensive erythema 
with desquamation was observed in an adult who ingested single doses of boric acid powder (Schillinger 
et al. 1982). The exact amount ingested was not stated. However, 14 g (equivalent to 22.5 mg boron/kg 
based on 109 kg body weight) was measured as missing from a container from which the patient admitted 
consuming half its contents.
In animals studies, skin lesions were observed in Sprague-Dawley rats fed 150 mg boron/kg/day as borax 
or boric acid in the diet for 90 days (skin desquamations on the paws and tails) or 81 mg boron/kg/day for 
2 years (scaly tails and desquamation on footpads) (Weir and Fisher 1972), but dermal lesions were not 
observed in B6C3F1 mice exposed to boric acid in the diet for 13 weeks or 2 years (Dieter 1994; NTP
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1987) or in mongrel dogs exposed to boric acid or borax in the diet for 90 days or 2 years (Weir and 
Fisher 1972).
Ocular Effects. There are no reports of ocular effects in humans following oral exposure to humans.
Sprague-Dawley rats fed 150 mg boron/kg/day as borax or boric acid for 90 days exhibited inflammation 
of the eyes, while 81 mg boron/kg/day as borax or boric acid in the diet for 2 years resulted in bloody 
ocular discharge (Weir and Fisher 1972). No ocular effects were seen in dogs fed 60.5 mg boron/kg/day 
as borax or boric acid for 90 days or 6.8 mg boron/kg/day borax or boric acid for 2 years (Weir and Fisher 
1972). Likewise, mice fed 201 mg boron/kg/day as boric acid for 2 years exhibited no ocular effects.
Body Weight Effects. Fisher 344 rats fed 68 mg boron/kg/day as boric acid (9,000 ppm) for 9 weeks 
had 6% lower body weight gain than controls (Ku et al. 1993a). Male and female B6C3F1 mice fed 
288 and 577 mg boron/kg/day as boric acid (0.5% of diet) for 13 weeks had 17 and 23% decreased weight 
gains, respectively, while 2-year exposures to 201 mg boron/kg/day as boric acid resulted in 19% lower 
weight gains in both sexes (NTP 1987, Dieter 1994).
3.2.2.3 Immunological and Lymphoreticular Effects
No studies were located regarding immunological effects in humans or animals after oral exposure to 
boron.
3.2.2.4 Neurological Effects
Case reports in humans have indicated neurological effects after accidental ingestion of high levels of 
boron (as boric acid). Newborn infants who ingested 4.5-14 g boric acid showed central nervous system 
involvement manifested by headache, tremors, restlessness, and convulsions followed by weakness and 
coma (Wong et al. 1964). Histological examination of 2 of 11 infants revealed congestion and edema of 
brain and meninges with perivascular hemorrhage and intravascular thrombosis at a dose >505 mg 
boron/kg/day (Wong et al. 1964). Seizure disorders have been associated with boron exposures (as 
borax) in infants who ingested 12-120 g borax for 4-10 weeks (O'Sullivan and Taylor 1983) and 9-125 g 
borax over a period of 5-12 weeks (Gordon et al. 1973). Estimates of boron dose could not be 
determined since the authors did not provide body weight data. Blood boron levels in the infants exposed 
who ingested borax ranged from 2.6 to 8.5 ^g/mL (O'Sullivan and Taylor 1983). In one infant with a
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seizure disorder who ingested (via pacifier dipped in honey and borax mixture) approximately 125 g 
borax over 3 months, the blood boron level was 1.64 mg/100 mL (Gordon et al. 1973).
Existing animal studies do not provide evidence that the nervous system is a toxicity target of repeated 
oral exposure to boric acid or borates, but no studies have examined batteries of neurological end points 
in animals following exposure to boron compounds. Relative brain weights were increased in mongrel 
dogs fed 60.5 mg boron/kg/day as borax, but not boric acid, for 90 days and in rats fed 170 or 81 mg 
boron/kg/day as borax or boric acid for 90 days or 2 years, respectively (Weir and Fisher 1972). No 
histological lesions were observed in these animals or in the brain or spinal cord of mice fed 577 or 
201 mg boron/kg/day as boric acid for 13 weeks or 2 years, respectively (NTP 1987; Dieter 1994).
In Wistar rats, exposure to approximately 20.8 mg boron/kg/day as borax (based on weight of 0.35 kg and 
average water consumption of 20.7 mL) in drinking water for up to 14 weeks caused increased cerebral 
succinate dehydrogenase activity after 10 and 14 weeks of exposure (Settimi et al. 1982). Increased 
ribonucleic acid (RNA) concentration and increased acid proteinase activity in brain occurred after 
14 weeks (Settimi et al. 1982). The neurological significance of these biochemical changes is unclear.
All LOAEL values for neurological effects in humans and animals are recorded in Table 3-2 and plotted 
in Figure 3-2.
3.2.2.5 Reproductive Effects
A survey of Turkish subpopulations compared fertility rates of 1,068 families living in two Turkish 
villages having drinking water boron levels of 2-29 mg/liter (from nearby geological deposits of calcium 
borate) with 610 families living in three other villages having drinking water boron levels of 0.03­
0.4 mg/liter (Sayli 1998a, 1998b; Sayli et al. 1998). Assuming 70-kg body weights and 2-L/day drinking 
water consumption, these boron levels would results in an estimated range of daily doses of 0.06­
0.8 mg/kg/day. Three generations of families were represented. No significant differences in frequencies 
of infertility were observed between high- (2.34% infertility) and low-exposure (2.62% infertility) village 
groups. A separate analysis of the same subpopulation found no association of higher drinking water 
borate concentrations with increased rates of spontaneous abortions, stillbirths, or infant death (Tuccar et 
al. 1998). A follow-up study of this population reported no significant differences in infertility 
frequencies between the two populations (Sayli 2003).
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A questionnaire was administered to 542 male workers at a borax and boric acid production facility in 
California inquiring about the ability to conceive a child after at least 9 months of employment at the 
facility (Whorton et al. 1994). The worker population was categorized as having low, mid, or high 
exposures to borax or boric acid (exposure levels were not reported). A standardized birth ratio (SBR) 
was calculated as the number of children born to wives compared to the number of births expected in the 
same fraction of the U.S. population. The calculated SBR of 113 indicated higher birth rates among the 
borate workers relative to the U.S. population. Thus, this survey provided no evidence for association 
between occupational exposure to borax or boric acid and impaired fertility; however, the study is limited 
by non-rigorous survey design, lack of quantitative exposure data, and lack of a comparable comparison 
(control) group.
A cross-sectional survey of 1,187 Chinese boron mining and processing workers examined the 
association of boron exposure and various lifestyle factors to multiple reproductive indices (Chang et al. 
2006). No exposure estimates were reported, but boron levels in drinking water and staple foodstuffs 
were significantly higher for surveyed workers compared to a comparison population. After correcting 
for age, race, diet, alcohol consumption, smoking, and education, there were no statistically significant 
differences between workers and the comparison population for ability to sire offspring, delayed 
pregnancy, multiple births, miscarriages, induced abortions, stillbirths, or tubal or ectopic pregnancies.
Liu et al. reported two studies of 176 (2006a) and 195 (2006b) Chinese men exposed to between 13 and 
430 mg boron/day. The investigators found no significant difference in semen quality and sperm motility, 
speed, or departure from a straight-line path in groups of borate workers, non-occupationally exposed 
men from a nearby community with high environmental levels of borates, and men from a community 
with low environmental levels of borates. However, data for estimated boron exposures for each group 
were not available.
A study of 146 Chinese men comprising borate workers, a community group, and controls were assessed 
for chromosomal shifts in the ratio of Y:X chromosomes in sperm (Robbins et al. 2008). A significant 
correlation was found for Y :X ratios and internal boron doses in blood, semen, and urine. Estimated daily 
boron exposures of 41.2, 4.3, and 2.3 mg/day in the borate workers, community group, and controls were 
associated with mean Y :X sperm ratios of 0.93, 0.96, and 0.99, respectively. However, no dose-response 
relationship was observed in the reported percentage of men who had fathered “more boys than girls”, 
which was 57.7, 42.3, and 76.7% in the borate workers, community group, and controls, respectively. 
There were several possible confounding factors in this study, including (1) the exclusion of men who had
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fathered equal numbers of boys and girls, (2) the average number of children/subject was 
<2 (approximately 1.3), and (3) a high rate of elective abortions across groups (49.2, 28.2, and 50.0% for 
borate workers, community group, and controls, respectively), in which some men may have favored 
raising male offspring while complying with China’s one-child-only policy. Thus, it cannot be 
determined from these data if a boron-associated shift in the Y :X sperm ratio resulted in a change in sex 
of offspring.
While the human survey database is extensive in that large populations with chronic exposure durations 
were sampled from multiple locations (Chang et al. 2006; Liu et al. 2006a, 2006b; Robbins et al. 2008; 
Sayli 1998a, 1998b, 2003; Sayli et al. 1998; Whorton et al. 1994), they are limited for informing dose 
response relationships for reproductive effects. Specifically, the reliance on questionnaires and lack of 
clinical observations, absence of an appropriate comparison population (Robbins et al. 2008; Whorton et 
al. 1994), or low confidence in estimates of personal or group boron exposure (Liu et al. 2006a, 2006b) 
preclude these data from providing a basis for deriving an oral MRL.
Animal studies of acute-, intermediate-, and chronic- oral exposure to boric acid or borax consistently 
identified testicular atrophy and histological lesions and the associated impacts on spermatogenesis as the 
most sensitive reproductive effect. The majority of studies were performed in rats; however, the effects 
observed in rats were also observed in mice and dogs. The effects of boron on animal testes appear to be 
dose- and duration-related.
Acute-duration (2-week) oral gavage or dietary exposures of Wistar rats to 88 mg boron/kg/day as boric 
acid produced significant damage to male reproductive tissues, but doses of 53 or 44 mg boron/kg/day 
were without effect (Fukuda et al. 2000; Ku et al. 1993a; Kudo et al. 2000). Exposure to 88 mg 
boron/kg/day resulted in 12 and 13% reduction in absolute and relative testes weights, respectively, 
multinucleated giant cell formation, increased residual body-like structures in the testes, 
degeneration/necrosis of germ cells, increased cellular debris in the epididymal ducts, exfoliation of round 
spermatids, and mild inhibition of spermiation (retention of step 19 spermatids at stages IX-XI) (Fukuda 
et al. 2000; Kudo et al. 2000).
Intermediate-duration gavage studies in rats resulted in similar effects as observed in the acute studies, but 
at lower exposure levels. Wistar rats given gavage doses of 26 mg boron/kg/day as boric acid for 3 weeks 
exhibited decreased sperm motility, morphologically-abnormal sperm heads and tails, and increased 
preimplantation fetal loss when treated males were mated with untreated females; no reproductive effects
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occurred in this study with exposure to 9 mg boron/kg/day (Y oshizaki et al. 1999). Four-week daily 
gavage doses of 44 mg boron/kg/day as boric acid resulted in exfoliation of testicular and epididymal 
germ cells in Wistar rats (Kudo et al. 2000). Fukuda et al. (2000) gave gavage doses of 53 mg 
boron/kg/day to Wistar rats for 4 weeks and observed 13 and 15% reductions in absolute and relative 
testes weights, respectively, cellular debris in the testes, caudal and caput epididymis, focal atrophy of the 
seminiferous tubules, and decreased number of sperm in the ducta lumina. Rats given 4-week daily 
gavage doses of SS mg boron/kg/day group exhibited reduced sperm motility, reduced total sperm in 
caudal epididymis, atrophy of seminiferous tubules, atypical residual bodies, multinucleated giant cell 
formation, and the inability to impregnate females (Yoshizaki et al. 1999).
Intermediate-duration feeding studies in rats reported effects similar to those of the gavage studies. Rats 
fed 100 mg boron/kg/day as borax in the diet, but not 50 mg boron/kg/day, for 30 and 60 days showed 
testicular atrophy (Lee et al. 197S). Sprague-Dawley rats fed S6 mg boron/kg/day as borax in the diet for 
30 or 60 days were infertile for 3 or 5 weeks after exposure, respectively (Dixon et al. 1979). Exposure to 
43 mg boron/kg/day as borax for 60 days produced reduced testicular and epididymal weights and 
diameter of seminiferous tubules occurred, and reduced testicular levels of hyaluronidase, sorbitol 
dehydrogenase, and lactic acid dehydrogenase (isoenzyme-X) at 30 days (Dixon et al. 1979). Mildly 
inhibited spermiation was observed in Fischer 344 rats exposed to 26 mg boron/kg/day in the diet for 5­
9 weeks (Ku et al. 1993a). Fischer 344 rats fed 61 mg boron/kg/day as boric acid for 4 weeks showed 
inhibited spermiation, appearance of peripheral spermatid nuclei, and spermatocyte sloughing/epithelial 
disorganization (Treinen and Chapin 1991), while severe inhibition of spermiation and testicular atrophy 
were observed in Fischer 344 rats exposed to 6S or 52 mg boron/kg/day as boric acid in the diet for 6 or 
9 weeks (Ku et al. 1993a). Full recovery from inhibition of spermiation was observed in a 3S mg 
boron/kg/day group by 16 weeks after cessation of exposure for 9 weeks, but no recovery from testicular 
atrophy was observed in the 52 and 6S mg boron/kg/day groups up to 32 weeks after exposure ended (Ku 
et al. 1993a). Dose-related elevations of FSH and LH suggested that boron exposure did not affect the 
compensatory response to atrophy (Ku et al. 1993a). In a recent study, Sprague-Dawley rats fed 136 mg 
boron/kg/day as boric acid for 60 days exhibited decreased weights of testes, epididymes, seminal 
vesicles, prostate, and vas deferens; decreased sperm motility, spermatocyte, spermatid, and Leydig cell 
numbers; decreased testosterone levels, sexually aggressive behavior, sexual mounts, number of females 
impregnated, and viable pups/impregnated female; and increased cellular degeneration, ejaculation time, 
postejaculatory interval, and fetal resorptions in impregnated females (Nusier and Bataineh 2005).
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In intermediate-duration drinking water studies in rats, no reproductive effects (reproductive organ weight 
or histolopathology) were evident in Sprague-Dawley rats following exposure to 0.6 mg boron/kg/day as 
borax for 90 days (Dixon et al. 1976). In another study, impaired spermatogenesis was observed in Long- 
Evans rats given 44.7 mg boron/kg/day as borax in drinking water for 70 days (Seal and Weeth 1980). 
Complete sterility was observed in Sprague-Dawley rats fed 1,170 ppm boron equivalents in the diet as 
boric acid or borax (at an estimated dose level of 101 and 116 mg boron /kg/day for males and females); 
sterility was associated with a lack of viable sperm in atrophied testes in males and decreased ovulation in 
females (Weir and Fisher 1972). Rats were exposed for 14 weeks before mating in this study. No 
pregnancies occurred when female rats exposed to this dose level were mated with non-exposed male rats. 
At lower exposure levels (10 or 30 mg boron/kg/day for males and 12 or 35 mg boron/kg/day for 
females), no exposure-related adverse effects were found on overall fertility indices in three successive 
generations (Weir and Fisher 1972).
Studies in mice and dogs support the observations of reproductive effects seen in rats. In a study in which 
male CD-1 mice were exposed to gavage doses of boric acid of 0, 21, 70, or 210 mg boron/kg/day for 
21 days (5 days before mating, during 5 days of mating, and extending to 21 total days of exposure), 
average testes weights were decreased at doses >70 mg boron/kg/day, and exfoliation/disruption of 
seminiferous tubules and inhibited spermiation were observed at 210 mg boron/kg/day (Harris et al.
1992). Exposed male mice were mated to similarly exposed female mice (except that females were 
exposed for 8 days before mating), but no exposure-related effects were found on the percentage of 
females who became pregnant, the number of live pups per litter, or the weight of pups at birth (Harris et 
al. 1992). Degeneration of the seminiferous tubules was seen in mice exposed to 288 mg boron/kg/day as 
boric acid in the diet for 13 weeks, while 103-week dietary exposure to 201 mg boron/kg/day as boric 
acid resulted in testicular atrophy, degeneration of the seminiferous tubules, and interstitial hyperplasia 
(Dieter 1994; NTP 1987).
In a 2-generation (27-week) feeding study in CD-1 mice using a continuous breeding protocol, 
seminiferous tubule degeneration, impaired spermatogenesis, and reduced sperm motility resulted from 
>111 mg boron/kg/day as boric acid (Fail et al. 1991). These doses were also associated with reduced 
litter size and fetal body weight. No effects were observed in a 27 mg boron/kg/day dose group.
In mongrel dogs fed boric acid or borax for 90 days, severe testicular atrophy was seen at 60.5, but not at 
6 mg boron/kg/day (Weir and Fisher 1972). With 2 years of exposure, testicular atrophy and
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spermatogenic arrest were observed in dogs exposed to 22.8, but not in dogs exposed to 6.8 mg 
boron/kg/day (Weir and Fisher 1972).
Effects of boric acid or borates on female reproductive organs and their functions are less clearly 
identified and studied in animals than effects on male reproductive organs. When pregnant CD-1 mice 
were exposed to gavage doses of 210 mg boron/kg/day on gestation days 8-14, all dams failed to deliver 
litters (Harris et al. 1992). Exposure to 21 or 70 mg boron/kg/day during the same period did not affect 
littering ability, average litter weight, or the number of live neonates at postnatal days 0, 1, and 4 (Harris 
et al. 1992). Mechanistic aspects of this effect of gestational exposure on littering capability of pregnant 
rats are unstudied. As discussed earlier, female Sprague Dawley rats exposed for 14 weeks to 1,170 ppm 
boron equivalents in the diet as boric acid or borax (estimated dose level of 116 mg boron/kg/day) did not 
become pregnant when mated with non-exposed males (Weir and Fisher 1972). The female sterility 
response at this dose level was associated with decreased ovulation.
The highest NOAEL values and all reliable LOAEL values for reproductive effects in animals and 
duration category are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.6 Developmental Effects
No studies were available identifying developmental toxicity in humans from exposure to boron. 
However, several types of developmental effects (e.g., decreased fetal body weight, increased incidence 
of skeletal abnormalities) in animals were observed in standard developmental toxicity studies involving 
oral exposure of pregnant mice, rats, and rabbits to boric acid of borate salts. In addition, reduced pup 
weight at birth has been observed in animals receiving intermediate-duration exposures.
In mice, reduced fetal body weight and skeletal malformations were seen following acute- and 
intermediate-duration maternal oral exposures to boric acid.
Pregnant CD-1 mice fed 79 mg boron/kg/day as boric acid on gestation days 0-17 had fetuses with 33% 
lower body weight compared with controls, while fetal skeletal effects (e.g., short rib XIII, agenesis of 
lumbar vertabra, fused ribs) were reported at 175.3 mg boron/kg/day on gestation days 0-17 (Heindel et 
al. 1992, 1994). No effects on fetal development were observed in the 43.4 mg boron/kg/day dose group 
(Heindel et al. 1992, 1994).
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No effects on implantation sites, littering, number of live pups per litter, or postnatal pup weight were 
observed following gavage exposure of pregnant CD-1 mice to 70 mg boron/kg/day as boric acid on 
gestation days 8-14 (Harris et al. 1992).
In an acute-duration study, pregnant CD-1 mice were given gavage doses of boric acid on various 
gestation days to examine the influence of stage of fetal development on skeletal malformations caused 
by boric acid (Cherrington and Chernoff 2002). When two gavage doses of 70 mg boron/kg as boric acid 
were given on gestation day 6, 7, 8, 9, or 10, increased incidence of fetuses with cervical rib and rib 
agenesis were observed in the groups treated on gestation day 8, but not with exposure on gestation days 
6, 7, 9, or 10 (Cherrington and Chernoff 2002). Similarly, increased incidences of fetuses with cervical 
rib, rib agenesis, reduced rib length, and fused ribs were seen after twice daily doses of 70 mg boron/kg 
on gestation days 6- 8. Reduction in length of fetal rib XIII was seen in groups dosed once daily with 
88 mg boron/kg/day on gestation days 6-10. A single dose of 131 mg boron/kg on gestation day 
8 resulted in increased incidence of fetuses with cervical ossification, while two doses of 131 mg 
boron/kg on gestation day 8 caused multiple thoracic skeletal malformations. Reduced fetal weight was 
observed in all treated groups (Cherrington and Chernoff 2002). This study did not identify acute 
NOAELs for fetal skeletal effects in mice. The study authors suggested that boric acid may alter 
gastrulation and presomitic mesoderm formation in CD-1 mice, which are key gestational milestones for 
axial skeletal development.
In rats, acute-duration developmental toxicity data were not available. However, intermediate-duration 
oral exposure of pregnant rats exhibited effects on fetal skeletal development and fetal weight, similar to 
those observed in mice. Pregnant Sprague-Dawley rats fed 13.6 boron/kg/day as boric acid in the diet on 
gestation days 0-20 had reduced fetal body weight, and increased incidence of fetuses with skeletal 
abnormalities at gestation day 20 occurred in groups of dams fed 28.4 mg boron/kg/day (Heindel et al.
1992). Skeletal abnormalities observed in groups fed 28.4 mg boron/kg/day included agenesis or 
shortening of rib XIII, increased incidence of fetuses with enlargement of the lateral ventricles of the fetal 
brain, and increased resorptions (Heindel et al. 1992). Pregnant Sprague-Dawley rats fed 10 mg 
boron/kg/day as boric acid on gestation days 0-20 exhibited no developmental effects, but exposures of 
13 mg boron/kg/day as boric acid resulted in decreased fetal body weight and skeletal abnormalities seen 
on gestation day 0. However, in a second phase of this study, identically treated dams were allowed to 
litter and pups were observed through postnatal day 21. Upon necropsy, these pups did not exhibit 
significantly different body weights or incidences of skeletal abnormalities seen and fetuses examined on 
gestation day 0 (Price et al. 1996a, 1998).
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Developmental toxicity data in rabbits are available only for acute-duration oral exposures (Price et al. 
1996b). Pregnant New Zealand white rabbits given gavage doses of 44 mg boron/kg/day as boric acid on 
gestation days 6-19 exhibited increased maternal body weight (corrected for gestation) and reduced 
maternal kidney weight, gravid uterine weight, fetal body weight, number of ovarian corpora lutea, 
number of implantation sites, and live fetuses, compared with controls. Resorptions and fetal external 
(cleft palate), visceral (enlarged lateral ventricle of the brain), skeletal (cleft sternum, fused sternebrae), 
and cardiovascular (enlarged aorta, interventricular septal defect) malformations were increased, 
compared with controls. No significant maternal or fetal effects were observed following gavage doses of 
22 mg boron/kg/day as boric acid. The observed effects are consistent with those seen in acute-, 
intermediate-, and chronic-duration oral exposures in other animals. These data represent the most 
sensitive adverse effects observed in any species following acute-duration oral exposures. Thus, an acute- 
duration MRL of 0.2 mg boron/kg/day was derived based on a NOAEL of 22 mg boron/kg/day and a 
LOAEL of 44 mg boron/kg/day for developmental effects in New Zealand white rabbits (Price et al. 
1996b).
With intermediate-duration oral exposure to boric acid, reduced fetal body weight and skeletal 
abnormalities were consistently observed in developmental toxicity assays of mice, rats, and rabbits. 
Skeletal malformations increased in variety and severity with dose. However, reductions in fetal body 
weight appear to occur at lower exposure levels than those associated with skeletal abnormalities. With 
intermediate-duration exposure during gestation, the most sensitive developmental effect identified across 
all three species was reduced fetal weight in pregnant Sprague-Dawley rats fed 13.6 mg boron/kg/day in 
the diet on gestation days 0-20. This effect was seen at lower intermediate-duration exposure levels than 
the lowest intermediate-duration oral dose associated with reproductive effects in rats (i.e., a LOAEL of 
26 mg boron/kg/day was identified for inhibition of spermiation in rats) (Ku et al. 1993a). An 
intermediate oral MRL of 0.2 mg boron/kg/day was calculated as described in the footnote on Table 3-2, 
based on a benchmark dose analysis (Allen et al. 1996) of combined data sets (Heindel et al. 1992; Price 
et al. 1996a) for reduced fetal body weight in rats.
The highest NOAEL values and all reliable LOAEL values for developmental effects in animals and 




Three epidemiological studies have associated increased boron intake in drinking water with decreased 
incidences of prostate and vaginal cancer. Cui et al. (2004) used the cross-sectional data from the 
NHANES III study, conducted from 1988 to 1994, which contained health and diet information for the 
non-institutionalized U.S. population. These investigators reported that men with mean intakes of 
>1.54 mg boron/day had significantly less risk of developing prostate cancer than men ingesting 
<0.52 mg/day. This study was limited by its cross-sectional design and reliance on 1-day recall of diet 
information to estimate boron exposure. A second study (Barranco et al. 2007) on a Texas population 
correlated increased boron in groundwater with reduced prostate cancer incidence rates. However, the 
observed correlation appeared to be driven primarily by 2-3 specific cases. Korkmaz et al. (2007) studied 
1,059 rural Turkish women and associated higher boron intake (as evidenced by approximately 8-fold 
higher urinary boron concentration) with lower incidences of cervical cytopathology (0 findings in the 
high-boron group, 15 cases in the low-boron group). While this study did attempt to correct for lifestyle 
factors and other genotoxic confounders, it was cross-sectional in design. The hypotheses drawn from 
these studies are interesting; however, no clinical studies in humans or animals are available to 
substantiate effects of anti-tumor protection offered by boron.
No evidence of exposure-related cancer was observed in rats exposed to 81 mg boron/kg/day as boric acid 
or borax for 2 years (Weir and Fisher 1972), dogs exposed to 6.8 mg boron/kg/day as boric acid or borax 
for 2 years (Weir and Fisher 1972), or mice exposed to 201 mg boron/kg/day as boric acid for 2 years 
(Dieter 1994; NTP 1987). In nude mice subcutaneously injected with human LNCaP cells (prostate 
tumor clones), oral gavage doses of boric acid were given for 8 weeks (Gallardo-Williams et al. 2004) to 
determine if boron offered protection against prostate tumor growth. Although there was no significant 
difference between control and boron-treated mice in tumor incidences, the tumor sizes in mice given
1.7 mg boron/kg/day were significantly smaller and the serum level of tumor specific antigen (PSA) was 
significantly less than controls.
3.2.3 Dermal Exposure
Information on dermal toxicity in humans involves exposure to the borates (as boric acid or borax), while 
the animal data involves exposure to boron oxide, which easily converts to boric acid in humid air or 




No studies were located regarding death in humans or animals after dermal exposure to boron.
3.2.3.2 Systemic Effects
No studies were located regarding hematological and dermal/ocular effects in humans or regarding 
respiratory, cardiovascular, gastrointestinal, musculoskeletal, hepatic, or renal effects in humans or 
animals after dermal exposure to boron.
Hematological Effects. Draize and Kelley (1959) reported the application of 25-200 mg/kg/day 
boric acid in aqueous solution did not produce hematological changes when rubbed onto intact skin 
during a 90-day rabbit study. No quantitative data were provided; therefore, these results could not be 
evaluated.
Dermal Effects. Human data are limited to case reports of accidental exposure of the head. Three 
male workers (59-year-old waste handler and 34- and 36-year-old automotive mechanics) presented with 
general or focal alopecia of the scalp, presumably from spillage or wiping of boric acid or borax, 
respectively, onto the head (Beckett et al. 2001). In the case of the waste handler, the concentration of 
boric acid in the milieu of other known solvents in the waste tank was unknown. In the cases of the 
automotive workers, exposure was determined to arise from under-the-chassis flushing of automobile 
radiators which contained coolant solutions of ethylene glycol and 1-5% borax. Actual exposures could 
not be determined. Blood sample analysis revealed no elevated blood boron levels in any of the subjects. 
Gradual and full hair re-growth occurred.
In animals, application of 1 g boron oxide dust to a 25 cm2 area of the skin of four rabbits produced 
erythema that lasted for 2-3 days (Wilding et al. 1959).
Ocular Effects. Instillation of boron oxide dust (50 mg) into the eyes of four rabbits produced 
conjunctivitis (Wilding et al. 1959).
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No studies were located regarding the following effects in humans or animals after dermal exposure to 
boron:





3.2.4 Other Routes of Exposure
Direct application of a solution containing 6.3 mg boron (as sodium perborate monohydrate) onto the 
cornea of rabbits resulted in mild irritancy of the epithelium and superficial stroma (Maurer et al. 2001).
3.3 GENOTOXICITY
No studies were located regarding genotoxic effects of boron by inhalation, oral, or dermal exposure in 
humans.
Results were predominantly negative in bacterial assays and in in vitro (Table 3-3) mammalian assays, 
including tests for chromosomal aberrations, gene mutation (Benson et al. 1984; Demerec et al. 1951; 
Haworth et al. 1983; Landolph 1985; NTP 1987), and cell transformation (Landolph 1985). Induction of 
P-galactosidase as part of the SOS response was observed in Escherichia coli PQ37, both with and 
without S-9 metabolic activation (Odunola 1997). Structural chromosomal aberrations, but not sister 





Table 3-3. Genotoxicity of Boron In Vitro
Species (test system ) End point
Results
W ith W ithou t 
activation activation Reference
Prokaryotic organisms:
Salmonella typhimurium Gene mutation - - Haworth et al. 1983
Gene mutation - - Benson et al. 1984
Gene mutation - - NTP 1987
Escherichia coli Gene mutation - - Demerec et al. 1951
Mammalian cells:
Mouse lymphoma Gene mutation - - NTP 1987
Mouse embryo fibroblast Gene mutation NA - Landolph 1985
Human foreskin fibroblast Gene mutation NA - Landolph 1985
Chinese hamster ovary Gene mutation NA - Landolph 1985
Chinese hamster ovary Chromosomal
aberration
- - NTP 1987
Human lymphocytes Sister chromatid 
exchange
NA - Arslan et al. 2008
Human lymphocytes Chromosomal
aberrations
NA + Arslan et al. 2008





Reports of upper respiratory tract symptoms of irritation following exposure to boron oxide and boric acid 
dusts suggest that boron can deposit in the upper airway (Garabrant et al. 1984, 1985). Borax production 
workers were found to have approximately an order of magnitude higher blood and urine concentrations 
of boron at the end of a work shift compared to the beginning, suggesting that inhaled boron is absorbed 
and systemically distributed (Culver et al. 1994a).
3.4.1.2 Oral Exposure
Near-complete gastrointestinal absorption was indicated in humans as evidenced by the urinary recovery 
of 93.9% of the ingested dose of boric acid over a 96-hour collection period (Jansen et al. 1984a).
Dourson et al. (1998) reviewed data from the literature to estimate oral absorption fractions of 81-92% 
for humans and 95% for animals (rats).
3.4.1.3 Dermal Exposure
Volunteers exhibited 0.23 and 0.21% percutaneous absorption of 1.8 mL of 5% solutions of boric acid 
and borax (Wester et al. 1998). Urinary excretion studies in humans (Section 3.4.4.3) suggest there is 
very little absorption of boron through intact skin. Excretion studies (Section 3.4.4.3) in rabbits suggest 
that boron is readily absorbed following contact with damaged skin (Draize and Kelley 1959).
3.4.2 Distribution
No quantitative studies were located regarding distribution in humans.
3.4.2.1 Inhalation Exposure




Boron evenly distributed to liver, kidney, brain, muscle, adrenals, epididymis, testes, seminal vesicles, 
and blood, but not fat, of male rats fed 61 mg boron/kg/day as boric acid (9,000 ppm) for 1-28 days (Ku 
et al. 1991; Moseman 1994; Treinen and Chapin 1991), reaching steady-state by 4 days. Blood and testes 
boron levels were similar in rats fed 26-68 mg boron/kg/day as boric acid (3,000-9,000) for 9 weeks (Ku 
et al. 1991). However, boron accumulated in bone in male rats fed 61 mg boron/kg/day (as boric acid) for 
9 weeks, with achievement of steady-state at 4 weeks. Bone levels were approximately 3-fold higher than 
soft tissue levels (Moseman 1994).
3.4.2.3 Dermal Exposure
No studies were located regarding distribution of boron in animals after dermal exposure.
3.4.3 Metabolism
As an inorganic chemical, boron is not expected to be metabolized by humans or animals 
inhalation and oral exposure of animals and humans to borates have consistently reported 
parent borate only in the blood, tissues, and urine (Culver et al. 1994a; Draize and Kelley 
al. 1984a; Ku et al. 1991; Moseman 1994; Treinen and Chapin 1991).
3.4.4 Elimination and Excretion
3.4.4.1 Inhalation Exposure
Over 94% of estimated total boric acid (mean 11.84 mg boron/day) inhaled and ingested by Chinese 
borate workers was eliminated 24 hours later in the urine (Xing et al. 2005) as determined by the percent 
estimated daily dose recovered in the urine. In rats that inhaled average concentrations of 
77 mg/m3 boron oxide aerosols over a 22-week period, an average of 11.90 mg boron/kg/day was 
detected in the urine compared to 0.24 mg/kg/day in untreated control groups (Wilding et al. 1959).
3.4.4.2 Oral Exposure
Over 93% of the administered dose was excreted in the urine of six male volunteers 96 hours after 
administration of a single oral dose of 1.9 mg boron/kg (as boric acid) (Jansen et al. 1984a). An analysis 
of nine cases involving boric acid poisoning revealed a mean half-life of 13.4 hours (range 4-27.8 hours).
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There was no correlation between half-life and calculated serum boric acid level at to (r=0.08, p=0.84) 
(Litovitz et al. 1988). Boric acid was detected in urine of patients 23 days after a single ingestion (Wong 
et al. 1964). Renal clearance of dietary boron from fifteen pregnant women was calculated to be 
1.02 mL/minute/kg, or 66.1 mL/minute (Pahl et al. 2001).
In rabbits, 50-66% of the administered dose was recovered in urine after ingestion of 17.1-119.9 mg 
boron/kg/day as boric acid (Draize and Kelley 1959). In rats fed 26-68 mg boron/kg/day as boric acid 
(3,000-6,000 ppm) for 9 weeks, boron concentrations in bone began decreasing after cessation of 
exposure; however, bone levels remained approximately 3-fold higher than controls for up to 32 weeks 
(Chapin et al. 1997; Moseman 1994). Blood levels in these same animals returned to control levels 
within 7 days of exposure cessation (Ku et al. 1991). Using literature data, Dourson et al. (1998) 
estimated the fraction eliminated of absorbed boron to be 67-98% in humans and 99% in rats. These 
investigators also calculated clearance values of 40 mg/kg/hour in humans, 163 mg/kg/hour in rats, and 
397 mg/kg/hour in pregnant rats. Pregnancy did not affect renal clearance (0.2 L/hour/kg or
1.0 mL/minute) or elimination half-life (3.2 hours) in rats given gavage doses of 0.05-5 mg boron/kg/day 
(as boric acid) on gestation day 16 (Vaziri et al. 2001).
3.4.4.3 Dermal Exposure
Limited data in humans suggest that very little absorption of boron occurs through intact skin. There was 
no increase in the urinary excretion of boron in one human subject following the application of 15 g boric 
acid (37.5 mg boron/kg body weight) on the forearm for 4 hours (Draize and Kelley 1959). In volunteers 
having 1.8 mL of 5% boric acid or borax solutions applied to the back and left for 24 hours, urinary boron 
levels increased to peak values of <0.1% above background levels at 14 days following exposure (Wester 
et al. 1998).
Animal studies support human findings. Draize and Kelley (1959) applied 200 mg/kg as boric acid to 
intact, abraded or burnt, and partially denuded skin of rabbits. Net urinary excretion of boric acid per 
24 hours during 4 consecutive days of compound treatment was 1.4, 7.6, and 21.4 mg/kg, respectively 
(0.25, 1.3, and 3.7 mg boron/kg, respectively).
3.4.4.4 Other Routes of Exposure
In eight adult volunteers administered a single dose of boric acid (562-611 mg) by intravenous infusion, 
98.7% of the administered dose was recovered in urine 120 hours after injection (Jansen et al. 1984b).
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Renal blood clearance averaged 39.1 mL/minute per 1.73 m2 surface area in eight adult human subjects 
administered intravenous injections of 35 mg boron/kg (as sodium pentaborate). Urine boron 
concentrations on the day of administration averaged 1.19 mg/mL (Farr and Konikowski 1963). In rats 
administered an intravenous infusion of 86 mg boron/kg (as borax) (Tagawa et al. 2000), boron 
distributed rapidly to the extravascular tissues, giving a steady state volume of distribution of 1.19 L/kg. 
Excretion of boron was rapid, with 87.6% eliminated in the urine by 2 hours after infusion. 
Pharmacokinetic analysis of the blood time course data resulted in an estimated elimination rate constant 
(Kel) of 0.15 hour-1 and a clearance rate of 0.11 L/hour/kg. The elimination half-life was 8.43 hours. 
Guinea pigs given intra-tympanic doses of 0.2 mL/day of 4% boric acid in saline did not exhibit changes 
in hearing level (Oztukcan et al. 2008).
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry 
models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species. The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of
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toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical substance- 
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations 
provides the predictions of tissue dose. Computers then provide process simulations based on these 
solutions.
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems. If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). 
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species. 
Figure 3-3 shows a conceptualized representation of a PBPK model.
If PBPK models for boron exist, the overall results and individual models are discussed in this section in 
terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.
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Figure 3-3. Conceptual Representation of a Physiologically Based 
Pharmacokinetic (PBPK) Model for a Hypothetical 
Chemical Substance
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Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source: adapted from Krishnan and Andersen 1994
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3.5 MECHANISMS OF ACTION
3.5.1 Pharmacokinetic Mechanisms
Absorption. Boron is absorbed across pulmonary tissues into the blood, as seen in workers exposed to 
borate dusts, who were found to have higher blood and urine boron concentrations at the end of a work 
shift compared to the beginning of the shift (Culver et al. 1994a). Boron is almost completely absorbed in 
the gastrointestinal tract, with up to 92 and 95% of ingested dose being recovered in the urine (Dourson et 
al. 1998). No data are available to indicate whether boron is actively transported or passively diffused 
across pulmonary or gastrointestinal tissues. Diet may influence the rate of boron absorption in the gut, 
as higher initial boron levels were found in the urine of humans given boron in an ointment vehicle, 
compared to administration via a water vehicle (Schou et al. 1984). Boron was found to be minimally 
absorbed across intact human or animal skin (Draize and Kelley 1959; Wester et al. 1998).
Distribution. Boron is distributed readily to all body tissues. Tissue levels from daily doses were 
observed to achieve steady-state with plasma in all tissues examined, including neurological and 
reproductive tissues, with the exception of bone and adipose tissues (Ku et al. 1991. Bone serves as a 
storage depot for boron, while adipose tissue has a lower affinity for boron than other soft tissues. The 
mechanism(s) of transport across tissue membranes and into bone are not known. No data were available 
identifying binding of boron to a carrier protein in the blood or plasma membranes.
Metabolism. Boron is a trace element and is not metabolized in the body. Borates exist in the body as 
boric acid, the only form of boron recovered in the urine.
Excretion. Excretion of systemically absorbed born is accomplished primarily through renal 
elimination, with minor fractions excreted in the saliva, sweat, and feces (Jansen et al. 1984a). No data are 
available regarding the contribution of tubular absorption of boron in the kidney. Glomerular filtration rate 
is likely the dominant factor in renal elimination of boron. As such, the systemic elimination of boron may 
be compromised in populations with reduced glomerular filtration rates (Dourson et al. 1998), such as 
preeclamptic women. This assumption is used in deriving chemical-specific uncertainty factors, which 
themselves are used for deriving the intermediate-duration oral MRL (Appendix A).
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3.5.2 Mechanisms of Toxicity
No studies were available in humans describing a mechanism of toxicity for neurological, gastrointestinal, 
hepatic, or renal effects observed in case reports of high-dose poisoning incidents. In animals, 
reproductive and developmental effects have been the most sensitive toxic end points observed.
Although several studies have examined possible mechanisms for reproductive toxicity, the actual toxic 
mechanism remains unknown. In rats, delayed spermiation (inhibited release of mature sperm) appears to be 
the hallmark event in testicular toxicity, followed by exfoliation of germ epithelium and atrophy at higher 
doses (Treinen and Chapin 1991). Leydig and Sertoli cell cultures exposed to 10 mM boric acid did not 
exhibit reduced responsiveness to induction of testosterone production, but exhibited reduced intracellular 
cAMP levels following FSH stimulation (Ku et al. 1993b). Further, lactate and pyruvate (the primary energy 
sources for Sertoli cells) production (possibly from boronation of NAD cofactors [Ku et al. 1993b]) and 
deoxyribonucleic acid (DNA) synthesis were significantly reduced, suggesting that germ epithelial sloughing 
and testicular atrophy may result from impaired energy production and mitosis/meiosis in the Sertoli cells 
(Fail et al. 1998). However, in vivo delayed spermiation appears to occur at lower Sertoli cell exposure levels 
than disruption of energy production and DNA synthesis, making it difficult to conclude whether reproductive 
effects are hormonally or metabolically-mediated (Fail et al. 1998; Ku et al. 1993a).
The mechanism of toxicity for developmental effects is also unknown. Fail et al. (1998) suggest that the 
reduction in fetal body weight (the most sensitive end point observed in rats [Heindel et al. 1992]) may be 
due to mitotic inhibition observed in viruses, bacteria, insects, yeasts, and animals. Hyperacetylation of 
embryonic mouse tissues is highly associated with skeletal malformations following exposure to histone 
deacetylase inhibitors such as valproic acid and trichostatin A. Mice given intraperitoneal doses of 
175 mg boron/kg (as boric acid) on gestation day 8 exhibited hyperacetylation of embryonic somites, 
inhibition of histone deacetylase, and increased incidences of skeletal malformations (fused ribs and 
vertebra, changes in the typical number of axial segments in different axial districts). The association of 
these biochemical and morphological effects suggest that boric acid-induced skeletal malformations may 
result from inhibition of histone deacetylase. Wery et al. (2003) reported a cranial shift in the anterior 
limits of the hoxa6 and hoxc6 genes in the fetuses of pregnant rats given two gavage doses of 
88 mg/boron/kg/day (as boric acid) on gestation day 9. The control of position and development of the 
fetal vertebrae have been associated with the activity of these genes (see Section 3.3). It is not known 
whether inhibition of histone deacetylase, as suggested by Fail et al. (1998) is involved with the response 





Similarities in rodents and humans for boron toxicokinetics and reproductive physiology suggest that the 
animal toxicity data are relevant for human risk assessment. Animal and rodents studies indicate that 
boron is readily absorbed (particularly via the oral route), not metabolized, and extensively eliminated via 
urinary excretion (Section 3.4). Male humans and rodents share similar physiological structures and 
hormonal control mechanisms of the reproductive system, suggesting a similar target of toxicity for 
reproductive effects. Similarly, the sequence of fetal developmental steps is similar between the species. 
Lack of human data, particularly reproductive and developmental data, for effects observed in animal 
studies introduce uncertainty into the extrapolation of animals data to humans.
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones. Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial. The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife. However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment. Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992). These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen. Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction,
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development, and/or behavior (EPA 1997). Stated differently, such compounds may cause toxicities that 
are mediated through the neuroendocrine axis. As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function. Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992).
No studies were located regarding endocrine disruption in humans after exposure to boron.
While depressed testosterone blood levels was observed in rats fed diets with 61 mg boron/kg/day as 
boric acid (Treinen and Chapin 1991), GnRH challenge in boron-fed rats (Fail et al. 1998) resulted in LH 
responses similar to controls and an exacerbated FSH response relative to controls, suggesting that 
peripheral hormonal changes were not due to neuroendocrine toxicity, but possibly to Leydig and Sertoli 
cell-specific effects (Fail et al. 1998).
No in vitro studies were located regarding endocrine disruption of boron.
3.7 CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed. Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.
Relevant animal and in vitro models are also discussed.
Children are not small adults. They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the 
extent of their exposure. Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a 
particular structure or function will be most sensitive to disruption during its critical period(s). Damage
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may not be evident until a later stage of development. There are often differences in pharmacokinetics 
and metabolism between children and adults. For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978). Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger than adults (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and 
Brozek 1966; Widdowson and Dickerson 1964). The infant also has an immature blood-brain barrier 
(Adinolfi 1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 
1975). Many xenobiotic metabolizing enzymes have distinctive developmental patterns. At various 
stages of growth and development, levels of particular enzymes may be higher or lower than those of 
adults, and sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; 
Leeder and Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism 
make the child more or less susceptible also depends on whether the relevant enzymes are involved in 
activation of the parent compound to its toxic form or in detoxification. There may also be differences in 
excretion, particularly in newborns who all have a low glomerular filtration rate and have not developed 
efficient tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 
1948). Children and adults may differ in their capacity to repair damage from chemical insults. Children 
also have a longer remaining lifetime in which to express damage from chemicals; this potential is 
particularly relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical. For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993).
Human data of boron toxicity in children and humans due to high-dose exposures are not adequate to 
identify the presence or lack of children’s susceptibility. Normal boron blood levels in children and 
infants range from 0 to 1.25 ^g/mL (Fisher and Freimuth 1958; O'Sullivan and Taylor 1983). Infants 
exhibiting adverse effects after ingestion of boric acid in infant formula had boron blood levels (reported 
as borate) of 20-150 ^g/mL, with fatal cases having blood levels of 200-1,600 ^g/mL (Wong et al. 1964). 
Comparatively, adult serum boron level (as boric acid) of 2,320 ^g/mL was not associated with 
significant toxicity (Linden et al. 1986).
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No animal studies were located regarding susceptibility of immature animals to boron toxicity. However, 
oral exposure studies in pregnant animals have identified developmental effects in fetus exposed to boron 
(as borax or boric acid) in utero. No developmental effects were observed in animals following 
inhalation exposures. The observed effects from oral exposure include skeletal malformations and 
cardiovascular abnormalities. The most sensitive effect identified was reduced fetal body weight, which 
consistently occurred in animals at lower doses than required for skeletal malformations or other effects. 
The acute- and intermediate-duration oral MRLs are based on reduced fetal body weight in rats and 
should be protective of children developing in the womb.
3.8 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction 
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment 
of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta. However, several 
factors can confound the use and interpretation of biomarkers of exposure. The body burden of a 
substance may be the result of exposures from more than one source. The substance being measured may 
be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from 
exposure to several different aromatic compounds). Depending on the properties of the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
all of its metabolites may have left the body by the time samples can be taken. It may be difficult to 
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids 
(e.g., essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of exposure to boron 
are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
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cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity. Note that these markers are not often substance specific. They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused 
by boron are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Boron
Boron in blood and urine can be used as an indicator of exposure to boron. Normal dietary concentrations 
of boron in the blood of humans range from 0 to 1.25 ^g/mL in children and infants (Fisher and Freimuth 
1958; O'Sullivan and Taylor 1983). Boron blood levels (reported as borate) of 20-150 ^g/mL have been 
associated with adverse systemic effects in infants who ingested boric acid in infant formula (Wong et al. 
1964). Boron concentrations, expressed as borate, reported in fatal cases vary from 200 to 1,600 ^g/mL 
in infants (Wong et al. 1964). In adults, a serum boron level (as boric acid) of 2,320 ^g/mL was not 
associated with significant toxicity (Linden et al. 1986).
Urinary excretion levels can also be useful indicators of elevated total body burden of boron. 
Concentrations of boron in the normal population range from 0.07 to 0.15 mg/100 mL (Vignec and Ellis 
1954) and from 0.004 to 0.66 mg/100 mL (Imbus et al. 1963). In one infant, the urine contained 13.9 mg 
boron/liter as borax or 1.38 mg boron/mL of boric acid following ingestion of a borax and honey mixture 
over a period of 12 weeks (Gordon et al. 1973). Virtually complete urinary excretion was indicated by 
the recovery of 93.9% (over a 96-hour collection period) of a boric acid solution ingested by three 
volunteers (Jansen et al. 1984a).
Neurological, dermal, gastrointestinal, liver, and kidney effects in humans have been associated with 
exposure to boron. Studies in animals have demonstrated gonadal injury. Various clinical and 
biochemical tests exist that may provide useful information on exposure. However, similar effects are 
caused by a variety of other substances and are, therefore, not specific for boron exposure.
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3.8.2 Biomarkers Used to Characterize Effects Caused by Boron
Central nervous system injury, gastrointestinal effects, and skin damage are characteristic manifestations 
of boron toxicity in humans. Liver and kidneys in humans and testes in animals can also be affected. 
Various clinical and biochemical changes associated with these effects may be measured to detect the 
extent of exposure to boron. There is no single biological indicator of boron exposure; consequently, 
several parameters must be measured including boron levels in urine and blood and biochemical changes 
for systemic and neurological effects.
Neurological damage has been reported in humans. Neurological effects reported in humans have 
focused primarily on histopathological alterations. No data were provided on biochemical changes. In 
animals, testicular atrophy and reduced sperm production have been demonstrated following chronic 
boron exposure. There are clinical and biochemical tests to detect neurological and gonadal injury, but 
these are not specific for boron exposure. Sparse data in animals suggest some biochemical changes; for 
instance, cerebral succinate dehydrogenase was increased in rats after boron exposure. Animal data 
further demonstrate biochemical alterations following gonadal injury. Dose-dependent reduction in 
hyaluronidase, sorbitol dehydrogenase, and lactic acid dehydrogenase (isoenzyme-X) were observed in 
rats following boron exposure.
3.9 INTERACTIONS WITH OTHER CHEMICALS
No studies were located regarding the influence of other chemicals on the toxicity of boron.
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to boron than will most persons 
exposed to the same level of boron in the environment. Reasons may include genetic makeup, age, health 
and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). These parameters 
result in reduced detoxification or excretion of boron, or compromised function of organs affected by 
boron. Populations who are at greater risk due to their unusually high exposure to boron are discussed in 
Section 6.7, Populations with Potentially High Exposures.
No data were located identifying a population that is unusually susceptible to boron toxicity. Case reports 
in humans suggest that large variability exists with the human population to the lethal effect of boron. 
However, there are no data to suggest which segment of the population is more susceptible to boron.
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3.11 METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to boron. However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to boron. When specific 
exposures have occurred, poison control centers and medical toxicologists should be consulted for 
medical advice. The following texts provide specific information about treatment following exposures to 
boron:
Ellenhorn MJ, Schonwald S, Ordog G, et al., eds. 1997. Ellenhorn's medical toxicology. Diagnosis 
and treatment of human poisoning. 2nd ed. Baltimore, MA: Williams & Wilkins, 1098-1100, 160t,
162t.
Goldfrank LR, Flomenbaum NE, Lewin NA, et al., eds. 2002. Goldfrank's toxicologic emergencies. 7th 
ed. New York, NY: McGraw-Hill, 1282, 1289-1290, 1134.
Viccellio P, Bania T, Brent J, et al., eds. 1998. Emergency toxicology. 2nd ed. Philadelphia, PA: 
Lippincott-Raven, 448-449, 470, 1141.
Human exposure to boron may occur by inhalation, ingestion, or dermal contact (see Chapter 6). Boron 
in the form of boric acid or borate dust is an upper respiratory tract irritant following inhalation and may 
also irritate the eyes and skin. Ingestion of boron may cause gastrointestinal, neurological, hepatic, renal, 
and dermal effects (see Section 3.2). General recommendations for reducing absorption of boron 
following exposure have included removing the exposed individual from the contaminated area and 
removing the contaminated clothing. If the eyes and skin were exposed, then they should be flushed with 
water.
3.11.1 Reducing Peak Absorption Following Exposure
Nausea, vomiting, and diarrhea have been induced by ingestion of boron in humans. Some authors 
recommend reducing absorption of boron from the gastrointestinal tract by administration of emetics 
(e.g., syrup of ipecac) and cathartics (e.g., magnesium sulfate) (Stewart and McHugh 1990). Caution 
should be taken, however, not to induce further damage to the esophageal mucosa or to cause aspiration 
of the vomit into the lungs during emesis. There is disagreement regarding the efficiency of activated 
charcoal in preventing absorption of boron from the gastrointestinal tract following oral exposure 
(Ellenhorn and Barceloux 1988; Stewart and McHugh 1990). It has been suggested that activated 
charcoal be administered following gastric evacuation, but its effectiveness has not been established
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(Ellenhorn and Barceloux 1988). Administration of intravenous fluids may be required if severe 
dehydration or shock develop and local skin care may be necessary if skin desquamation occurs (Stewart 
and McHugh 1990). In addition, the treatment of boron poisoning may require a control for convulsions.
3.11.2 Reducing Body Burden
Elemental boron is not metabolized (see Section 3.4). Studies in volunteers indicated that most of the 
administered dose is excreted in the urine within few days (Jansen et al. 1984a). Saline diuresis has been 
suggested to enhance urinary excretion of boron (Goldfrank et al. 1990). Exchange transfusions, 
peritoneal dialysis, or hemodialysis may be employed to lower plasma boron levels following either acute 
or chronic intoxication. There are indications that hemodialysis is the most effective of these procedures 
(Goldfrank et al. 1990; Naderi and Palmer 2006; Stewart and McHugh 1990).
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
No studies were available to support measures to interfere with the mechanism of action for boron once it 
has been absorbed.
3.12 ADEQUACY OF THE DATABASE
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of boron is available. Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of boron.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
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3.12.1 Existing Information on Health Effects of Boron
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
boron are summarized in Figure 3-4. The purpose of this figure is to illustrate the existing information 
concerning the health effects of boron. Each dot in the figure indicates that one or more studies provide 
information associated with that particular effect. The dot does not necessarily imply anything about the 
quality of the study or studies, nor should missing information in this figure be interpreted as a “data 
need”. A data need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific Data 
Needs Related to Toxicological Profiles (Agency for Toxic Substances and Disease Registry 1989), is 
substance-specific information necessary to conduct comprehensive public health assessments.
Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from 
the scientific literature.
Most of the information concerning health effects of oral exposure to boron in humans is found in case 
reports of accidental acute and intermediate ingestion of boron. Controlled-exposure studies of volunteers 
and cross-sectional surveys of borate mining and production workers have identified acute upper 
respiratory and ocular irritation as an effect of concern from acute inhalation exposure. Epidemiology 
studies of intermediate- to chronic-duration exposures (involving repeated occupational exposure to dusts 
of borates or repeated exposure to boron in drinking water) have not clearly identified a toxic effect in 
humans, but have found no associations between boron exposure and impaired pulmonary function or 
impaired fertility. Information on acute dermal exposure exists, but none was found on effects after 
intermediate- and chronic-duration exposure.
In animals, information exists on health effects following acute, intermediate, and chronic oral exposure 
to boric acid or borax. Comprehensive acute toxicity studies involving inhalation exposure to boron 
compounds are not available, with the exception of a study of mice exposed by inhalation to diborane gas 
for 2 or 4 weeks. Diborane gas is expected to have a very short half-life in the environment because of its 
reactivity. Thus, it is not expected to be a significant environmental toxicant, except in workplaces where 
it might be used and accidentally released. Health effects have been examined in rats and dogs exposed 
by inhalation to boric oxide aerosols for intermediate durations. Studies of health effects in animals 
exposed by inhalation to boron compounds for chronic durations are not available. Health effects have 
been observed in animals following acute dermal exposure, but no toxicity studies of animals dermally 
exposed for intermediate and chronic durations are available.
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3.12.2 Identification of Data Needs
Acute-Duration Exposure. Associations between acute inhalation exposure to borate dusts and 
increased prevalence of self-reported symptoms of irritation of the eyes, nose, and throat of volunteers 
under controlled exposure conditions (Cain et al. 2004, 2008) form the basis of an acute-duration 
inhalation MRL. These data are supported by self-reported data for mild upper respiratory tract irritation 
in workers under workplace conditions (Garabrant et al. 1984, 1985; Hu et al. 1992; Wegman et al. 1991, 
1994). Dose-response relationships for mild respiratory and ocular irritation from studies of animals 
exposed by inhalation for acute durations are not available.
Case reports of acute oral poisonings with boric acid do not clearly identify toxicity targets and dose- 
response relationships in humans, but reported effects in fatal cases include degenerative changes in the 
liver, kidney, and brain (Chao et al. 1991a, 1991b; Wong et al. 1964). In animal studies, acute-duration 
oral exposure to boric acid or borates has been associated with effects on the male reproductive organs 
(e.g., decreased testicular weight and altered sperm morphology) in Wistar rats exposed to gavage boric 
acid doses of 88 mg boron/kg/day for 2 weeks (Fukuda et al. 2000; Kudo et al. 2000) and 
developmentally toxic effects (including reduced fetal weight and increased skeletal variations or 
malformations) in CD-1 mice exposed during gestation to boric acid doses as low as 70 mg boron/kg 
(2 times/day) (Cherrington and Chernoff 2002) and in New Zealand rabbits exposed during gestation 
(days 6-19) to doses of 44 mg boron/kg/day (Price et al. 1996b). A NOAEL of 22 mg boron/kg/day for 
developmental effects in rabbits (Price et al. 1996b) serves as the basis of the acute-duration oral MRL for 
boron.
Dermal/ocular effects have been associated with dermal exposure in humans (Beckett et al. 2001) and 
animals (Wilding et al. 1959). The irritation effects observed in animals may have been due to the 
exothermic rehydration reaction of the anhydride boron oxide.
No further acute-duration health effect studies are recommended at this time.
Intermediate-Duration Exposure. No studies are available that establish associations between 
intermediate-duration oral exposures to boron compounds and health effects in humans. Case reports of 
intermediate-duration exposure to humans are limited to reports on infants exhibiting neurological effects 
after ingestion of high levels of boron as boric acid. Seizure disorders occurred during oral exposures of
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infants to borax lasting 4-12 weeks, with cumulative approximate doses of 12-120 g (Gordon et al. 1973; 
O'Sullivan and Taylor 1983). No associations were found between elevated levels of borates in drinking 
water and fertility rates in surveys of Turkish subpopulations expected to have intermediate- to chronic- 
duration exposures to boron (Sayli 1998a, 1998b, 2003; Sayli et al. 1998). Likewise, cross-sectional 
surveys of boron mining and processing workers in California (Whorton et al. 1994) and China (Chang et 
al. 2006; Liu et al. 2006a, 2006b) failed to find associations between boron exposure (which may have 
included oral exposure to boron) and adverse effects on indices of fertility. Robbins et al. (2008) 
associated a shift in Y :X sperm and male:female offspring ratios with boron exposure; however, this 
study had multiple confounders limiting the interpretation of reported results.
Studies in animals indicate that reproductive and developmental effects are the most sensitive effects 
associated with intermediate-duration oral exposures to boric acid or borates. Testicular atrophy and 
histopathology, sperm abnormalities, and reduced sperm production have been observed in mice, rats and 
dogs after intermediate-duration ingestion of doses >26 mg boron/kg/day as boric acid (Dieter 1994; 
Dixon et al. 1976, 1979; Fail et al. 1991; Fukuda et al. 2000; Harris et al. 1992; Ku et al. 1993a; Kudo et 
al. 2000; Lee et al. 1978; NTP 1987; Nusier and Bataineh 2005; Seal and Weeth 1980; Weir and Fisher 
1972; Yoshizaki et al. 1999). Complete sterility was observed in Sprague-Dawley rats fed boric acid or 
borax in the diet (101 and 116 mg boron/kg/day for males and females, respectively) for 14 weeks before 
mating; sterility was associated with a lack of viable sperm in atrophied testes in males and decreased 
ovulation in females (Weir and Fisher 1972). No pregnancies occurred, when female rats exposed to this 
dose level were mated with non-exposed male rats. At lower exposure levels (10 or 30 mg boron/kg/day 
for males and 12 or 35 mg boron/kg/day for females), no exposure-related adverse effects were found on 
overall fertility indices in three successive generations (Weir and Fisher 1972). Developmental effects 
(including decreased fetal weight, increased incidence of skeletal variations and malformations, and 
increased resorptions) have been observed in offspring of rat and mouse dams exposed to 13-79 mg 
boron/kg/day as boric acid during gestation (Heindel et al. 1992, 1994; Price et al. 1996a). Multiple 
developmental end point data from the rat studies by Heindel et al. (1992) and Price et al. (1996a) were 
pooled and subjected to benchmark dose analyses (Allen et al. 1996) to derive a benchmark-dose point of 
departure of 10.3 mg boron/kg/day for the intermediate-duration oral MRL for boron.
Studies of Chinese borate workers have evaluated specific clinical end points of semen quality, but do not 
provide adequate estimation of magnitude or duration of boron exposure. Additional cross-sectional or 
prospective surveys of reproductive health end points in populations exposed to elevated levels of boron 
compounds in drinking water may help to better identify reproductive toxicity and developmental toxicity
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as potential health effects in humans with elevated oral exposure to boron for intermediate or chronic 
durations.
Increased frequencies of symptoms of acute upper respiratory and ocular irritation have been reported in 
workers exposed repeatedly by inhalation to boron oxide and borate dusts at average concentrations of
1.8 and 3.1 mg boron/m3, and employed in the borax industry for a mean duration of 11.4 years 
(SD 8.1 years), compared with a reference population (Garabrant et al. 1984, 1985); however, it is 
uncertain if these acute symptoms were due to acute or repeated exposure. Later studies of a different 
design indicated that acute irritation symptoms in these workers are due to acute exposures, and that 
pulmonary function variables (e.g., FEVi) were not significantly influenced by exposure over a 7-year 
period of employment (Hu et al. 1992; Wegman et al. 1994). These results are adequate to form the basis 
of an acute inhalation MRL for boron, but do not clearly indicate whether the dose-response relationships 
for acute boron-induced upper respiratory and ocular irritation symptoms are changed with intermediate 
or chronic durations of exposure. Because exposure-related effects on pulmonary function variables were 
not evident during a 7-year period between the studies of Garabrant et al. (1984, 1985) and Wegman et al. 
(1994), the results provide some confidence that the acute-duration inhalation MRL may by protective for 
intermediate- and chronic-duration exposures.
Intermediate-duration inhalation exposure studies in animals are restricted to a series of studies in which 
albino rats were exposed to boric oxide aerosols for 6 hours/day, 5 days/week for 10 weeks at an average 
concentration of 73 mg boron/m3 (n=20 rats), 12 weeks at 27 mg boron/m3 (n=4), or 24 weeks at 12 mg 
boron/m3 (n=70) (Wilding et al. 1959). Histopathologic examination of a comprehensive set of tissues 
(lung, trachea, pancreas, thyroid, adrenal, eye, femur, rib, bone marrow, liver, heart, spleen, kidney, brain, 
stomach, intestine, ovary, testis, lymph node, and muscle) in exposed and control rats revealed no 
exposure-related lesions, with the exception that some rats exposed to the highest concentration (73 mg 
boron/m3) showed a reddish nasal exudate. Although dogs were included in this study (three dogs were 
exposed to 9 mg boron/m3 for 23 weeks), end points were restricted to clinical signs of toxicity, body 
weight, hematological end points, and sulfobromophthalein retention, a measure of liver function 
(Wilding et al. 1959). No exposure-related effects on these end points were found in exposed dogs, 
compared with controls. Because the NOAELs identified in the rat and dog studies were higher than 
concentrations associated with acute respiratory and ocular irritation in humans acutely exposed to boron 
(Cain et al. 2004; Wegman et al. 1994), the intermediate-duration inhalation database was considered 
inadequate for derivation of an MRL.
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Additional prospective health evaluations of respiratory function and reproductive and developmental 
variables in borate mining and processing workers with intermediate- and chronic-duration exposures 
may help to better identify impaired respiratory function, impaired reproductive performance, and 
developmental effects as critical effects in humans from intermediate- or chronic duration exposure to 
boron compounds.
Chronic-Duration Exposure and Cancer. No studies are available that establish associations 
between chronic-duration oral exposures to boron compounds and noncancer or cancer effects in humans. 
As discussed in the previous section, no associations were found between exposure to borates or boric 
oxide and indices of fertility in surveys of Turkish subpopulations expected to have intermediate- to 
chronic-duration oral exposures to boron (Sayli 1998a, 1998b, 2003; Sayli et al. 1998), or in surveys of 
boron mining and processing workers in California (Whorton et al. 1994) and China (Chang et al. 2006; 
Liu et al. 2006a, 2006b). Chronic-duration oral toxicity studies in animals include 2-year toxicity studies 
in Sprague-Dawley rats and beagle dogs exposed to boric acid or borax in the diet (Weir and Fisher 
1972), and a 2-year toxicity and cancer bioassay in B6C3F1 mice (Dieter 1994; NTP 1987). 
Histopathological examination of a comprehensive set of tissues from exposed and control rats and dogs 
(brain, pituitary, thyroids, lung, heart, liver spleen, kidneys, adrenals, pancreas, intestines, urinary bladder 
testes, ovary (rat only), bone, and bone marrow) found no exposure-related non-neoplastic or neoplastic 
lesions at dose levels up to 6.8 mg boron/kg/day in dogs or 81 mg boron/kg/day in rats, with the exception 
that rats exposed to 81 mg boron/kg/day, but not 24 mg boron/kg/day, showed testicular atrophy, 
decreased growth, decreased packed blood cell and hemoglobin levels, and scaly tails and desquamated 
footpad skin (Weir and Fisher 1972). In the mouse bioassay, no cancer responses were observed at dose 
levels up to 201 mg boron/kg/day (Dieter 1994; NTP 1987). Noncancer effects in mice included 
testicular atrophy and interstitial hyperplasia, lung hemorrhage, and 10-17% decreased body weight at 
201 mg boron/kg/day and splenic hematopoiesis and chronic hepatic inflammation and coagulative 
necrosis at 79 and 201 mg boron/kg/day, the only dose levels included in the study.
Although data are sufficient to develop a chronic oral MRL, a value was not derived. Because 
intermediate-duration LOAELs for developmental toxicity in rats (13.6 and 13 mg boron/kg/day [Heindel 
et al. 1992; Price et al. 1996a, 1998]) were lower than the NOAEL (24 mg boron/kg/day) for testicular 
atrophy and other non-cancer effects in chronically exposed rats (Weir and Fisher 1972), the intermediate 
MRL, which is based on developmental toxicity, should be protective against reproductive toxicity 
following chronic exposure. In mice, the intermediate-duration oral NOAEL (43.4 mg boron/kg/day) and 
LOAEL (79 mg boron/kg/day) for developmental toxicity in CD-1 mice (Heindel et al. 1992) were lower
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than the chronic-duration LOAEL for testicular atrophy and decreased body weight in B6C3F1 mice 
(201 mg boron/kg/day) and overlapped with the LOAEL (79 mg boron/kg/day) for splenic hematopoiesis 
and chronic hepatic inflammation and necrosis (Dieter 1994; NTP 1987). Additional studies may be 
useful in assessing the level of confidence in existing intermediate-duration NOAEL and LOAEL values 
for developmental toxicity in rats and mice. Additional chronic-duration oral exposure studies in animals 
do not seem necessary at this time.
As discussed in the previous section, symptoms of acute upper respiratory and ocular irritation have been 
reported in workers employed in the borax industry for an average of >10 years, but pulmonary function 
variables were not significantly influenced by exposure over a 7-year period of employment (Garabrant et 
al. 1984, 1985; Hu et al. 1992; Wegman et al. 1994). These results are the basis of an acute inhalation 
MRL for boron, but do not clearly indicate whether the dose-response relationships for acute boron- 
induced upper respiratory and ocular irritation effects are changed with intermediate or chronic durations 
of exposure. Because exposure-related effects on pulmonary function variables were not evident during a 
7-year period of employment, the results provide some confidence that the acute-duration inhalation MRL 
may by protective for intermediate- and chronic-duration exposures. Additional prospective health 
evaluations of respiratory function and reproductive and developmental variables in borate mining and 
processing workers with intermediate- and chronic-duration exposures may help to better identify 
impaired respiratory function, impaired reproductive performance, and developmental effects as critical 
effects in humans from intermediate- or chronic-duration inhalation exposure to boron compounds.
The available chronic oral bioassays in rats and dogs exposed to boric acid or borax (Weir and Fisher 
1972) and mice exposed to boric acid (Dieter 1994; NTP 1987) found no evidence for exposure-related 
cancer. Although no epidemiological studies have been conducted to examine possible associations 
between boron exposure and cancer, the results from the animal studies provide no strong impetus to 
conduct such studies.
Genotoxicity. No in vivo human data were located. Bacterial and limited mammalian assays were 
negative for mutagenicity (Benson et al. 1984; Landolph 1985; Demerec et al. 1951; Haworth et al. 1983; 
NTP 1987) or cell transformation (Landolph 1985). However, the in vivo animal study of Wery et al. 
(2003) reported specific alterations in gene expression in embryos at critical points of development that 
may be associated with skeletal malformations seen in several animal species. Thus, additional in vivo 
studies may be useful to establish whether direct genetic changes or indirect factors are responsible for the 
observed changes in gene expression associated with observed skeletal effects in animals.
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Reproductive Toxicity. No associations were found between exposure to borates or boric oxide and 
indices of fertility in surveys of Turkish subpopulations expected to have intermediate- to chronic- 
duration oral exposures to boron (Sayli 1998a, 1998b, 2003; Sayli et al. 1998), or in surveys of boron 
mining and processing workers in California (Whorton et al. 1994) and China (Chang et al. 2006).
Studies of Chinese borate workers and populations living in environments with high boron exposure did 
not find effects on semen quality (Liu et al. 2006a, 2006b); however, adequate estimation magnitude or 
duration of boron exposure for each study group was not available. One study of Chinese borate workers 
associated high boron exposure with a shift toward males in the ratio the sex of offspring (Robbins et al. 
2008); however, several confounding factors in this study limit the interpretation of study data.
Effects on the male and female reproductive organs have been clearly demonstrated in rats orally exposed 
to boric acid or borax; supporting evidence for effects on the male reproductive organs from oral exposure 
to boron has been reported in mice and dogs. Testicular atrophy and histopathology, sperm abnormalities, 
and reduced sperm production have been observed in mice, rats, and dogs after intermediate-duration 
ingestion of doses >26 mg boron/kg/day as boric acid (Dieter 1994; Dixon et al. 1976, 1979; Fail et al. 
1991; Fukuda et al. 2000; Harris et al. 1992; Ku et al. 1993a; Kudo et al. 2000; Lee et al. 1978; NTP 
1987; Nusier and Bataineh 2005; Seal and Weeth 1980; Weir and Fisher 1972; Yoshizaki et al. 1999). 
Complete sterility was observed in male and female Sprague-Dawley rats fed boric acid or borax in the 
diet for 14 weeks before mating at 101 and 116 mg boron/kg/day for males and females, respectively 
(Weir and Fisher 1972). Sterility was associated with a lack of viable sperm in males and decreased 
ovulation in females, and no pregnancies occurred when female rats exposed to this dose level were 
mated with non-exposed male rats. At lower exposure levels (10 or 30 mg boron/kg/day for males and 
12 or 35 mg boron/kg/day for females), no exposure-related adverse effects were found on fertility indices 
in three successive generations (Weir and Fisher 1972). With chronic-duration oral exposure, testicular 
atrophy occurred at 201, but not 79, mg boron/kg/day in B6C3F1 mice (Dieter 1994; NTP 1987) and at 
81, but not 24, mg boron/kg/day in Sprague-Dawley rats (Weir and Fisher 1972). No testicular atrophy 
was found in dogs exposed for 2 years to dietary doses of boric acid or borax at levels up to 6.8 mg 
boron/kg/day (Weir and Fisher 1972). In the chronic-duration oral exposure studies, no histologic effects 
on the ovaries were found in rats (Weir and Fisher 1972) or mice (Dieter 1994; NTP 1987), but the 
ovaries of chronically exposed female dogs were not examined (Weir and Fisher 1972).
With inhalation exposure to boron compounds, reproductive effects do not appear to be an effect of 
concern. In intermediate-duration inhalation studies with rats, no histologic effects on the testes or 
ovaries were found in albino rats exposed to boric oxide aerosols for 6 hours/day, 5 days/week for
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10 weeks at an average concentration of 73 mg boron/m3, 12 weeks at 27 mg boron/m3, or 24 weeks at 
12 mg boron/m3 (Wilding et al. 1959).
Additional prospective health evaluations of reproductive variables in borate mining and processing 
workers with intermediate- and chronic-duration exposures may help to better identify impaired 
reproductive performance as a critical effects in humans from intermediate- or chronic-duration inhalation 
exposure to boron compounds.
Developmental Toxicity. No studies were found on the developmental effects of boron and 
compounds in humans following inhalation, oral, or dermal exposure. In acute-duration oral exposure 
animal studies, developmentally toxic effects (including reduced fetal weight and increased skeletal 
variations or malformations) have been reported in CD-1 mice exposed during gestation to boric acid 
doses as low as 70 mg boron/kg (2 times/day) (Cherrington and Chernoff 2002) and in New Zealand 
rabbits exposed during gestation (days 6-19) to doses of 44 mg boron/kg/day (Price et al. 1996b). 
Developmental effects (including decreased fetal weight, increased incidence of skeletal variations and 
malformations, and increased resorptions) have been observed in offspring of rat and mouse dams 
exposed to 13-79 mg boron/kg/day as boric acid during gestation for intermediate durations (Heindel et 
al. 1992, 1994; Price et al. 1996a). Developmental effects observed in these animal studies are the critical 
effects for the acute- and intermediate-duration oral MRLs for boron.
Developmental toxicity studies in animals exposed to boron compounds by inhalation are not available. 
Such studies may be useful to determine if developmental effects are a critical effect from inhalation 
exposure to boron compounds.
Immunotoxicity. No studies were found in humans or animals on the effects of boron on the immune 
system by any route of exposure. Results of chronic studies do not suggest that the immune system is a 
potential target for boron toxicity. Additional studies are not needed at this time.
Neurotoxicity. Case reports in humans, primarily infants, indicate that neurological effects occur after 
ingestion of boron at high dose levels (Wong et al. 1964). Degenerative changes in brain cells, 
perivascular hemorrhage, and intravascular thrombosis have been reported in fatal case reports in infants, 
but neurochemical or neurophysiological changes have not been reported (Settimi et al. 1982; Wong et al. 
1964). No studies are available on neurotoxic effects of boron following inhalation or dermal exposure in 
humans. Animal data are limited to increased brain enzyme activity (Settimi et al. 1982), but no
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histopathological data are available. Since data on effects are limited primarily to acute oral exposures at 
high dose levels, additional studies in animals evaluating other dose levels and exposure routes and 
durations may be useful in evaluating potential risk to humans who may be exposed to low levels of 
boron compounds near hazardous waste sites.
Epidemiological and Human Dosimetry Studies. Information exists on the adverse health 
effects of boron compounds in humans. Symptoms of acute upper respiratory and ocular irritation have 
been reported in workers employed in the borax industry for an average of >10 years, but pulmonary 
function variables were not significantly influenced by exposure over a 7-year period of employment 
(Garabrant et al. 1984, 1985; Hu et al. 1992; Wegman et al. 1991, 1994). More precise quantitation of the 
irritation potential of airborne boron compounds comes from controlled exposure studies of human 
volunteers (Cain et al. 2004, 2008). No associations were found between exposure to borates or boric 
oxide and indices of fertility in surveys of Turkish subpopulations expected to have intermediate- to 
chronic-duration oral exposures to boron (Sayli 1998a, 1998b, 2003; Sayli et al. 1998), or in surveys of 
boron mining and processing workers in California (Whorton et al. 1994) and China (Chang et al. 2006). 
Studies of Chinese borate workers and populations living in environments with high boron exposure did 
not find effects on semen quality (Liu et al. 2006a, 2006b). Other human studies involve case reports of 
accidental or intentional ingestion of large quantities of boron compounds (Wong et al. 1964; Litovitz et 
al. 1988; Locatelli et al. 1987). The case report studies identified key health effects (gastrointestinal, 
respiratory, renal, neurological, hepatic) associated with boron exposure (Wong et al. 1964).
Results from animal studies indicate that the testes and developing fetus as the most sensitive targets 
following acute, intermediate, or chronic oral exposure to boron. Epidemiological studies that look for 
associations between boron exposure and reproductive and/or developmental toxicity end points would be 
useful to better identify impaired reproductive performance and developmental effects as critical effects 
in humans from intermediate- or chronic-duration exposure to boron compounds.
Biomarkers of Exposure and Effect.
Exposure. Blood and urine borate concentrations may be useful biomarkers of exposure (Jansen et al. 
1984a; Litovitz et al. 1988). Normal dietary concentrations of boron in the blood of humans range from 
0 to 1.25 ^g/mL in children and infants (Fisher and Freimuth 1958; O'Sullivan and Taylor 1983).
Elevated blood levels of boron have been reported in cases of acute ingestion of boric acid (Linden et al. 
1986; Wong et al. 1964). Urinary concentrations of boron in the normal population range from 0.07 to
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0.15 mg/100 mL (Vignec and Ellis 1954) and from 0.004 to 0.66 mg/100 mL (Imbus et al. 1963), whereas 
elevated concentrations have been measured in humans orally exposed to borax or boric acid (Gordon et 
al. 1973; Jansen et al. 1984a). Additional studies of exposure levels and blood or urinary levels of boron 
in borate mining and production workers may help to better characterize quantitative relationships 
between occupational exposure levels and blood or urinary levels of boron.
Effect. The most clearly identified effects in humans exposed to boron compounds are acute respiratory 
and ocular irritation from acute inhalation exposure to boron compounds. Several other types of effects, 
including degenerative changes in brain cells, gastrointestinal irritation, degenerative liver or kidney 
lesions, and skin changes (erythema involving palms, soles, and buttocks), have been observed in some, 
but not all, cases of acute- or intermediate-duration oral poisoning with boric acid or borax. In orally 
exposed animals, effects include testicular atrophy in males and decreased ovulation in females, and 
developmental effects (fetal body weight deficits and skeletal malformations) with gestational exposure. 
None of these effects, however, are necessarily specific to boron. To date, a specific biomarker of effect 
for boron has not been developed for humans or animals.
Absorption, Distribution, Metabolism, and Excretion. Limited quantitative information is 
available on the absorption, distribution, metabolism, and elimination of boron compounds following oral 
(Dourson et al. 1998; Ku et al. 1991; Moseman 1994; Treinen and Chapin 1991), inhalation (Wilding et 
al. 1959), and dermal (Draize and Kelley 1959; Wester et al. 1998) exposure. Since data on 
toxicokinetics of boron are limited, additional studies are needed by all routes of exposure that will 
provide data on absorption rates, amount and rate of accumulation in various tissues, and clearance rates. 
Limited data from oral and dermal studies suggest that boron is primarily excreted in urine. Since boron 
can deposit in the upper respiratory tract, additional excretion studies by this route would be useful in 
determining if excretion patterns are similar across all routes of exposure.
Comparative Toxicokinetics. Existing evidence from human and animal studies do not indicate 
whether or not boron compounds affect the same target tissues. Animal studies indicate the testes as a 
target tissue (Dieter 1994; Dixon et al. 1979; Fukuda et al. 2000; Ku et al. 1993a; Kudo et al. 2000; Lee et 
al. 1978; NTP 1990; Price et al. 1998; Seal and Weeth 1980; Weir and Fisher 1972). However, studies of 
Chinese borate workers found no effect of boron exposure on multiple indices of semen quality (Lui et al. 
2006a, 2006b). Data exist on excretion of boron compounds. Based on excretion studies, boron 
compounds are absorbed by the gastrointestinal tract. There are no available quantitative toxicokinetics
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data on absorption, distribution, and metabolism. Additional toxicokinetics studies may provide a better 
basis for extrapolation of animal data to human exposure risk.
Methods for Reducing Toxic Effects. Methods for the mitigation of acute effects of boron 
poisoning include prevention of absorption of boron from the gastrointestinal tract and standard 
procedures used to prevent convulsions, severe dehydration, or shock (Stewart and McHugh 1990).
Saline diuresis, exchange transfusions, peritoneal dialysis, or hemodialysis may be employed to enhance 
removal of absorbed boron from the body (Goldfrank et al. 1990; Stewart and McHugh 1990). No 
additional information was located concerning mitigation of effects of lower-level or longer-term 
exposure to boron. Further information on techniques to mitigate such effects may be useful in 
determining the safety and effectiveness of possible methods for treating boron-exposed populations in 
the vicinity of hazardous waste sites.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above.
The comparative susceptibility of children to the acute respiratory and ocular irritation potential of 
aerosols of boric acid or other boron compounds has not been examined. Results from animal studies 
indicate that developmental effects associated with gestational exposure are the most sensitive effects 
associated with acute- or intermediate-duration oral exposures. Degenerative changes in the male (e.g., 
testicular atrophy and altered spermiation) and female (decreased ovulation) have also been identified as a 
sensitive effect from boron, but no studies were located that examined the relative susceptibility of young 
animals (or children) to these effects.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs: 
Exposures of Children.
3.12.3 Ongoing Studies
Wendie A. Robbins of the University of California Los Angeles is being funded by the NIOSH to 
perform an epidemiologic study investigating the relationship between workplace exposure to boron- 
containing compounds (including boric acid, borax) and adverse male reproductive effects. Two 




fertility or development, while one study reported positive testicular atrophy and sterility and another 
associated a shift in the ratio of offspring sex with boron exposure. All of these studies have been 
criticized for inadequacies in study design exposure assessment. The specific aims of this research are to: 
( 1) describe the relationship between boron exposure and direct measures of toxicity on male 
reproduction, (2) describe the relationship between boron exposure and indirect measures of toxicity on 
male reproduction, and (3) describe the relationship between workplace, environmental, and dietary 
sources of boron with biomarkers of exposure and reproductive effect. The goal is to contribute critical 
information on the exposure level at which boron causes adverse effects on human male reproduction.
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4. CHEMICAL AND PHYSICAL INFORMATION
4.1 CHEMICAL IDENTITY
Boron appears in Group 13 (IIIA) of the periodic table and is the only nonmetal of this group (Jansen 
2003). Table 4-1 lists common synonyms, trade names, and other pertinent information to identify boron 
and selected compounds.
4.2 PHYSICAL AND CHEMICAL PROPERTIES
Boron is a nonmetal and is typically found in nature bound to oxygen. It is never found as the free 
element (Cotton et al. 1999). Boron has two stable isotopes, 10B and nB, which are naturally present at 
19.10-20.31 and 79.69-80.90%, respectively (Jansen 2003). There are ten other known non-radioactive 
isotopes of boron (Lide 2008). Elemental boron exists in several allotropic forms (Jansen 2003). In 
addition to being an amphorous powder, boron has four crystalline forms: a-rhombohedral, 
P-rhombohedral, a-tetragonal, and P-tetragonal (Jansen 2003).
The chemical properties of boron are more similar to carbon and silicon than elements of its own group, 
although boron is more electron deficient. Boron has a high affinity for oxygen-forming borates, and 
reacts with water at temperatures above 100 °C to form boric acid and other boron compounds. The 
electron deficiency of boron does not allow conventional two-electron bonds, but rather multicenter bonds 
that are exclusively covalent (Jansen 2003; Schubert and Brotherton 2006). Boron hydrides consequently 
have structures quite different from hydrocarbons (Jansen 2003). The multi-center nature of boron allows 
the formation of a diverse array of covalent networks, rings, cages, and clusters. Boron forms strong 
covalent bonds with electronegative elements such as fluorine and oxygen (Schubert and Brotherton
2006).
Table 4-2 lists important physical and chemical properties of boron and selected compounds.
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Table 4-1. Chemical Identity of Boron and Selected Boron Compounds3
C haracteris tic Boron Boron oxide Boric acid
Synonym(s) Boron, metallic Boric anhydride; boric 
acid, anhydride; boron 
sesquioxide; boron 
trioxide; diboron trioxide; 
fused boric acid





No data No data Optiborb
Chemical formula B B2O3 B(OH)3
Chemical structure Amphorous powder, as Randomly oriented B3O3 Planar BO33- units linked by









CAS registry 7440-42-8 1303-86-2 10043-35-3
NIOSH RTECSe ED7350000 ED7900000 ED4550000




OHM/TADS No data No data No data
DOT/UN/NA/IMDG
shipping
No data No data No data
HSDB 4482 1609 1432
EINECS 231-151-2 215-125-8 233-139-2
NCI No data No data C56417
BORON 121
4. CHEMICAL AND PHYSICAL INFORMATION
Table 4-1. Chemical Identity of Boron and Selected Boron Compounds3
C haracteris tic Borax Sodium  te trabora te Boron trib rom ide




Sodium borate; sodium 
borate anhydrous; 
disodium tetraborate; 
sodium biborate; sodium 
pyroborate; boric acid, 
disodium salt




Jaikin, Pyrobor, Three 
Elephant, V-Borb
Dehybor 65b No data
Chemical formula B4Na2Q7^10H2Q Na2B4Ü 7 BBr3
Chemical structure
OH
-X i; v \HO-----B o B----- OH
B
2-
Anhydrous borates have 
polymeric assemblies of 
planar BO3 and/or 
tetrahedral BO4 units 




L  OH —1
B r  B r
Tetraborate anion in 
solutiond
Identification numbers:
CAS registry 1303-96-4 1330-43-4 10294-33-4
NIOSH RTECSe VZ2275000 ED4588000 ED7400000
EPA hazardous waste No data No data No data
EPA/OPP Pesticide 
Code
029601 011112 No data
OHM/TADS No data No data No data
DOT/UN/NA/IMDG
shipping
No data No data UN 2692; IMDG 8.1
HSDB 328 5025 327
EINECS 233-139-2 215-540-4 233-657-9
NCI No data No data No data
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Table 4-1. Chemical Identity of Boron and Selected Boron Compounds3
C haracteris tic Boron trifluoride Boron trich loride









Chemical structure F Cl
F F Cl Cl
Identification numbers:
CAS registry 7637-07-2 10294-34-5
NIOSH RTECSe ED2275000 ED1925000
EPA hazardous waste No data No data
EPA/OPP Pesticide 
Code
No data No data




UN 1008; IMDG 6.1 
(boron trifluoride); UN 
2851; IMDG 8.2 (boron 
trifluoride dihydrate)
325
UN 1741; IMDG 2.2 
326
EINECS 231-569-5 233-658-4
NCI No data No data
aAll information obtained from HSDB 2009 and ChemlDplus 2009, except where noted.
bNIOSH 2005
Jansen 2003
dCotton et al. 1999
eRTECS 2007
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/Intergovernmental Maritime Dangerous Goods Code; EINECS = European Inventory of Existing Chemical 
Substances; EPA = Environmental Protection Agency; HSDB = Hazardous Substances Data Bank; NCI = National 
Cancer Institute; NIOSH = National Institute for Occupational Safety and Health; OHM/TADS = Oil and Hazardous 
Materials/Technical Assistance Data System; RTECS = Registry of Toxic Effects of Chemical Substances
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Table 4-2. Physical and Chemical Properties of Boron and Selected Boron
Compounds3
Property Boron Boron oxide Boric acid
Molecular weight 10.811 69.620 61.833
Physical Black or dark brown powder Colorless, glassy or Colorless, transparent
description (amorphous form); clear red hexagonal crystals, 
crystals (a-rhombohedral hygroscopic 
form); black, opaque 
crystals with metallic luster 
(a-tetragonal form); black 
(ß-rhombohedral form)
crystals; white granules or 
powder
Melting point 2,075 °C 450 °C (crystal) 170.9 °C
Boiling point 4,000 °C 1,500 °C (crystal) No data
Density 2.350 g/cm3 (amorphous); 
2.46 g/cm3 
(a-rhombohedral);
2.31 g/cm3 (a-tetragonal); 
2.35 g/cm3 
(p-rhombohedral)
1.8 g/cm3 (amorphous); 
2.46 g/cm3 (crystal)
1.435 g/cm3 at 15 °C
Odor
Solubility:
No data Odorless Odorless
Water Insoluble 4.0% at 20 °C 50 g/L at 25 °C
Organic
solvent(s)
Insoluble alcohol, ether Soluble in alcohol, 
glycerol
17.5% in glycerol; 18.5% in 
ethylene glycol; 173.9 g/L in 
methanol; 94.4 g/L in ethanol; 
0.6% in acetone; 1.5% in ethyl 
acetate (all at 25 °C)
Other Soluble in concentrated 
nitric and sulfuric acids
No data No data
pKa No data No data 9.42
Log Kqw No data No data 0.175
Vapor pressure 0.0119 mm Hg at 2,140 °C Negligible at 20 °C Negligible at 20 °C
Autoignition
temperature
580 °C No data No data
Flashpoint No data No data No data
Flammability 
limits in air





No data No data No data
Explosive limits No data No data No data
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Table 4-2. Physical and Chemical Properties of Boron and Selected Boron
Compoundsa
Property Borax Sodium  te trabora te Boron trib rom ide
Molecular weight 381.373 201.220 250.52
Physical
Description
White, monoclinic crystals Colorless glassy solid; 
hygroscopic
Colorless, fuming liquid
Melting point 75 °C (decomposes) 743 °C -46.0 °C
Boiling point No data 1,575 °C (decomposes) 90 °C
Density 1.73 g/cm3 2.367 g/cm3 2.698 g/cm3 at 0 °C
Odor Odorless Odorless Sharp, irritating odor, pungent
Solubility:
Water 59.3 g/L at 25 °C 3.1% at 25 °C Decomposes in water
Organic
solvents
1 g/1 mL in glycerol; 
insoluble in alcohol
16.7% in methanol; 30% 
in ethylene glycol;
40.6 g/L in formamide (all 
at 25 °C)
Decomposes in alcohol; 
soluble in carbon 
tetrachloride, sulfur dioxide 
(liquid), carbon disulfide
Other Insoluble in acid No data No data
pKa No data No data No data
Log Kow No data No data No data
Vapor pressure Negligible Negligible at 20 °C 100 mm Hg at 33.5 °C
Autoignition
temperature
No data No data No data
Flashpoint No data No data No data
Flammability 
limits in air
Not flammable Noncombustible Nonflammable
Conversion
factors
No data No data 1 ppm=10.25 mg/m3b
Explosive limits No data No data No data
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Table 4-2. Physical and Chemical Properties of Boron and Selected Boron
Compoundsa
Property Boron trifluoride Boron trich loride
Molecular weight 67.81 117.17
Physical
Description
Colorless gas Colorless fuming liquid at low temperature
Melting point -126.8 °C -107 °C
Boiling point -101 °C 12.5 °C
Density 3.07666 g/L at 1 atm, 0 °C 1.3728 g/cm3 at 0 °C
Odor
Solubility:
Pungent, suffocating odor, irritatingc Pungent, suffocating odor, irritating, sharp
Water 332 g/100 g water at 0 °C with some 
hydrolysis forming fluoboric and boric 
acids
Decomposes in water, hydrolyzed easily
Organic
solvents
Soluble in benzene, dichlorobenzene, 
chloroform, carbon tetrachloride, carbon 
sulfide; soluble in most saturated and 
halogenated hydrocarbons and in 
aromatic compounds
Decomposes in alcohol
Other 1.94 g/100 g in anhydrous sulfuric acid, 
soluble in concentrated nitric acid
No data
pKa No data No data
Log Kow No data No data
Vapor pressure 3.656x104 mm Hg at -13.2 °C 1 mm Hg at 25 °C (extrapolated)
Autoignition
temperature
No data No data






1 ppm=2.77 mg/m3b No data
Explosive limits No data No data
aAll information from HSDB 2009, except where noted. 
bNIOSH 2009
cOdor threshold 4.50 mg/m3 (Ruth 1986)
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1 PRODUCTION
Boron is the 51st most common element found in the earth’s crust and is found at an average 
concentration of 8 mg/kg (Cotton et al. 1999; Jansen 2003). Boron is a nonmetal and is typically found in 
nature bound to oxygen. It is never found as the free element (Cotton et al. 1999). There are over 
200 minerals containing boron oxide; however, only four boron-containing minerals (borax, kernite, 
colemite, and ulexite) comprise the majority, nearly 90%, of the borates used by industry worldwide. 
These minerals are extracted mainly from California and Turkey. The majority of domestic boron 
production is from Kern County, California, with the remainder from San Bernardino and Inyo Counties 
in California (USGS 2008).
The most widely used commercial process for producing boron is the Moissan process, which involves 
the reduction of boric oxide with magnesium (Jansen 2003). This process yields 90-92% pure boron, 
which is then leached with acid to separate it from the magnesium oxide formed during the process, 
followed by multiple washes and drying. The purity of the boron can be increased to 95-97% by further 
chemical processing (Jansen 2003). Due to boron’s tendency to bind to electron-rich elements (carbon, 
nitrogen, and oxygen) it can be very difficult to isolate boron in high purity (Cotton et al. 1999). High 
purity boron (>99.9%) is prepared by the reduction of boron trihalides or by the decomposition of boron 
triiodide or boron hydrides at high temperatures. Other methods include electrolytic reduction of 
potassium tetrafluoroborate (KBF4) in molten potassium chloride-potassium fluoride mixtures. High 
purity boron can generally only be obtained in kilogram quantities (Cotton et al. 1999).
In 2005, 1.15 million metric tons of boron ore were produced in the United States, with a boron oxide 
(B2O3) content of 612,000 metric tons. Colemanite, kernite, tincal (natural borax), and ulexite were the 
most common mineral of commercial importance in the United States. Boron compounds and minerals 
are produced both by surface and underground mining, as well as from brine (USGS 2008).
Boron trifluoride is prepared by the reaction of a boron-containing material and a fluorine-containing 
substance in the presence of an acid (e.g., borax, fluorspar, and sulfuric acid) (Alam et al. 2003). It can 
also be produced by the treatment of fluorosulfonic acid with boric acid. Large-scale production of boron 
trichloride involves the reaction of chlorine with a mixture of borax and crude oil residue heated in a 
rotary kiln. On a smaller-scale, boron trichloride can be prepared by reacting chlorine and a mixture of 
boron oxide, petroleum coke, and lampblack (carbon black) in a fluidized bed. Large-scale production of
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boron tribromide involves reaction of bromine and granulated boron carbide (B4C) at 850-1,000 °C or by 
reaction of hydrogen bromide with calcium boride (CaB6) at high temperatures (Alam et al. 2003).
Tables 5-1 and 5-2 list facilities in each state that manufacture or process boron trifluoride and boron 
trichloride, respectively, as well as the intended use and the range of maximum amounts of these boron 
compounds that are stored onsite. In 2006, there were 50 and 19 reporting facilities that produced, 
processed, or used boron trifluoride and boron trichloride, respectively, in the United States. The data 
listed in Tables 5-1 and 5-2 are derived from the Toxics Release Inventory (TRI06 2008). Only certain 
types of facilities were required to report. Therefore, this is not an exhaustive list. Current U.S. 
manufacturers of boron and selected boron compounds are given in Table 5-3.
5.2 IMPORT/EXPORT
Turkey was a major import source in 2004-2007 for boric acid, supplying 55%, followed by Chile (24%), 
Bolivia (8%), Peru (5%), and other (8%) (USGS 2009). In 2008, U.S. imports of borax, boric acid, 
colemanite, and ulexite were 1x103, 65x103, 27x103, and 90x103 metric tons, respectively. In 2008, U.S. 
exports of boric acid and refined sodium borates were 260x103 and 470x103 metric tons, respectively 
(USGS 2009).
5.3 USE
In 2008, the estimated use distribution pattern for boron compounds in the United States was 74% for 
glass and ceramics, 6% for soaps and detergents and bleaches, 3% for agriculture, 3% for enamels and 
glazes, and 14% remaining for other (USGS 2009). Boric acid is used in cosmetics, pharmaceuticals, and 
toiletries. It is also used to reduce the flammability of cellulose insulation, cotton batting in mattresses, 
and wood composites. Boron oxide is incorporated into cellulose materials to inhibit combustion.
Borates are used in the manufacture of adhesives and are added to lubricants, brake fluids, metalworking 
fluids, water treatment chemicals, and fuel additives (USGS 2008).
Pesticide products containing boric acid and its sodium salts (sodium tetraborate decahydrate, sodium 
tetraborate pentahydrate, anhydrous sodium tetraborate, disodium octaborate tetrahydrate, anhydrous 
disodium octaborate, and sodium metaborate) are registered in the United States for use as insecticides, 
fungicides, and herbicides. There are 189 pesticide products registered that contain boric acid or its
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Table 5-1. Facilities that Produce, Process, or Use Boron Trifluoride
State3
N um ber of 
facilities
M inim um  
am ount on site 
in poundsb
M axim um  
am ount on site 
in poundsb Activ ities  and usesc
AL 4 1,000 99,999 2, 3, 6, 10
AR 3 1,000 99,999 2, 3, 6
DE 2 100,000 999,999 1, 4, 8
FL 3 0 99,999 6, 10
KY 2 10,000 99,999 10, 12
LA 5 0 999,999 2, 3, 10, 11
MD 2 1,000 99,999 6
NJ 2 0 9,999 6
NY 3 1,000 999,999 6
OH 1 10,000 99,999 6
OK 3 10,000 999,999 1, 3, 6
PA 8 0 999,999 6, 7, 9, 10, 12
SC 6 1,000 99,999 2, 3, 6, 12
TN 1 10,000 99,999 10
TX 13 0 999,999 2, 3, 4, 6, 9, 10, 11, 12
aPost office state abbreviations used
















Source: TRI07 2009 (Data are from 2007)
BORON 130
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-2. Facilities that Produce, Process, or Use Boron Trichloride
State3
N um ber of 
facilities
M inim um  
am ount on site 
in poundsb
M axim um  
am ount on site 
in poundsb Activ ities  and usesc
AZ 1 100 999 11, 12
CA 2 1,000 99,999 1, 2, 3, 4, 9
IN 3 10,000 999,999 6, 7, 10, 11
MA 2 1,000 9,999 2, 3, 6
MI 1 1,000 9,999 10
NM 2 100 9,999 11
NV 1 0 0 0
OH 1 1,000 9,999 6
PA 4 0 99,999 2, 4, 9
SC 2 1,000 9,999 2, 3, 6, 7, 10, 11, 12
WI 2 1,000 99,999 6
WV 1 10,000 99,999 6
aPost office state abbreviations 

















Source: TRI07 2009 (Data are from 2007)
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Table 5-3. Current U.S. Manufacturers of Boron and Selected Boron Compounds
C om pany Location
Boron
Eagle-Picher Incoroporated, Eagle-Pitcher Boron LLC Quapaw, Oklahoma
SB Boron Corporation Franklin Park, Illinois
TETRA Micronutrients Fairbury, Nebraska
Tronox Incorporated Henderson, Nevada
Boron oxide
Johnson Matthey, Inc., Alfa Aesar Ward Hill, Massachusetts
Boric acid
InCide® Technologies, Inc. Phoenix, Arizona
Searles Valley Minerals, Argus-Trona-Westend Complex Trona, California
Rio Tinto Minerals Boron, California
Sodium tetraborate pentahydrate (borax pentahydrate)
Searles Valley Minerals, Argus-Trona-Westend Complex Westend, California
Rio Tinto Minerals Boron, California
Sodium tetraborate decahydrate (borax decahydrate)
Searles Valley Minerals, Argus-Trona-Westend Complex Westend, California
Rio Tinto Minerals Boron, California
Sodium tetraborate (Borax)
Searles Valley Minerals, Argus-Trona-Westend Complex Trona, California
Westend, California
Rio Tinto Minerals Boron, California
Boron tribromide
Air Liquide America L.P., Air Liquide Electronics Division Dallas, Texas
EP Scientific Products, LLC Miami, Oklahoma
Schumacher Carlsbad, California
Boron trifluoride dihydrate
Atotech USA, Inc. Rock Hill, South Carolina
Boron trichloride
Tronox Incorporated Henderson, Nevada
Source: Stanford Research Institute (SRI 2008), except where otherwise noted. SRI reports production of 
chemicals produced in commercial quantities (defined as exceeding 5,000 pounds or $10,000 in value annually) by 
the companies listed.
BORON
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
132
sodium salt as an active ingredient. Boric acid and its sodium salts are used on several agricultural and 
many non-agricultural sites including residential, commercial, medical, veterinary, industrial, forestry, 
and food/feed handling areas. Various formulations are available, including liquids, soluble and 
emulsifiable concentrates, granulars, powders, dusts, pellets, tablets, solids, paste, baits, and crystalline 
rods (EPA 1993).
Boron halides are important industrial chemicals. Their Lewis acid properties make them useful as 
catalysts. Boron trichloride is widely used to prepare boron filaments by chemical vapor deposition 
(CVD). Much of the boron tribromide produced in the United States is used in the manufacture of 
proprietary pharmaceuticals (Alam et al. 2003).
Boron isotopes have also found several medical and analytical uses. BNCT, a biologically targeted form 
of radiotherapy, offers the potential use of the non-radioactive, stable 10B isotope for cancer imaging.
This technique may allow selective delivery of 10B to tumors and, as a result, better targeted irradiation of 
the tumor (Schubert and Brotherton 2006; Wittig et al. 2008). The measured ratio of 10B to 11B is 
frequently used as a hydrologic and geochemical tracer (Chetelat and Gaillardet 2005; Moore et al. 2008). 
The natural abundance of 10B and 11B is specific to location, making anthropogenic boron isotopic ratios 
from a mined location distinctly different than that found in most groundwater and soil ratios (Davidson 
and Bassett 1993). This allows utilization of the boron isotopic ratio to determine potential contamination 
in groundwater (Vengosh et al. 1994), river water (Chetelat and Gaillardet 2005), marine water (Xiao et 
al. 2007), and effluent (Kloppmann et al. 2008).
5.4 DISPOSAL
Boron trifluoride and boron trichloride are classified as extremely hazardous substances under the 
Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA), 
commonly known as Superfund, and the Superfund Amendments and Reauthorization Act (SARA) of 
1986 and the Emergency Planning and Community Right-to-Know Act (EPCRA), also known as Title III 
of SARA. Under CERCLA, spills or discharges into the environment of more than 500 pounds of boron 
trifluoride or boron trichloride must be reported immediately to the National Response Center (EPA 
2008b).
Boron trifluoride and boron trichloride are also regulated under the chemical accident prevention 
provisions of the Clean Air Act (CAA) amendments of 1990. Owners and operators of stationary sources
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who produce, process, handle, or store boron trifluoride in excess of 5,000 pounds are required to initiate 
specific activities to prevent and mitigate accidental releases (i.e., hazard assessment, a prevention 
program, and an emergency response program) (EPA 2008a).
Boron recycling in the United States during 2008 was insignificant (USGS 2009). No other information 
regarding disposal of boron or other boron compounds was located.
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1 OVERVIEW
Boron and boron compounds have been identified in at least 164 of the 1,689 hazardous waste sites that 
have been proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2007). However, 
the number of sites evaluated for boron and boron compounds is not known. The frequency of these sites 
can be seen in Figure 6-1. Of these sites containing boron and boron compounds, 163 are located within 
the United States and 1 is located in Guam (not shown).
Boron is the 51st most common element found in the earth’s crust and is found in an average 
concentration of 8 mg/kg (approximately 0.0008%) (Cotton et al. 1999; Jansen 2003). Boron is a 
nonmetal and is typically found in nature bound to oxygen. It is never found as the free element (Cotton 
et al. 1999). There are over 200 minerals containing boron oxide; the four most important boron- 
containing minerals are borax, kernite, colemite, and ulexite (USGS 2008). Boron is an essential 
micronutrient for most plants and there is evidence that it is also essential for animals, including humans 
(Rainey et al. 1999, 2002).
In 2008, the primary use of boron compounds in the United States was for glass and ceramics, followed 
by soaps and detergents, bleaches, agriculture, and enamels and glazes (USGS 2009). Boric acid is used 
in cosmetics, pharmaceuticals, and toiletries. It is also used to reduce the flammability of cellulose 
insulation, cotton batting in mattresses, and wood composites. Boron oxide is also incorporated into 
cellulose materials to inhibit combustion. Borates are used in the manufacture of adhesives and are added 
to lubricants, brake fluids, metalworking fluids, water treatment chemicals, and fuel additives (USGS 
2008). There are 189 pesticide products registered in the United States that contain boric acid or its 
sodium salt as an active ingredient (EPA 1993).
Borates are widespread, naturally-occurring substance found mainly as inorganic compounds in sediments 
and sedimentary rock. Boron is released to the environment slowly in low concentrations by weathering 
processes. Although few data are available quantifying boron releases from industrial sources, it is 
estimated that natural weathering releases more boron to the environment worldwide than do these 
industrial sources (Butterwick et al. 1989).
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Boron can be released from municipal sewage waste water, coal-burning power plants, copper smelters, 
and industries using boron compounds. Boron can also be released from runoff where boron-containing 
fertilizers and herbicides are used (Butterwick et al. 1989; Fox et al. 2002; Nolte 1988; Waggott 1969).
Adsorption-desorption reactions are expected to be the only significant mechanism that will influence the 
fate of boron in water (Rai et al. 1986). The extent of boron adsorption depends on the pH of the water 
and the chemical composition of the soil. The greatest adsorption is generally observed at pH 7.5­
9.0 (Keren and Mezuman 1981; Keren et al. 1981; Waggott 1969). The abundance of amorphous 
aluminum oxide in soil is the single-most important property of soil that will influence the mobility of 
boron (Bingham et al. 1971).
Rainey et al. (2002) reported mean daily intakes of boron for male and female adults to be 1.28 and
1.00 mg, respectively, from food and beverages. Daily dietary boron intakes were 0.75 mg for infants 
aged 0-6 months and 0.99 mg for infants aged 7-11 months. Daily boron intakes were 0.86 mg for 
children aged 1-3 years, 0.80 mg for children aged 4-8 years, 0.90 and 1.02 mg, respectively, for 
adolescent males aged 9-13 and 14-18 years, and 0.83 and 0.78 mg, respectively, for adolescent females 
aged 9-13 and 14-18 years.
Ingestion of boron from food (primarily fruits and vegetables) and water is the most frequent route of 
human exposure, but occupational exposures to boron dusts may be significant. Boron is also a 
component of several consumer products, including cosmetics medicines and insecticides. Populations 
residing in areas of the western United States with natural boron-rich deposits may be exposed to higher- 
than-average levels of boron.
Boron is widely distributed in surface water and groundwater. An average surface water boron 
concentration in the United States is about 0.1 mg/L (Butterwick et al. 1989; EPA 1986b), but 
concentrations vary greatly, depending on boron content of local geologic formations and anthropogenic 
sources of boron (Butterwick et al. 1989). A survey of U.S. surface waters detected boron in 98% of
1,577 samples at concentrations ranging from 0.001 to 5 mg/L (Butterwick et al. 1989). Concentrations 
of boron in tap water have been reported in a range of 0.007-0.2 mg/L in the United States, Canada, and 
England (Choi and Chen 1979; Davies 1990; Waggott 1969). In a 1987 survey of 989 public water 
supplies, boron concentrations ranged from <0.005 to >2 mg/L (NIRS 1987). Mean boron concentrations 
in soil in the United States are about 30 mg/kg, with concentrations ranging up to 300 mg/kg (Eckel and 
Langley 1988; USGS 1984).
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6.2 RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005). This is not an exhaustive list. Manufacturing and processing 
facilities are required to report information to the TRI only if  they employ 10 or more full-time 
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20-39, 4911 (limited to facilities that combust coal and/or oil for the 
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust 
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities 
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes >25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI 
chemical in a calendar year (EPA 2005).
6.2.1 Air
Estimated releases of 3,600 pounds (~1.6 metric tons) of boron trifluoride to the atmosphere from 
21 domestic manufacturing and processing facilities in 2006, accounted for about 100% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI06 2008). Estimated 
releases of 520 pounds (~0.24 metric tons) of boron trichloride to the atmosphere from five domestic 
manufacturing and processing facilities in 2006, accounted for about 100% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI06 2008). These releases for 
boron trifluoride and boron trichloride are summarized in Tables 6-1 and 6-2, respectively. There is no 
information on releases of other boron compounds to the atmosphere from manufacturing and processing 
facilities because these releases are not required to be reported (EPA 1997).
Borates are released to air from natural and industrial sources. Natural sources include oceans, volcanoes, 
and geothermal steam (Graedel 1978). Boron compounds are released from anthropogenic sources such 
as coal-fired and geothermal steam power plants, chemical plants, and rockets as well as manufacturing
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Table 6-1. Releases to the Environment from Facilities that Produce, Process, or
Use Boron Trifluoridea
Statec RFd
Reported amounts released in pounds per yearb
Aire Waterf UIg Landh Other1 On-siteJ
Total release 
Off-sitek On- and off-site
AR 1 10 0 0 0 0 10 0 10
DE 1 500 0 0 0 3,770 500 3,770 4,270
FL 1 0 0 0 0 0 0 0 0
LA 3 6 0 0 0 0 6 0 6
MD 1 55 0 0 0 0 55 0 55
NJ 1 0 0 0 0 0 0 0 0
OK 1 1,750 0 0 0 0 1,750 0 1,750
PA 3 0 0 0 0 0 0 0 0
SC 2 11 0 0 4,983 0 11 4,983 4,994
TX 7 2,306 0 0 0 0 2,306 0 2,306
Total 21 4,638 0 0 4,983 3,770 4,638 8,753 13,391
aThe TRI data should be used with caution since only certain types of facilities are required to report. This is not an
exhaustive list. Data are rounded to nearest whole number.
bData in TRI are maximum amounts released by each facility.
cPost office state abbreviations are used.
dNumber of reporting facilities.
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
and metal compounds).
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 
impoundments, other land disposal, other landfills.
Storage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs.
RF = reporting facilities; UI = underground injection
Source: TRI07 2009 (Data are from 2007)
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Table 6-2. Releases to the Environment from Facilities that Produce, Process, or
Use Boron Trichloridea
Statec RFd
Reported amounts released in pounds per yearb
Aire Waterf UIg Landh Other1 On-siteJ
Total release 
Off-sitek On- and off-site
CA 1 0 0 0 0 0 0 0 0
MA 1 0 0 0 0 0 0 0 0
NV 1 0 0 0 0 0 0 0 0
OH 1 0 0 0 0 0 0 0 0
PA 1 0 0 0 0 0 0 0 0
SC 1 35 0 0 2,422 0 2,422 35 2,422
WI 1 35 0 0 0 0 0 35 0
WV 1 0 0 0 0 0 0 0 0
Total 8 70 0 0 2,422 0 2,422 70 2,422
aThe TRI data should be used with caution since only certain types of facilities are required to report. This is not an
exhaustive list. Data are rounded to nearest whole number.
bData in TRI are maximum amounts released by each facility.
cPost office state abbreviations are used.
dNumber of reporting facilities.
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
and metal compounds).
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 
impoundments, other land disposal, other landfills.
Storage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs.
RF = reporting facilities; UI = underground injection
Source: TRI07 2009 (Data are from 2007)
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facilities producing fiberglass and other products (EPA 1987; Graedel 1978; Hollis et al. 1988; Lang et al. 
1986; Rope et al. 1988; Stokinger 1981).
Boron or boron compounds have been identified in 1 air sample collected from 1,689 current or former 
NPL hazardous waste sites where it was detected in some environmental media (HazDat 2007).
6.2.2 Water
No releases of boron trifluoride or boron trichloride to surface water were reported from 21 and 
5 domestic manufacturing and processing facilities, respectively, in 2006 (TRI06 2008). Releases for 
boron trifluoride and boron trichloride are summarized in Tables 6-1 and 6-2, respectively. There is no 
information on releases of other boron compounds to surface water from manufacturing and processing 
facilities because these releases are not required to be reported (EPA 1997).
Boron compounds are released to water in municipal sewage from perborates in detergents and in waste 
waters from coal-burning power plants, copper smelters, and industries using boron. Borate levels above 
background may be present in runoff waters from areas where boron-containing fertilizers or herbicides 
were used (Butterwick et al. 1989; Nolte 1988; Waggott 1969). An average boron concentration of 
1 mg/L was reported in sewage effluents in California (Butterwick et al. 1989). Waggott (1969) reported 
that boron concentrations in municipal sewage in a treatment plant in England ranged from 2.5 to 
6.5 mg/L, releasing between 130 and 240 kg boron/day. Matthijs et al. (1999) reported boron 
concentrations of 0.41-1.2, 0.39-0.96, and 0.44-1.0 mg/L in raw sewage, settled sewage, and effluent, 
respectively, collected in 1994 from seven Dutch sewage treatment plants. These data demonstrate that 
boron passes through the sewage treatment process virtually unchanged. Since boron cannot be degraded 
and is not substantially absorbed during processing, there is almost no removal during the sewage 
treatment process (Fox et al. 2002).
Boron is also found in water produced from coal bed natural gas produced water (Jackson and Reddy
2007), irrigation, geothermal waste water, and thermal springs (Ko9 2007) used for power generation and 
heating. In the Powder River Basin, Wyoming, boron was detected in coal natural gas waste water outfall 
and disposal ponds at 5.89-13.08 (0.064-0.14) and 7.72-15.20 ^M (0.083-0.16 mg/L), respectively 
(Jackson and Reddy 2007). In the Great Menderes Basin, Turkey, boron is brought to the surface and 
released from natural borate mineral deposits into local rivers via geothermal waste waters and crop
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irrigation canals (Ko9 2007). The hot waste waters of a geothermal power plant released into the Buyuk 
Menderes River contained approximately 25-30 mg/L boron (Akar 2007).
Boron or boron compounds have been identified in 100 groundwater and 57 surface water samples 
collected from 1,689 NPL hazardous waste sites, where it was detected in some environmental media 
(HazDat 2007).
6.2.3 Soil
Estimated releases of 1,300 pounds (~0.59 metric tons) of boron trifluoride to soil and 6 pounds 
(3 kilograms) by underground injection from 21 domestic manufacturing and processing facilities in 
2006, accounted for about 100% of the estimated total environmental releases from facilities required to 
report to the TRI (TRI06 2008). Estimated releases of 136 pounds (61.7 kg) of boron trichlorideto soil 
and 18 pounds (8.2 kilograms) by underground injection from five domestic manufacturing and 
processing facilities in 2006, accounted for about 100% of the estimated total environmental releases 
from facilities required to report to the TRI (TRI06 2008). These releases for boron trifluoride and boron 
trichloride are summarized in Tables 6-1 and 6-2, respectively. There is no information on releases of 
other boron compounds to soil or by underground injection from manufacturing and processing facilities 
because these releases are not required to be reported (EPA 1997).
Boron is naturally released to soil and water by rainfall, weathering of boron-containing minerals, 
desorption from clays, and decomposition of boron-containing organic matter. Human-made sources 
include application of boron-containing fertilizers or herbicides, application of fly ash or sewage sludge 
as a soil amendment, the use of waste water for irrigation, or land disposal of boron-containing industrial 
wastes (Butterwick et al. 1989; Hollis et al. 1988; Mumma et al. 1984; Nolte 1988; Rope et al. 1988). In 
the Great Menderes Basin, Turkey, the hot waste waters of a geothermal power plant contained high 
levels of boron (~25-30 mg/L). This water becomes part of the irrigation systems and is thus deposited in 
sediments and soils. The boron concentrations of surrounding irrigated soils before the waste water 
discharges began were 0.15 ppm (0-20 cm depth) and 0.19 ppm (80-100 cm depth), while after the 
discharges, the boron concentrations were 13.90 ppm (0-20 cm depth) and 3.66 ppm (80-100 cm depth) 
(Akar 2007). Barber et al. (2006) reported that daily loads of boron in the Boulder Creek, Colorado of 0­
55 kg/day are mostly due to the effluent of the Boulder waste water treatment plant. Mumma et al. (1984) 
reported that the boron concentration in sewage sludges from 23 U.S. cities ranged from 7.1 to
53.3 mg/kg. Landfilling or land application is a common disposal method for these sludges.
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Boron or boron compounds have been identified in 37 soil and 21 sediment samples collected from 
1,689 NPL hazardous waste sites, where it was detected in some environmental media (HazDat 2007).
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning
Boron is generally found in nature bound to oxygen and is never found as the free element (Cotton et al. 
1999). Atmospheric boron may be in the form of particulate matter or aerosols as borides, boron oxides, 
borates, boranes, organoboron compounds, trihalide boron compounds, or borazines. Borates are 
relatively soluble in water, and will probably be removed from the atmosphere by precipitation and dry 
deposition (EPA 1987). The half-life of airborne particles is usually on the order of days, depending on 
the size of the particle and atmospheric conditions (Nriagu 1979). No specific information on the fate of 
atmospheric boron was located.
Boron readily hydrolyzes in water to form the electrically neutral, weak monobasic acid, boric acid 
(H3BO3), and the monovalent ion, B(OH)4". In concentrated solutions, boron may polymerize, leading to 
the formation of complex and diverse molecular arrangements. Rai et al. (1986) concluded that because 
most environmentally relevant boron minerals are highly soluble in water, it is unlikely that mineral 
equilibria will control the fate of boron in water. Boron was found to not be significantly removed during 
the conventional treatment of waste water (Matthijs et al. 1999; Pahl et al. 2001; Waggott 1969). Boron 
may, however, be co-precipitated with aluminum, silicon, or iron to form hydroxyborate compounds on 
the surfaces of minerals (Biggar and Fireman 1960).
Waterborne boron may be adsorbed by soils and sediments. Adsorption-desorption reactions are expected 
to be the only significant mechanism that will influence the fate of boron in water (Rai et al. 1986). The 
extent of boron adsorption depends on the pH of the water and the chemical composition of the soil. The 
greatest adsorption is generally observed at pH 7.5-9.0 (Keren and Mezuman 1981; Keren et al. 1981; 
Waggott 1969). Bingham et al. (1971) concluded that the single most important property of soil that will 
influence the mobility of boron is the abundance of amorphous aluminum oxide. The extent of boron 
adsorption has also been attributed to the levels of iron oxide (Sakata 1987), and to a lesser extent, the 
organic matter present in the soil (Parks and White 1952), although other studies (Mezuman and Keren 
1981) found that the amount of organic matter present was not important.
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The adsorption of boron may not be reversible in some soils. The lack of reversibility may be the result 
of solid-phase formation on mineral surfaces (Rai et al. 1986) and/or the slow release of boron by 
diffusion from the interior of clay minerals (Griffin and Burau 1974).
Partition coefficients such as adsorption constants describe the tendency of a chemical to partition from 
water to solid phases. Adsorption constants for inorganic constituents such as boron cannot be predicted 
a priori, but must be measured for each soil-water combination. Compilations of available data for boron 
are given elsewhere (Rai et al. 1986). In general, boron adsorption will be most significant in soils that 
contain high concentrations of amorphous aluminum and iron oxides and hydroxides such as the reddish 
Ultisols in the southeastern United States.
It is unlikely that boron is bioconcentrated significantly by organisms from water. A bioconcentration 
factor (BCF) relates the concentration of a chemical in the tissues of aquatic and terrestrial animals or 
plants to the concentration of the chemical in water or soil. The BCFs of boron in marine and freshwater 
plants, fish, and invertebrates were estimated to be <100 (Thompson et al. 1972). Experimentally 
measured BCFs for fish have ranged from 52 to 198 (Tsui and McCart 1981). These BCFs suggest that 
boron is not significantly bioconcentrated.
6.3.2 Transformation and Degradation
6.3.2.1 Air
There is no information available that suggests that particulate boron compounds are transformed or 
degraded in the atmosphere. Particulate-phase boron compounds would be removed from the atmosphere 
by wet and dry deposition. Volatile boron trihalides are moisture sensitive and will hydrolyze to boric 
acid and their corresponding halogen acid (Culver et al. 1994b).
6.3.2.2 Water
As an element, boron itself cannot be degraded in the environment; however, it may undergo various 
reactions that change the form of boron (e.g., precipitation, polymerization, and acid-base reactions) 
depending on conditions such as its concentration in water and pH. In nature, boron is generally found in 
its oxygenated form (Cotton et al. 1999). In aqueous solution, boron is normally present as boric acid and
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borate ions, with the dominant form of inorganic boron in natural aqueous systems as undissociated boric 
acid (Choi and Chen 1979). Boric acid acts as an electron acceptor in aqueous solution, accepting an 
hydroxide ion from water to form (B(OH)4)- ion. In dilute solution, the favored form of boron is B(OH)4 
(Cotton et al. 1999). In more concentrated solutions (>0.1 M boric acid) and at neutral to alkaline pH (6­
11), polymeric species are formed (e.g., B3O3(OH)4", B5O6(OH)4", B3O3(OH)52-, and B4O5(OH)42-) (Choi 
and Chen 1979; Cotton et al. 1999).
6.3.2.3 Sediment and Soil
Most boron compounds are transformed to borates in soil due to the presence of moisture. Borates 
themselves are not further degraded in soil. However, borates can exist in a variety of forms in soil (see 
Section 6.2.3). Borates are removed from soils by water leaching and by assimilation by plants.
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to boron depends in part on the reliability of 
supporting analytical data from environmental samples and biological specimens. Concentrations of 
boron in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits of 
current analytical methods. In reviewing data on boron levels monitored or estimated in the environment, 
it should also be noted that the amount of chemical identified analytically is not necessarily equivalent to 
the amount that is bioavailable. The analytical methods available for monitoring boron in a variety of 
environmental media are detailed in Chapter 7.
6.4.1 Air
Boron concentrations in ambient air samples have been reported to range from <5x10-7 to 8x10-5 mg/m3, 
with an average concentration of 2x10-5 mg/m3 (Howe 1998). Bertine and Goldberg (1971) estimated that 
approximately 11,600 tons of boron are injected into the atmosphere as a component of fly ash produced 
by coal combustion, which was estimated to contain an average boron concentration of about 75 mg/kg. 
Mean dust concentrations ranging from 3.3 to 18 mg particulates/m3 were measured in air samples from 
U.S. facilities where borax was packaged and shipped (Culver et al. 1994a). Dust samples in these 
facilities were predominantly composed of various types of borates and ranged from 11.8 to 15.2% boron 
by weight.
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6.4.2 Water
Boron is widely distributed in surface water and groundwater. The average surface water boron 
concentration in the United States is about 0.1 mg/L (Butterwick et al. 1989; EPA 1986b), but 
concentrations vary greatly, depending on boron content of local geologic formations and anthropogenic 
sources of boron (Butterwick et al. 1989). A survey of U.S. surface waters detected boron in 98% of
1,577 samples at concentrations ranging from 0.001 to 5 mg/L. Mean boron concentrations calculated for 
the 15 drainage basins in the continental United States ranged from 0.019 mg/L in the Western Great 
Lakes Basin to 0.289 mg/L in the Western Gulf Basin (Butterwick et al. 1989). Mean boron 
concentration ranging from 0.28 to 7.8 mg/L were reported in samples collected during 1985-2002 from 
26 sites in the San Joaquin River, California (Hall et al. 2004). The concentration of boron in sea water is 
about 4.5 mg/L (Butterwick et al. 1989; EPA 1986b).
Several studies have measured boron concentrations in water in those areas of California with boron-rich 
deposits. Reported high boron concentrations in surface waters ranged from 15 mg/L in coastal drainage 
waters to 360 mg/L in a boron-rich lake (Butterwick et al. 1989; Deverel and Millard 1988). Mean boron 
concentration in a California river ranged from 0.30 to 0.50 mg/L over a 20-year period (Butterwick et al. 
1989). Reported boron concentrations in groundwater in the San Joaquin Valley ranged from 0.14 to 
120 mg/L with a median concentration of about 4 mg/L (Butterwick et al. 1989; Deverel and Millard
1988). Waggott (1969) reported that groundwater boron concentrations >100 mg/L are common in 
California.
Drinking water surveys generally do not report boron concentration. Concentrations of boron in tap water 
have been reported in a range of 0.007-0.2 mg/L in the United States and England (Choi and Chen 1979; 
Waggott 1969), and the National Inorganics and Radionuclides Survey completed in 1987 reported 
relatively widespread occurrence of boron in 989 public water supplies (NIRS 1987). Boron 
concentrations ranged from <0.005 to >2 mg/L, with concentrations of up to 0.4 mg/L in 90% of systems 
(NIRS 1987). A survey of 969 public water supply systems showed that 99% contained boron at 
<1 mg/L. The maximum level measured was 3.28 mg/L (McCabe et al. 1970). Davies (1990) reported 
an average boron concentration of 0.0258 mg/L in drinking water from Toronto, Canada (1978-1984).
6.4.3 Sediment and Soil
Background boron levels in U.S. soils were reported at a geometric mean concentration of 26 mg/kg with 
a maximum concentration of 300 mg/kg (Eckel and Langley 1988). Similar concentrations were reported
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in a U.S. Geological Survey report (USGS 1984), with an average boron concentration of 33 mg/kg 
(range <20-300 mg/kg) in surface soils from the conterminous United States. Mean boron 
concentrations in soil collected in the summer of 1981 from the Idaho National Engineering Laboratory 
and a reference site were 10.1 and 4.7 mg/kg dry weight, respectively (Rope et al. 1988). A geometric 
mean boron concentration of 8.98 mg/kg (range 2.90-38.0 mg/kg) was reported in soil collected from 
Aviles, northern Spain (Ordonez et al. 2003).
Boron is an essential nutrient for plants. Boron soil concentrations for optimum plant growth reportedly 
range from 0.1 to 0.5 mg/kg for several plant species (Butterwick et al. 1989).
Geometric mean boron concentration in sediment collected in 1993 and 1994 from 16 Great Lake 
embayments and riverine environments of eastern Lake Erie, southern Lake Ontario, and the Niagara 
River ranged from 0.5 to 7.9 mg/kg dry weight (Lowe and Day 2002). Boron concentrations in sediments 
collected in 1992 from the Neosho River Basin in Kansas ranged from 2 to 6.5 mg/kg dry weight (Allen 
et al. 2001).
6.4.4 Other Environmental Media
Boron concentrations in various foods are summarized in Table 6-3. Rainey et al. (1999, 2002) reported 
the highest content of boron in foods such as raisins, peanut butter, peanuts, dried fruits, and avocados 
with concentrations of 2.20, 1.45, 1.70, 1.87, and 1.22 mg/100 g food, respectively. The top two items 
that contribute to boron intake were coffee and milk, due to the volume with which they are consumed 
(Rainey et al. 1999, 2002). Hunt et al. (1991) determined boron concentrations various foods. In general, 
boron concentrations were lowest in foods such as meats, cereal and grain products, and confections, 
ranging from <0.015 mg/kg in many of these foods to 1.470 mg/kg in grape jelly. Fruits, vegetables, 
herbs, and spices contained the highest concentrations of boron, including parsley flakes (26.878 mg/kg), 
ground cinnamon (10.370 mg/kg); dried onion flakes (6.573 mg/kg), and applesauce (2.828 mg/kg). 
Meacham and Hunt (1994) studied the boron content in infant (6-11 months) foods. Foods containing 
fruit typically had the highest concentrations of boron: prunes with tapioca (2.6 mg/kg); apples with ham 
(2.5 mg/kg); applesauce with apricot (2.5 mg/kg); pears (1.9 mg/kg); and applesauce (1.8 mg/kg). Boron
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Table 6-3. Boron Levels in Food
Food item Level (^g /100  g)a





Beans, string, cooked 120
Broccoli, boiled 250
Cantaloupe, raw 180
Carrots, raw or frozen 140
Coleslaw with dressing 120
Corn, yellow, cooked 46








Peas, green, cooked 130







Coffee, from ground beans 29
Fruit-flavored drink from powder 16
Grape juice unsweetened 300
Milk, whole 18
Orange juice 72
Soft drink, cola-type 13
Tea, leaf, brewed 9
Wine, table, dry 610
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Table 6-3. Boron Levels in Food
Food item Level (^g /100  g)a
Meat/fish products
Beef and vegetable stew 120
Beef, burgers 23b
Beef vegetable soup with potato, stew type 140
Chicken breast, broiled, without skin 27
Chili con carne, with beans 170
Hamburger, with tomato and/or ketchup 51
Tuna, canned, water packed 54
Other
Beans, lima, dry cooked, fat added 370
Beans, refried 400
Bran flakes with raisins 450
Bread, white 46
Cakes 100b
Cereal, ready to eat 128b
Cookies, brownies 112b
French fries, from frozen, deep fried 110
Donuts, sweet rolls, etc. 69




Peanuts, roasted, salted 1,700
Peas, black-eyed, cooked, fat added 65
Pizza with meat, thin crust 490
Potato chips 325
Rice, white, cooked 32
Spaghetti sauce 120
Spaghetti with meat sauce 65
Tomato sauce 132b
aRainey et al. 1999 (CSFII 1989-1991), unless otherwise noted. 
bRainey et al. 2002 (CSFII 1994-1996)
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is also found in infant formula (120 ^g/L) and expressed human breast milk (10-100 ^g/L) (Hunt and 
Meacham 2001; Hunt et al. 2004, 2005; Lopez-Garcia et al. 2009).
Minoia et al. (1994) determined the concentrations of various elements in beverages available in Italy. 
Mean boron concentrations in wine, mineral water, beer, ready-to-drink-infusion of tea, and instant 
coffees were 1.164, 0.112, 0.166, 0.219, and 0.085 mg/L, respectively. In this study, it was estimated that 
beverages contributed 34% to the estimated weekly total dietary intake of 9 mg of boron (Minoia et al. 
1994). Red and white Australian wine samples that were analyzed contained boron concentrations of 
approximately 2.5 mg/L (Cozzolino et al. 2008).
Boric acid, anhydrous sodium tetraborate, and sodium tetraborate decahydrate (borax) are found in 
various commercial products including pesticides, plant foods, household cleaners, laundry detergents, 
facial creams and cleaners, shampoo, diaper rash ointments, and pet products. Typical amounts of borax 
in detergents range from 1 to 5%. Boric acid concentrations in various ant and roach pesticide products 
range from 5 to 100% (NIH 2004).
Gonzales et al. (2004) determined elements found in dust collected from homes of Native Americans in 
Zuni Pueblo, New Mexico where jewelry was produced. Surface dust samples were collected from work 
and living areas of jewelers’ homes and from control homes. A surface area of 715 cm2 was wiped at 
each location. Mean boron concentrations were found to be significantly higher in work areas 
(0.87 ^g/sample) than in living areas (0.28 ^g/sample) of homes where jewelry was made. The geometric 
mean boron concentration was 0.19 ^g/sample in living areas of homes in which no jewelry was made 
(Gonzales et al. 2004).
The geometric mean boron concentration in soft tissues of zebra mussels collected in 1993 and 1994 from 
16 Great Lake embayments and riverine environments of eastern Lake Erie, southern Lake Ontario, and 
the Niagara River ranged from 0.92 to 6.89 ^g/g dry weight (Lowe and Day 2002). Boron was not 
detected (detection limit 2-4 ^g/g dry weight) in the soft tissues of mussels collected in 1991 or in fish 
composites collected in 1990-1992 from the Neosho River Basin in Kansas (Allen et al. 2001).
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Human exposure to borates may occur through ingestion of food and water or insecticides used to control 
cockroaches, inhalation of boron-containing powders or dusts, or the use of boron from cosmetics or
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medical preparations. The most appreciable boron exposure to the general population is likely to be 
ingestion of food and to a lesser extent in water (Beyer et al. 1983; Waggott 1969). As boron is a natural 
component of the environment, individuals will have some exposure from foods and drinking water.
Dietary intakes of boron in children and adults in the United States are summarized in Table 6-4. Rainey 
et al. (1999) reported mean daily intakes of boron for male and female adults to be 1.17 and 0.96 mg/day, 
respectively (range 0.02->9 mg/day). The highest median boron intake of 1.30 mg/day was found for 
adult male vegetarians, and the lowest median boron intake of 0.72 mg/day was found for women aged 
19-30 years. Median boron intakes were higher in adult male and female vegetarians, 1.47 and 
1.29 mg/day, respectively, than for all adult males and females, 1.17 and 0.96 mg/day, respectively 
(Rainey et al. 1999). Consumption of fruits and vegetables contribute largely to boron intake in the 
human diet. An average daily intake of 1 mg was reported for boron for individuals in the United States. 
Consumption of wine may contribute an additional 3-4 mg/day of boron (Pahl et al. 2001).
Concentrations of various elements were determined in hair samples from women in two areas (acid and 
alkaline) of southern Sweden (Rosborg et al. 2003). Median boron concentrations were 281 and 
<1 mg/kg in hair samples from the acid and alkaline areas, respectively. In this study, the boron levels in 
drinking water were similar, 10.6 and 9.3 ^g/L, in the acid and alkaline areas, respectively, and the 
authors noted that drinking water did not explain the significantly higher concentrations of boron in the 
individuals living in the acid area (Rosborg et al. 2003). A mean boron concentration of 0.50 mg/kg wet 
weight was reported in lung tissue collected from 26 nonsmoking individuals, aged >50 years with no 
history of occupational exposure to elements living in Terni, central Italy (Alimonti et al. 1992). Boron 
was not detected in a national survey of human adipose tissue (EPA 1986a).
Occupational exposure to boron compounds may be higher. Workers in other industries, including 
manufacture of glass wool (Jensen 2009), fiberglass and other glass products, cleaning and laundry 
products, fertilizers, pesticides, and cosmetics, may also be exposed to boron compounds (Stokinger 
1981). Culver et al. (1994a) reported average end-of-shift boron concentrations in blood and urine of 
0.11-0.26 ^g/g and 3.16-10.72 ^g/mg creatinine, respectively, collected from workers at a facility where 
borax is packaged and shipped. Average boron concentrations in blood and urine collected Monday 
morning prior to the first shift of the week were 0.09 ^g/g and 2.75 ^g/mg creatinine, respectively 
(Culver et al. 1994a). In 2004, workers from Kuandian City, China with occupations in boron mines or 
processing plants producing borax or boric acid were monitored over a 24-hour period for boron
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Table 6-4. Dietary Boron Intake
1 9 8 9 -19 91a 1 9 9 4 -1 9 9 6 b
A ge group M ean±standard devia tion (m g/day)
School aged male and female children
4 -8  years (n=993a, 1,650b) 0.85±0.040 0.80±0.01
9-13 years (n=943a, 552b males) 0.91±0.45 0.90±0.03 (m)
(n=560b females) 0.83±0.03 (f)
14-18 years (n=759a, 446b males) 0.88±0.47 1.02±0.04 (m)
(n= 436b, females) 0.078±0.04 (f)
Adult males (>19 years ) (n=3,433a, 4,817b) 1.17±0.65 1.28±0.02
19-30 years (n=878a, 853b) 1.07±0.64 1.15±0.03
31-50 years (n=1,297a, 1,684b) 1.17±0.64 1.33±0.03
51-70 years (n=884a, 1,606b) 1.28±0.67 1.34±0.02
>70 years (n=374a, 674b) 1.19±0.61 1.25±0.03
Vegetarian (n=49a) 1.47±0.70 No data
Adult females (>19 years ) (n=4,881a, 4,536b) 0.96±0.55 1.00±0.01
19-30 years (n=1,199a, 760b) 0.86±0.55 0.87±0.03
31-50 years (n=1,734a, 1,614b) 0.96±0.55 1.00±0.02
51-70 years (n=1,220a, 1,539b) 1.05±0.55 1.11 ±0.02
>70 years (n=728a, 623b) 0.97±0.52 0.98±0.03
Vegetarian (n=130a) 1.29±1.12 No data
Pregnant women (n=130a, 70b) 1.01±0.72 1.16±0.09
aRainey et al. 1999 (CSFII 1989-1991) 
bRainey et al. 2002 (CSFII 1994-1996)
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exposure. Total daily boron measured in food, fluids, and personal air averaged 41.2 mg/day for workers 
in the boron industry, 4.3 mg/day in the surrounding community, and 2.3 mg/day for the comparison 
group. Blood, post-shift urine, and semen levels of boron determined for the boron industry workers were 
19.3, 499.2, and 793.9 mg/day, respectively while the comparison group only had 1.7, 48.0, and 
215.0 mg/day, respectively (Xing et al. 2008).
Workers in other industries, including manufacture of fiberglass and other glass products, cleaning and 
laundry products, fertilizers, pesticides, and cosmetics, may also be exposed to boron compounds 
(Stokinger 1981). Reported concentrations of borax dust in different areas of a large borax mining and 
refining plant ranged from 1.1 to 14.6 mg/m3 for total particulate (Garabrant et al. 1985) and the mean 
boric acid/boron oxide dust concentration in a boric acid manufacturing plant was 4.1 mg/m3 for total 
particulate (Garabrant et al. 1984). Mean dust concentrations ranging from 3.3 to 18 mg particulates/m3 
were measured in air samples from U.S. facilities where borax was packaged and shipped (Culver et al. 
1994a). Dust samples in these facilities were predominantly composed of various types of borates and 
ranged from 11.8 to 15.2% boron by weight. In another study of dust concentrations in air samples from 
a U.S. borax production facility, mean total dust concentrations ranged from 0.29 to 18.95 mg 
particulates/m3, with average percent boron contents in dust ranging from 5.6 to 10.1% (Woskie et al. 
1994).
NIOSH estimated that the number of workers potentially exposed to boron increased from 6,500 in the 
early 1970s (NOHS 1989) to 35,600 in the early 1980s (NOES 1989). Neither the National Occupational 
Hazard Survey (NOHS) nor the National Occupational Exposure Survey (NOES) databases contain 
information on the frequency, concentration, or duration of exposures of workers to any of the chemicals 
listed therein. These surveys provide only estimates of the number of workers potentially exposed to 
chemicals in the workplace. Sittig (1985) reports that NIOSH estimated that the numbers of workers 
potentially exposed to borax, boron oxide, and boron trifluoride are 2,490,000, 21,000, and 50,000, 
respectively.
6.6 EXPOSURES OF CHILDREN
This section focuses on exposures from conception to maturity at 18 years in humans. Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
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Children are not small adults. A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume. A child’s diet often differs from that of adults.
The developing human’s source of nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults. A child’s 
behavior and lifestyle also influence exposure. Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors. Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
Exposure to boron for children will be similar to adults and will occur primarily through the diet. As 
boron is a natural component of the environment, children, as with the general population, will have some 
exposure from foods and drinking water. Rainey et al. (2002) reported that average daily boron intakes 
ranged from 0.75 to 0.99 mg in infants and children aged 0-8 years. In adolescent males and females 
aged 9-18 years, average daily boron intakes were 0.9-1.02 and 0.78-0.83 mg, respectively. A daily 
boron intake of 1.16 mg was reported for pregnant women. Dietary intake of boron in children in the 
United States is summarized in Table 6-4. Meacham and Hunt (1994) reported a daily intake of 0.333 mg 
for infants (6-11 months) from baby foods and beverages.
Children and infants may be exposed to boric acid or its sodium salts in homes where pesticide products 
containing boric acid or its sodium salts are used. Individuals applying these products in residential 
setting should take appropriate precautions to avoid exposing children.
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
The populations living in areas of California and other western states with boron-rich geological deposits 
have potentially high exposure to boron from drinking water and locally grown foods (Butterwick et al.
1989). Individuals using boron-containing cosmetics or medicines extensively, especially on damaged 
skin, may be exposed to higher-than-normal levels of boron (Beyer et al. 1983). Workers in industries 
producing or using boron-containing materials also have potentially high exposure as noted above 
(Section 6.5). People living in the vicinity of waste sites are also at risk of higher-than-normal exposure 
levels.
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6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of boron is available. Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of boron.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
6.8.1 Identification of Data Needs
Physical and Chemical Properties. Table 4-2 summarizes many of the relevant physical and 
chemical properties of boron and selected boron compounds. There are adequate data for the physical 
and chemical properties of boron and boron compounds. No data needs are identified.
Production, Import/Export, Use, Release, and Disposal. According to the Emergency 
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA. The TRI, which contains this 
information for 2006, became available in May of 2008. This database is updated yearly and should 
provide a list of industrial production facilities and emissions.
Current data on the production volume and uses of boron and boron compounds are available and no 
further production data are necessary at this time (Alam et al. 2003; USGS 2008, 2009); however, a data 
need exists for disposal methods of boron-containing wastes.
Environmental Fate. The only quantifiable mechanism that influences the fate of boron is soil 
adsorption (Rai et al. 1986). A data need exists for the adsorption and mobility of boron in soils low in 
aluminum oxide, since aluminum oxide content of soils is an important property of soil that will influence 
the mobility of boron (Bingham et al. 1971).
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Bioavailability from Environmental Media. Boron compounds can be absorbed following 
inhalation of contaminated workplace air, ingestion of contaminated food, or through damaged skin 
(Draize and Kelley 1959; Wong et al. 1964). The most significant routes of exposure near hazardous 
waste sites are likely to be through drinking boron-contaminated water and ingestion of locally grown 
food (Beyer et al. 1983; Butterwick et al. 1989). A data need exists for the amount of boron that is 
bioavailable from environmentally relevant media, such as drinking water, food, and soil.
Food Chain Bioaccumulation. Only one study was located where boron bioconcentration was 
actually measured (Tsui and McCart 1981). Future research may be helpful, but it appears that boron is 
not significantly bioconcentrated. There are no data on the biomagnification of boron in the food chain, 
but it is not likely that bioaccumulation is a major environmental concern. Therefore, there are no data 
needs at this time.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of boron in 
contaminated media at hazardous waste sites are needed so that the information obtained on levels of 
boron in the environment can be used in combination with the known body burden of boron to assess the 
potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites.
Data on boron levels in surface water and soil are available (Butterwick et al. 1989; Eckel and Langley 
1988; EPA 1986b; Hall et al. 2004; Ordonez et al. 2003; Rope et al. 1988; USGS 1984). Data on boron 
concentration in drinking water are limited (Choi and Chen 1979; Davies 1990; McCabe et al. 1970;
NIRS 1987; Waggott 1969). Boron concentrations in foods and beverages have been reported (Hunt et al. 
1991; Minoia et al. 1994; Rainey et al. 1999, 2002). Additional data on boron concentrations in air and 
food, and more recent data on boron concentrations in drinking water would be useful in estimating the 
exposure of humans to boron.
Exposure Levels in Humans. Background levels of boron in human blood, urine, and hair have 
been reported (Alimonti et al. 1992; Culver et al. 1994a; Rosborg et al. 2003; Stokinger 1981).
Additional data on blood and/or urine concentrations in individuals with potentially high exposure to 
boron would be useful in assessing the magnitude of human exposure.
This information is necessary for assessing the need to conduct health studies on these populations.
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Exposures of Children. Children are exposed to boron by the same routes as adults. Rainey et al. 
(2002) reported daily boron intakes of 0.75 and 0.99 mg for infants aged 0-6 and 7-11 months 
respectively. In children, 0.86 and 0.80 mg daily boron intakes were reported for 1-3 and 4-8 year olds, 
respectively. In male adolescents, 0.90 and 1.02 mg were reported for 9-13 and 14-18 year olds, 
respectively. In female adolescents, 0.83 and 0.78 mg were reported for 9-13 and 14-18 year olds, 
respectively. Meacham and Hunt (1994) reported a daily intake of 0.333 mg for infants (6-11 months) 
from baby foods and beverages. There do not appear to be any childhood-specific means to decrease 
exposure to boron.
Boron intake from infant food was estimated to supply 47% of the 0.55 mg of daily boron to infants aged 
6-11 months and toddlers aged 2 years 0.54 mg; 38% from fruits and juices and 19% from milk and 
cheese (Hunt and Meacham 2001). Children may also be exposed to boron by breastfeeding mothers. 
Boron has been detected in breast milk with concentrations ranging from 10 to 100 ^g/L, although higher 
levels have been found in infant formulas (120 ^g/L) and whole cow milk (280 ^g/L) (Lopez-Garcia et al. 
2009). Another study from St. John’s, Newfoundland measured boron concentrations of lactating 
mothers’ milk for full-term infants to be 30 and 28 ^g/L at 1 and 12 weeks postpartum, respectively. In 
lactating mothers’ milk for preterm infants boron concentrations were found to be 37 and 27 ^g/L at 
1 and 12 weeks, respectively (Hunt et al. 2004). The concentration of boron was determined in archived 
milk collected (1980-1984) from lactating mothers of full-term, exclusively breastfed infants living in 
Houston, Texas. The results indicated that infants were supplied average concentrations of 42±6.5 ^g/L 
at 1 month old and 35±6.5 ^g/L at 4 months old via breast milk (Hunt et al 2005). Hunt et al. (2004, 
2005) indicated that boron concentrations over the first 4 months of lactating did not vary widely and 
were stable over time. The highest concentrations of boron detected in each study were 88 ^g/L (Hunt et 
al. 2005) and 100 ^g/L (Hunt et al. 2004).
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data 
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for boron were located. This substance is not currently 
one of the compounds for which a sub-registry has been established in the National Exposure Registry. 
The substance will be considered in the future when chemical selection is made for sub-registries to be 
established. The information that is amassed in the National Exposure Registry facilitates the 
epidemiological research needed to assess adverse health outcomes that may be related to exposure to this 
substance.
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6.8.2 Ongoing Studies
Ongoing studies pertaining to boron or boron compounds were identified in a search of the Federal 
Research in Progress database (FEDRIP 2009). A large comprehensive study on boron by C. Hunt at the 
United States Department of Agriculture in Grand Forks, North Dakota is collecting and analyzing dietary 
data and biochemical indices aimed at enhancing the quality of life through establishing mineral intakes, 
which support optimal bone health as well as general micronutrient roles in physiology and health.
D. Evans at Columbia University Health Sciences, New York, New York is sponsored by the Institute of 
Environmental Health Sciences to investigate the use of low-toxicity pesticides such as baits, gels, and 
boric acid. The USDA Water Management Research Unit in Parlier, California is attempting to develop 
strategies for sustainable agronomic systems for water reuse and bioremediation of soils impacted by the 
use of saline water containing high concentrations of boron and trace elements. B. Hoenisch at Colombia 
University is funded by the National Science Foundation to investigate validation of the boron/calcium 




The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring boron, its metabolites, and other biomarkers of exposure and effect to 
boron. The intent is not to provide an exhaustive list of analytical methods. Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis. Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH). Other 
methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision.
7.1 BIOLOGICAL MATERIALS
Methods for the determination of boron in biological materials are summarized in Table 7-1. Methods for 
the determination of boron in samples of toxicological interest have been summarized (Stokinger 1981; 
Van Ormer 1975). Total boron is usually determined after the material is digested or ashed. No 
techniques are available to quantitatively analyze for specific boron compounds in biological matrices 
(Culver et al. 1994a). The most common analytical procedure to analyze boron in biological materials 
involves digestion of the sample in hot acid or base, followed by analysis of the resulting solution by 
inductively coupled plasma-atomic emission spectrometry (ICP-AES) (Culver et al. 2001).
Goulle et al. (2005) assessed inductively coupled plasma-mass spectrometry (ICP-MS) for detecting 
metals and metalloids in whole blood, plasma, urine, and hair. ICP-MS is a fast, sensitive method that 
requires a small sample size. Analysis required 0.4 mL of blood, plasma, or urine and 25 mg of hair. 
Usuda et al. (1998) noted that boron levels in urine can be influenced by dietary intake of boron and 
recommended that the intake of large amounts of boron-rich foods or drinks should be avoided if the 
boron status is being evaluated for possible environmental- or labor-related exposure. Xing et al (2008) 
suggested that creatinine-corrected, post-shift urine boron concentration can be used as a biomarker of 
human boron exposure in worker populations when monitored by ICP-MS.
Colorimetric analysis can also be used to determine boron concentrations in biological samples; however, 
colorimetric procedures are more time-consuming and require more laboratory care and technical skill
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Table 7-1. Analytical Methods for Determining Boron in Biological Materials
S am ple m atrix Preparation m ethod
Analytica l
m ethod
S am ple detection Percent 
lim it recovery R eference
Urine Dilution; direct analysis ICP-AES 6.24 pg/L 100.8­
104.2%




Dilution with purified 
water, acid, buffer, and 
butanol
ICP-MS 1.33 pg/L (blood) 
1.26 pg/L (plasma) 
0.25 pg/L (urine)
No data Goullé et al. 
2005
Hair Mineralization after 
decontamination with 
water/acetone
ICP-MS 0.14 ng/mg No data Goullé et al. 
2005





















ICP-AES = inductively coupled plasma-atomic emission spectroscopy; ICP-MS = inductively coupled plasma-mass 
spectrometry
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(Culver et al. 2001). Spectrophotometric methods suffer from interferences from other elements (e.g., Al, 
Cu, Fe, Zn, and Mo), as well as pH (Sah and Brown 1997).
Neutron activation analysis (NAA) is another analytical technique used to determine boron in biological 
samples. In NAA, the sample is bombarded with neutrons, and the element of interest is made 
radioactive. The amount of the element present in the sample is then determined by measurement of the 
radioactivity or radioactive decay products. This process involves 10B, which is a naturally occurring, 
stable isotope of boron that occurs with about 20% abundance. When 10B is bombarded with neutrons, it 
does not become radioactive, but results in a neutron-capture reaction, resulting in the emission of a 
a-particle and y-photon. NAA methods for boron determination are based on the measurement of one of 
more of the products (a-particle and y-photon), using techniques such as neutron activation mass 
spectrometry (NA-MS) or prompt y-ray spectroscopy. An advantage of NAA is that it is a nondestructive 
method. However, the requirements of a neutron source and the abundance of 10B restrict its use (Culver 
et al. 2001; Sah and Brown 1997).
7.2 ENVIRONMENTAL SAMPLES
Methods for the determination of boron in environmental samples are summarized in Table 7-2.
Boron is readily measured in multielement analyses of air, water, and solid waste samples by ICP-AES 
atomic emission spectroscopy, the method of choice for the determination of boron in modern practice. 
Although not multielement procedures, colorimetric cucumin and colorimetric carmine methods are still 
reliable methods for the determination of boron in water, air, and solid waste samples (APHA 1998b; 
1998c; EPA 1983). These colorimetric procedures provide adequate methods when ICP instrumentation 
is not available. Alkali fusion or wet digestion with hydrofluoric acid or a mixture of hydrofluoric acid 
and other acids are used to digest soils and other geological and silica-rich materials (Sah and Brown 
1997). A highly sensitive and selective method for determining boron at ng/dm3 levels was developed by 
Takahashi et al. (2008) by derivatization reaction of boron with reversed-phase partition high­
performance liquid chromatography (HPLC) separation and ultraviolet spectrophotometric detection. A 
detection limit as low as 22 ng/dm3 was achieved without any preconcentration. No significant 
interference was observed in the determination of 16 ^mol/dm3 of boron with the addition of nine metal 
ions (Al3+, CuI2+, Co2+, Fe2+, Fe3+, Ni2+, Mn2+, V5+, and Zn2+) at concentrations 100 times greater than that 




Table 7-2. Analytical Methods for Determining Boron in Environmental Samples
Sam ple
m atrix Preparation m ethod
Analytica l S am ple Percent











Collection on filter, hot NIOSH
block/HCl/HNO3 digestion Method 7303
followed by dilution with water ICP-AES
Collection on filter, ashed, NIOSH
suspended in 2-propanol, Method 7506
redeposited on silver X-ray powder
membrane filter diffraction
A known volume of air is OSHA
drawn through a solution of Method
ammonium fluoride; ID216SG
fluoroborate ion is measured Fluoroborate
using an ion specific electrode ion specific
electrode
Acidify, inject





10 pg or 
0.4 pg/mL of 
solution
Direct analysis
























No data NIOSH 1994







0.1-1.0 mg/L 22.8% 
(optimal range) RSD
b







Water, Aqueous and solid matrices
sediments, require acid digestion prior to
solid wastes, analysis; pre-filtered, acidified 
sludges groundwater samples do not
need acid digestion
Water Direct analysis
Aquatic Nitric acid digestion followed





3.8 pg/L No data EPA 2000
USGS-NWQL Applicable 
Method I- range: 10­
1114 DCP- 1,000 pg/L
AES








Table 7-2. Analytical Methods for Determining Boron in Environmental Samples
Sam ple
m atrix Preparation m ethod
Analytica l
m ethod
S am ple Percent 
detection lim it recovery R eference














0.5 jg /L 70-103% USGS 1999




13 jg /L 98%
(average)
USGS 1998
aPercent recovery and relative standard deviation were reported by NEMI (2007). 
bSame method as APHA (1998b).
APHA = American Public Health Association; DCP = direct current plasma; EPA = U.S. Environmental Protection 
Agency; ICP-AES = inductively coupled plasma-atomic emission spectroscopy; ICP-OES = inductively coupled 
plasma-optical emission spectroscopy; NIOSH = National Institute for Occupational Safety and Health;
NWQL = National W ater Quality Laboratory; OSHA = Occupational Safety and Health Administration; RSD = relative 




Anthropogenic-derived boron concentrations can be effectively distinguished by the the measurement of 
the 10B to nB isotopic ratio (Chetelat and Gaillardet 2005; Moore et al. 2008). The natural abundance of 
10B and 11B is specific to location, making anthropogenic boron isotopic ratios distinctly different than 
groundwater (Davidson and Bassett 1993). This allows utilization of the boron isotopic ratio to determine 
potential contamination in groundwater (Vengosh et al. 1994), river water (Chetelat and Gaillardet 2005), 
marine water (Xiao et al. 2007), and effluent (Kloppmann et al. 2008).
7.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of boron is available. Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of boron.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification of Data Needs
Analytical methods are available and are adequately sensitive to detect boron in biological materials (e.g., 
blood and urine) and in environmental samples (e.g., water, sediments, and air). No data needs are 
identified at this time.
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Methods for Determining Biomarkers of Exposure and Effect.
Exposure. Boron can be determined sensitively and selectively by ICP-AES and ICP-MS in urine and 
blood (Goulle et al. 2005; Sah and Brown 1997; Usuda et al. 1998). Analytical methods with satisfactory 
sensitivity and precision are available to determine levels of boron in human tissues and body fluids.
Effect. Existing methods are sensitive enough to measure background levels for boron in the population 
and levels at which biological effects occur.
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. ICP-AES is a satisfactory multielement method available for the determination of boron in 
water, air, and solid waste samples (APHA 1998a; EPA 1994; 2000; NIOSH 2003; USGS 1989, 1996a, 
1996b, 1999). Colorimetric procedures are as sensitive and precise, but are more labor intensive. 
Colorimetric procedures do provide adequate methods for those laboratories that do not have ICP 
instrumentation. An alternative method to the expensive and highly skill-dependent ICP-MS has been 
developed by boron derivatization and analysis by standard reverse-phase HPLC without sacrificing 
sensitivity (Takahashi et al. 2008).
Sampling methodologies for very low level elemental substances like boron continue to pose problems 
such as nonrepresentative samples, insufficient sample volumes, contamination, and labor-intensive, 
tedious extraction and purification procedures (Green and Le Pape 1987).
7.3.2 Ongoing Studies
No ongoing studies pertaining to analytical methods for boron were identified in a search of the Federal 
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8. REGULATIONS, ADVISORIES, AND GUIDELINES
MRLs are substance specific estimates, which are intended to serve as screening levels, are used by 
ATSDR health assessors and other responders to identify contaminants and potential health effects that 
may be of concern at hazardous waste sites.
ATSDR has derived an acute-duration inhalation MRL of 0.3 mg boron/m3 for boron. This MRL is based 
on a NOAEL of 0.8 mg boron/m3 for significantly increased nasal secretions in volunteers (Cain et al. 
2004) and an uncertainty factor of 3 (1005 for human variability in the pharmacodynamic response to 
boron).
ATSDR has derived an acute-duration oral MRL of 0.2 mg boron/kg/day for boron. This MRL is based 
on a NOAEL of 22 mg boron/kg/day associated with a LOAEL of 44 mg boron/kg/day for increased 
incidence of external, visceral, and cardiovascular malformations and reduced body weight in the fetuses 
of rabbits administered boric acid via gavage on gestation days 6-19 (Price et al. 1996b) and an 
uncertainty factor of 100 (10 for interspecies extrapolation and 10 for human variability).
ATSDR has derived an intermediate-duration oral MRL of 0.2 mg boron/kg/day for boron. This MRL is 
based on a BMDL05 of 10.3 mg boron/kg/day estimated from fetal body weight data from two studies in 
which pregnant rats were exposed to boron in the diet on gestation days 0-20 (Heindel et al. 1992; Price 
et al. 1996a) and chemical-specific uncertainty factor of 66 (3.3 for toxicokinetic extrapolation from 
animals to humans, 3.16 for toxicodynamic extrapolation from animals to humans, 2.0 for variability in 
human toxicokinetics, and 3.16 for variability in human toxicodynamics).
EPA has established an oral reference dose (RfD) of 0.2 mg/kg/day based on decreased fetal weight in a 
developmental study in Sprague-Dawley rats orally exposed to boric acid from gestation days 0 to 
20 (IRIS 2007). EPA has not established an inhalation reference concentration (RfC) for boron and 
compounds.
Under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), boron oxide, boric acid, borax, 
and sodium tetraborate are exempt from tolerances for pesticide chemicals in food (EPA 2007b); they are 
also listed as inerts of unknown toxicity (List 3) in EPA’s Categorized List of Inert Pesticide Ingredients 
(EPA 2004).
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The international and national regulations, advisories, and guidelines regarding boron in air, water, and 
other media are summarized in Table 8-1.
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Table 8-1. Regulations, Advisories and Guidelines Applicable to Boron and
Boron Compounds
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Regulated toxic substances and threshold 
quantities for accidental release prevention 






Boron oxide (10-hour TWA)
Boron tribromide (ceiling)
Boron trifluoride (ceiling)







PEL for general industry
Boron oxide, total dust (8-hour TWA)
Boron trifluoride (ceiling)
PEL for shipyard industry
Boron oxide, total dust (8-hour TWA)
Boron tribromide (8-hour TWA)
Boron trifluoride (ceiling)
PEL for construction industry
Boron oxide, total dust (8-hour TWA)
Boron tribromide (8-hour TWA)
Boron trifluoride (ceiling)
Threshold quantity of highly hazardous 
chemicals, toxics, and reactives
Boron trichloride 2,500 pounds
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Table 8-1. Regulations, Advisories and Guidelines Applicable to Boron and
Boron Compounds
Agency Description Inform ation Reference
NATIONAL (cont.)
NTP Carcinogenicity classification No data NTP 2005
aProvisional guideline value because calculated guideline value is below the level that can be achieved 
through practical treatment methods, source protection, etc.
bERPG-1 is the maximum airborne concentration below which nearly all individuals could be exposed for up to 1 hour 
without experiencing other than mild, transient health effects; ERPG-2 is the maximum airborne concentration below 
which nearly all individuals could be exposed for up to 1 hour without experiencing irreversible or other serious 
adverse effects; and ERPG-3 is the maximum airborne concentration below which nearly all individuals could be 
exposed for up to 1 hour without life-threatening health effects (AIHA 1999).
cAEGL-1 is the airborne concentration of a substance above which it is predicted that the general population, 
including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic nonsensory 
effects; AEGL-2 is the airborne concentration of a substance above which it is predicted that the general population, 
including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects or 
an impaired ability to escape; and AEGL-3 is the airborne concentration of a substance above which it is predicted 
that the general population, including susceptible individuals, could experience life-threatening health effects or death 
(EPA 2007c).
List 3: inerts of unknown toxicity
eThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 
additives or listed or affirmed as GRAS. 
fA4: not classifiable as a human carcinogen
gData are inadequate for an assessment of human carcinogenic potential.
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = Acute Exposure Guideline Levels; 
AIHA = American Industrial Hygiene Association; CFR = Code of Federal Regulations; DWEL = drinking water 
equivalent level; EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency; 
ERPG = Emergency Response Planning Guidelines; FDA = Food and Drug Administration; FR = Federal Register; 
GRAS = Generally Recognized As Safe; IARC = International Agency for Research on Cancer; IDLH = immediately 
dangerous to life or health; IRIS = Integrated Risk Information System; NIOSH = National Institute for Occupational 
Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration;
PEL = permissible exposure limit; REL = recommended exposure limit; RfC = inhalation reference concentration;
RfD = oral reference dose; STEL = short-term expsoure limit; TLV = threshold limit values; TWA = time-weighted 
average; WHO = World Health Organization
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment.
Benchmark Dose (BMD)—The dose expected to result in a specified change of a biological effect (the 
benchmark response, or BMR), generally 1% to 10% from the untreated population. The BMD is 
determined by modeling the dose response data in the region of the dose response relationship where 
biologically observable data are feasible.
Benchmark Dose, Lower Limit (BMDL)—The lower confidence limit on the benchmark dose. For 
example, a BMDL10 would be the dose at the 95% lower confidence limit on a 10% response, and the 
benchmark response (BMR) would be 10%.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD.
Bioconcentration F actor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals). In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure. These may suggest 
some potential topics for scientific research, but are not actual research studies.
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Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome. At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs— Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point 
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero 
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information. A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects.
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Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals.
Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period.
Intermediate Exposure—Exposure to a chemical for a duration of 15-364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal C oncentration^) (LClo)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals.
Lethal Concentration^) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying F actor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1.





Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
Mutagen—A substance that causes mutations. A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control. Effects may be produced at this dose, but they are not 
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in «-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system. There are two types of pharmacokinetic models: data-based 
and physiologically-based. A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose- 
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 




Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows. These models require a 
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters. PBPK models are also 
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time.
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study. A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure. The qi* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually ^g/L for water, mg/kg/day for food, and 
^g/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime. 
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime. The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical. The RfDs are not applicable to 
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related 
endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system.
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Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past. Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may 
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
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Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest- 
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1 (see for example, Dourson, 1994).
Xenobiotic—Any chemical that is foreign to the biological system.
10. GLOSSARY
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APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99­
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance. During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or 
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects. MRLs are derived for acute (1-14 days), intermediate (15-364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level 
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that
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are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public. They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels. For additional information 
regarding MRLs, please contact the Division of Toxicology and Environmental Medicine, Agency for 
















Final Draft Post-Public Comment
[X] Inhalation [ ] Oral
[X] Acute [ ] Intermediate [ ] Chronic
2
Human
Minimal Risk Level: 0.3 [X] mg/m3 [ ] ppm
Reference: Cain WS, Jalowayski AA, Kleinman M, et al. 2004. Sensory and associated reactions to 
mineral dusts: Sodium borate, calcium oxide, and calcium sulfate. J Occup Environ Hyg 1:222-236.
Cain WS, Jalowayski AA, Schmidt R, et al. 2008. Chemesthetic responses to airborne mineral dusts: 
boric acid compared to alkaline materials. Int Arch Occup Environ Health 81:337-345.
Experimental design: Male and female volunteers were trained to recognize the difference in 
chemesthetic feel (pungency or irritancy) of various levels of CO2 offered to the eyes, nose, and throat. 
Exposures of >17.7% CO2 resulted in a “feel” described by the volunteers as irritating. Twelve male 
volunteers were exposed to 0, 0.8, 1.5, 3.0, 4.5, or 6.0 mg boron/m3 (0, 5, 10, 20, 30, or 40 mg sodium 
borate pentahydrate/m3) for 20 minutes while performing light exercise (Cain et al. 2004). At 5-minute 
intervals, they reported the magnitude of “feel” of borate dust in terms of equivalent CO2 irritancy. They 
were also observed for changes in nasal secretions (by mass) and nasal airway resistance relative to pre­
exposure measurements. Data were reported as means of all responses at each concentration and time 
point.
In a similar fashion, six male and six female volunteers were exposed to 1.5 mg boron/m3 (10 mg sodium 
borate/m3) or 1.8 mg boron/m3 (10 mg boric acid/m3) for 47 minutes while exercising. They reported the 
magnitude of “feel” of boric acid and borate dusts in terms of equivalent CO2 irritancy. They were also 
observed for changes in nasal secretions (by mass), nasal airway resistance, and respiration frequency.
Effects noted in study and corresponding doses: Male volunteers exposed to <3.0 mg boron/m3 (<20 mg 
sodium borate/m3) for 20 minutes reported increasingly higher magnitude of feel of the dust in eyes, nose, 
and throat. However, the mean reported level of feel, compared to equivalent CO2 levels, was not 
considered irritating by the study subjects. The mean reported perception of feel at >4.5 mg boron/m 
(>30 sodium borate/m3) was reported to feel irritating to the nose (Cain et al. 2004). Significantly 
increased nasal secretions (by mass) occurred at 1.5 mg boron/m3 (10 mg sodium borate/m3), but not 
0.8 mg boron/m3 (5 mg sodium borate/m3) (Cain et al. 2004). Similarly, male and female volunteers 
exposed to 1.5 mg boron/m3 (10 mg sodium borate/m3) or 1.8 mg boron/m3 (10 mg boric acid/m3) for 
47 minutes while exercising reported a mean sense of feel that initially increased and peaked at the 
equivalent of slightly <17.7% CO2. Boron exposures with a mean reported feel equivalent to less than 
17.7% CO2 are considered non-irritating, although increases in nasal secretions were observed at 1.8 mg 
boron/mg3 (10 mg boric acid/m3), but not at 0.9 mg boron/mg3 (5 mg boric acid/m3) (Cain et al. 2008). 
Nasal airway resistance decreased, then increased, as a result of exercise, but did not change in a dose- 
related manner.
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Dose and end point used for MRL derivation: A NOAEL of 0.8 mg/m3 associated with a minimal 
LOAEL of 1.5 mg/m3 for significantly increased volume of nasal secretions.
[ X] NOAEL [ ] LOAEL
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL 
[ ] 10 for extrapolation from animals to humans 
[X] 3 for human variability
Was a conversion used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: 
Not applicable.
Other additional studies or pertinent information that lend support to this MRL: In an early cross­
sectional study of sodium borate workers, past occurrence of symptoms of respiratory irritation such as 
dryness of the mouth, nose, or throat, dry cough, nose bleeds, and sore throat were reported at elevated 
frequencies in workers in areas with mean dust concentrations of 8.4 and 14.6 mg particulates/m3 (1.8 and
3.1 mg boron/m3, respectively), compared with workers in areas with lower mean dust levels of 4.0 and
1.1 mg particulate/m3 (0.9 and 0.2 mg boron/m3) (Garabrant et al. 1984, 1985). In addition, a reduction in 
forced expiratory volume in 1 second (FEV1) was measured in a subgroup of smoking workers with 
estimated high cumulative exposure (>80 mg particulate/m3, >9 mg boron/m3) to sodium borate dusts, but 
not in groups of less-exposed smoking workers or in nonsmoking workers. However, a subsequent 
survey of FEV1 in 303 of the original 629 borax workers, 7 years after the original survey, found no 
exposure-related changes in FEV1 over this period, when adjustments were made for the effects of age, 
height, and smoking on FEV1 (Wegman et al. 1994). Acute-duration laboratory exposures of volunteers 
to sodium borate dust support the findings of respiratory irritation reported in the occupational studies.
The occurrence of acute respiratory symptoms as a possible consequence of acute exposure to dusts of 
sodium borate (the decahydrate, pentahydrate, and anhydrous tetraborates) was studied in a later study by 
interviewing workers about acute irritation symptoms before the work shift began and at regular hourly 
intervals during the work shift, and by measuring personal air concentrations of particulates at concurrent 
intervals for 4 consecutive days (Hu et al. 1992; Wegman et al. 1991, 1994). Seventy-nine exposed 
production workers and 27 nonexposed workers were included in the study. In the latest analysis of the 
collected data, the incidence rates for irritation symptoms in exposed workers were statistically 
significantly higher than those in nonexposed workers, with exposed workers 9-, 5-, and 3-fold more 
likely to report incidents of nasal, eye, and throat irritation, respectively, than comparison workers (Hu et 
al. 1992; Wegman et al. 1991, 1994). For the unexposed groups, the arithmetic means of the 6-hour 
TWA daily dust concentration was 0.45 mg particulates/m3 (0.02 mg boron/m3), with 100% of samples 
<1.0 mg particulates/m3 and about 90% of samples <0.5 mg particulates/m3. The arithmetic mean of the 
6-hour TWA daily dust concentrations for the exposed group was 5.72 mg particulates/m3 (0.44 mg 
boron/m3), with a majority of air concentrations between 1.0 and 10.0 mg particulates/m3 (Wegman et al. 
1991, 1994). Several factors make it difficult to identify a NOAEL or LOAEL for this study, precluding 
inclusion of this study in Figure and Table 3-1. Study participants rated their perception of individual 
episodes of eye, throat, and nasal irritancy on a scale of 0 (not at all) to 10 (very, very much), with ratings 
of 1, 2, and 3 representing “very little”, “fairly little”, and “moderate” irritation, respectively. Unexposed 
responders to the pre-shift survey reported a mean rating of 1.9 for all symptoms, while the mean rating 
for nasal irritation (the most commonly reported effect) among exposed workers was just slightly higher 
at 2.2. Thus, the cutoff for boron dust-induced effects is likely to be for ratings of >3. In the exposed
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group, 91% of reported symptoms were rated with severity scores <3 and 96% of symptoms were rated 
with severity scores of <4 (“pretty much”). For incidences in which the workers depressed a counter 
button to record time of symptom onset, and the study surveyor recorded an occurrence of effect, the 
probability of reporting an effect did not change markedly until 0.25-hour TWA exposure levels reached 
0.8-1.2 mg boron/m3 (Wegman et al. 1991). There was no significant difference in reporting of 
symptoms based on the type of borate dust, which differ in boron content by almost a factor of two (i.e.,
4.7 mg anhydrous borax/m3 and 8.8 mg/m3 of the decahydrate provide 1 mg boron/m3). Finally, the data 
do not indicate a temporal increase in effect intensity, as would be expected for a local irritant.
An uncertainty factor of 3 for human variability was based on the fact that inhaled borates and boric acid 
exert their adverse effects on respiratory tract tissues as portal-of-entry irritants. For portal-of-entry 
inhalation toxicants, the variability between humans in pharmacokinetics (i.e., toxicant deposition in the 
respiratory tract) is minimal. Thus, half (1005, or 3) of the composite uncertainty factor for 
pharmacokinetic and pharmacodynamic variability in humans should be applied to the identified NOAEL.
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[ ] Inhalation [X] Oral




Minimal Risk Level: 0.2 [X] mg/kg/day [ ] ppm
Reference: Price CJ, Marr MC, Myers CB, et al. 1996b. The developmental toxicity of boric acid in 
rabbits. Fundam Appl Toxicol 34:176-187.
Heindel JJ, Price CJ, Schwetz BA. 1994. The developmental toxicity of boric acid in mice, rats, and 
rabbits. Environ Health Perspect Suppl 102(7): 107-112.
NTP. 1991. Final report on the developmental toxicity of boric acid (CAS No. 10043-35-3) in New 
Zealand white rabbits. Research Triangle Park, NC: U.S. Department of Health and Human Services, 
Public Health Service, National Toxicology Program. PB92129550.
Experimental design: Groups of 30 pregnant New Zealand white rabbits were given gavage doses of 0, 
62.5, 125, or 250 mg boric acid/kg/day (0, 11, 22, or 44 mg boron/kg/day) on gestation days 6-19. 
Observations were made for clinical signs, maternal and fetal body weight, number of implantations, 
resorptions, number of live and dead fetuses, and fetal external, visceral, and skeletal defects.
Effects noted in study and corresponding doses: No adverse maternal effects were observed in the 11 or 
22 mg boron/kg/day groups. At 44 mg boron/kg/day, decreases in maternal body weight, relative kidney 
weight, and food consumption were observed. During the treatment period, the rabbits lost 137 g body 
weight compared to a weight gain of 93 g in controls. No differences in the number of implantation sites 
per litter were observed; however, there were significant increases in the percent resorptions per litter 
(6.3, 5.9, 7.7, and 89.9% in the 0, 11, 22, and 44 mg boron/kg/day groups, respectively), percent of litters 
with one or more resorptions (39, 39, 45, and 95%), and percent of litters with 100% resorption (0, 0, 0, 
and 73%). The number of live litters was 18, 23, 20, and 6 in the 0, 11, 22, and 44 mg boron/kg/day 
groups, respectively, and the number of live fetuses was 159, 175, 153, and 14, respectively. A decrease 
in fetal body weights (92% of controls) was observed at 44 mg boron/kg/day; although the body weight 
was not significantly different from controls, the effect was considered biologically significant. 
Significant increases in the percent of fetuses per litter with external (0.8, 1.4, 1.0, and 11.1% in the 0, 11, 
22, and 44 mg boron/kg/day groups, respectively), visceral (7.3, 5.9, 7.4, and 80.6%), cardiovascular 
malformations (2.7, 3.1, 4.2, and 72.2%) and cardiovascular variations (10.6, 5.7, 7.2, and 63.9%) were 
observed. Although the overall incidence of external malformations was increased at 44 mg 
boron/kg/day, there were no increases in a specific malformation. The visceral malformations primarily 
consisted of cardiovascular malformations, particularly interventricular septal defect, enlarged aorta, 
papillary muscle malformation, and double outlet right ventricle. The cardiovascular variations consisted 
of abnormal number of cardiac papillary muscles.
The results of this study have also been reported in the following references:
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Dose and end point used for MRL derivation: NOAEL of 22 mg boron/kg/day as boric acid associated 
with a LOAEL of 44 mg boron/kg/day as boric acid for developmental effects
[X] NOAEL [ ] LOAEL
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X] 10 for extrapolation from animals to humans
[X] 10 for human variability
Was a conversion used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: 
Not applicable.
Other additional studies or pertinent information that lend support to this MRL: A series of studies 
conducted by Cherrington and Chernoff (2002) also examined the developmental toxicity of boron. A 
variety of skeletal malformations (including rib agenesis, cervical rib, and fused ribs) were observed in 
the fetuses of mice receiving two gavage doses of 70 mg boron/kg on gestation day 8 or gestation days 6­
8, once daily dose of 88 mg boron/kg/day on gestation days 6-10, or one dose of 131 mg boron/kg on 
gestation day 8. Multiple thoracic skeletal malformations were observed in the fetuses of mice receiving 
two doses of 131 mg boron/kg on gestation day 8. Decreases in fetal body weight were also observed in 
these studies and in studies of mice receiving two gavage doses of 70 mg boron/kg on gestation day 6, 7, 
9, or 10.
Developmental effects have also been observed in intermediate-duration studies. Decreases in fetal body 
weight were observed in rats exposed to 13 or 13.6 mg boron/kg/day on gestation days 0-20 (Heindel et 
al. 1992; Price et al. 1996a), increases in skeletal abnormalities were observed in rats exposed to 13 mg 
boron/kg/day on gestation days 0-20 (Price et al. 1996a), and rib cage defects and enlargement of the 
brain lateral ventricles were observed in rats exposed to 28.4 mg boron/kg/day on gestation days 0­
20 (Heindel et al. 1992). In mice exposed to boric acid on gestation days 0-17, reduced fetal body weight 
and increased skeletal defects were observed at 79 and 175.3 mg boron/kg/day, respectively.
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Route: [ ] Inhalation [X] Oral
Duration: [ ] Acute [X] Intermediate [ ] Chronic
Graph Key: 60, 61
Species: Rat
Minimal Risk Level: 0.2 [X] mg/kg/day [ ] ppm
Reference: Heindel JJ, Price CJ, Field EA, et al. 1992. Developmental toxicity of boric acid in mice and 
rats. Fundam Appl Toxicol 18:266-277.
Experimental design: Groups of 26-28 pregnant Sprague-Dawley rats and Swiss mice were exposed to 0, 
0.1, 0.2, or 0.4% boric acid in the diet on gestation days 0-20. Estimated boron doses are 0, 13.6, 28.5, or
57.7 mg boron/kg/day (0, 78, 163, or 330 mg boric acid/kg/day) for rats and 0, 43, 79, or 176 mg 
boron/kg/day (0, 248, 452, or 1,003 mg boric acid/kg/day) for mice. Daily observations were made for 
clinical signs and food and water consumption. At death, body and organ weights were recorded. 
Maternal kidneys were examined microscopically. Live fetuses were excised, anesthetized, weighed, and 
examined for skeletal malformations.
Effects noted in study and corresponding doses: Decreased maternal weight gain was observed in the
57.7 mg boron /kg/day group of rats, but not when corrected for gravid uterine weight. Decreased relative 
kidney and liver weights were seen in the 28.4 mg boron/kg/day group. The incidence and severity of the 
minimal maternal nephropathy was not dose-related. Mean fetal body weight per litter was significantly 
reduced (7-15%) in all treated groups. Significant increases in the percentage of malformed fetuses/litter 
or litter with one or more malformed fetuses was observed at doses >28.5 mg boron/kg/day. Noted 
malformations included anomalies of the eye, central nervous system, cardiovascular system, and axial 
skeleton. Enlarged lateral ventricles of the brain and agenesis or shortening of the 13th rib were seen in 
the 57.7 mg boron/kg/day group.
Reference: Price PJ, Strong PL, Marr MC, et al. 1996a. Developmental toxicity NOAEL and postnatal 
recovery in rats fed boric acid during gestation. Fundam Appl Toxicol 32:179-193.
Experimental design: Groups of 60 female Sprague-Dawley rats were exposed to 0, 0.025, 0.050, 0.075, 
0.100, or 0.200% boric acid in the diet on gestation days 0-20. Observations were made for body weight, 
clinical signs, and food and water consumption. The study was performed in two phases; offspring were 
evaluated in both phases for post-implantation mortality, body weight, and external, visceral, and skeletal 
morphology. Phase I was terminated on gestation day 20. The calculated average maternal dose of boron 
was 0, 3.3, 6.3, 10, 13, or 25 mg boron/kg/day (0, 19, 36, 55, 76, or 143 mg boric acid/kg/day). Phase II 
dams were allowed to litter and rear their pups until postnatal day (pnd) 21. For these dams, the 
calculated average doses of boron were 0, 0.2, 6.5, 9.7, 12.9, and 25.3 mg/kg/day (0, 19, 37, 56, 74, and 
145 mg boric acid/kg/day). During this phase, the incidence of skeletal defects in control and exposed 
pups was evaluated at the end of the first 21 postnatal days.
Effects noted in study and corresponding doses: During Phase I of the study, no maternal deaths or 
clinical signs were associated with boric acid treatment. When corrected for gravid uterine weight,
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maternal weight gain was not affected. However, reduced gravid uterine weight resulted in significant 
trend tests for decreased maternal body weight (gestation days19 and 20) and decreased maternal body 
weight gain (gestation days 15-18 and 0-20). Dams in the 25 mg boron/kg/day group had a 10% 
reduction (statistically significant in the trend test, p<0.05) in gravid uterine weight compared with 
controls. Fetal body weights were significantly decreased in the 13 and 25 mg boron/kg/day groups 
(6 and 12% less than controls) on gestation day 20. Incidences of external or visceral malformations or 
variations were not treatment-related. However, a significant increase was observed for percentage of 
fetuses with skeletal malformations (short rib XIII) per litter and variations (wavy rib or wavy rib 
cartilage) in the 13 and 25 mg boron/kg/day groups. A significant trend test (p<0.05) resulted for 
decrease in rudimentary extra rib on lumbar I (a variation). The LOAEL for Phase I of this study was 
identified as 13 mg boron/kg/day, based on decreased fetal body weight and skeletal malformations. The 
NOAEL for this phase was identified as 10 mg boron/kg/day.
In the Phase II study, a significant trend for increased number and percent of dead pups was seen between 
pnd 0 and 4, but not between pnd 4 and 21. This appeared to be due to the non-significant early postnatal 
mortality in the 25.3 mg boron/kg/day group. There were no effects of boric acid on the pup body weight 
from pnd 0 to 21; therefore, fetal body weight deficits (identified in Phase I) did not continue into the 
postnatal period (Phase II). The percentage of pups per litter with short rib XIII was increased on pnd 
21 in the 25.3 mg boron/kg/day group. A LOAEL of 25.3 mg boron/kg/day, with an associated NOAEL 
of 12.9 mg boron/kg/day, was identified for skeletal malformations in Phase II of this study.
Dose and end point used for MRL derivation: BMDL05 of 10.3 mg/kg/day for reduced fetal body weight
[ ] NOAEL [ ] LOAEL [X] BMDL05
Allen et al. (1996) performed multiple benchmark dose (BMD) analyses on single-study or combined data 
from Heindel et al. (1992) and Price et al. (1996a) for all statistically significant developmental end points 
(Table A-1). Fetal body weight changes were analyzed using the average fetal weight for each litter with 
live fetuses. The modeling of rib effects aimed to differentiate whether treatment-related differences in 
the lumbar rib were variations or malformations. Thus, a weighting scheme was applied to represent 
three possible interpretations of severity of this effect; that is, a missing rib is: (a) trivially different from 
“normal” (1/6 weighting), (b) intermediate between a trivial or frank malformation (1/2 weighting), or 
(c) considered a frank malformation (5/6 weighting). Rib count analysis involved adjusting up (if 
rudimentary or full lumbar ribs present) or down (shortened rib XIII or rib agenesis) the base count of 
13 rib pairs for each fetus analyzed. Benchmark responses (BMRs) were chosen for each end point. The 
BMD expected to result in the BMR, while the BMDL05 was defined as the 95% lower bound on the 





Table A-1. Benchmark Dose Modeling of Developmental Effects of Oral Boric
Acid Exposure to Rats
E n d  p o in t S tu d y  d a ta
G o o d n e s s -o f- f it
p -v a lu e a
B M D b 
(m g  b o ro n / 
k g /d a y )
L o w e r  b o u n d  
o n  B M D c 
(m g  b o ro n / 
k g /d a y )
Feta l body w e igh t as H einde l et al. 1994 0.24 14.0 9.8
con tinuous data P rice e t al. 1996a 0.89 11.9 8.2
(B M R =5%  reduction)
C om bined 0.58 13.7 10.3
Feta l body w e igh t as H einde l et al. 1994 0.24 12.8 8.4
con tinuous data 
(B M R =1/2  s tandard  dev ia tion
P rice e t al. 1996a 0.89 8.6 5.4
be low  contro l) C om bined 0.58 11.4 8.4
Feta l body w e igh t as H einde l et al. 1994 0.44 22.6 20.1
d icho tom ous inc idence data P rice e t al. 1996a 0.01 8.2 5.4
(B M R =5%  reduction)
C om bined NA NA NA
S horten ing  o r agenes is  o f rib H e inde l et al. 1994 0.07 24.9 18.6
XIII P rice e t al. 1996a 0.64 29.9 21.5
C om bined 0.42 24.5 21.0
M issing lum ba r ribs H einde l et al. 1994 0.99 1.2 0.3
P rice e t al. 1996a 0.78 1.5 0.6
C om bined 0.99 2.1 0.9
R ib e ffec ts  analysis: H e inde l et al. 1994 0.27 21.2 16.5
1/6 w e igh ting  fo r absence  o f 
lum bar rib
P rice e t al. 1996a 0.78 32.9 25.7
C om bined NA NA NA
R ib e ffec ts  analysis: H e inde l et al. 1994 0.02 13.5 10.2
1/2 w e igh ting  fo r absence  o f 
lum bar rib
P rice e t al. 1996a 0.64 45.3 30.3
C om bined NA NA NA
R ib e ffec ts  analysis: H e inde l et al. 1994 <0.001 24.9 20.5
5/6 w e igh ting  fo r absence  o f 
lu m b a r rib
P rice e t al. 1996a 0.53 53.7 31.2
C om bined NA NA NA
R ib e ffec ts  analysis: H e inde l et al. 1994 0.002 16.5 12.8
rib coun t fo r absence  o f 
lu m b a r rib
P rice e t al. 1996a 0.08 25.6 16.5
C om bined NA NA NA
ap-values for assessing adequacy of the models for predicting the observed data of Heindel et al. (1992) and Price et 
al. (1996a)
bBenchmark dose: model estimated dose expected to result in the BMR 
c95% lower bound on the BMD
BMR = benchmark response; NA = not applicable
Source: Heindel et al. 1992; Price et al. 1996a
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A likelihood ratio test indicated that the response data from both studies could be modeled as a single 
dose-response function. Of the developmental end points modeled, the lowest resulting BMDL05 was 
10.3 mg boron/kg/day for fetal body weight (litter weight averages), which was similar to the NOAEL of 
10 mg boron/kg/day from the Price et al. (1996a) study.
Uncertainty Factors used in MRL derivation: A total uncertainty factor of 66 was used.
[ ] 10 for use of a LOAEL
[X] 3.3 for extrapolation of toxicokinetics from animals to humans 
[X] 3.16 for extrapolation of toxicodynamics from animals to humans 
[X] 2.0 for human toxicokinetic variability 
[X] 3.16 for human toxicodynamic variability
In deriving a reference dose (RfD) for chronic oral exposures to boron, the U.S. EPA applied chemical- 
specific uncertainty factors to the BMDL05 of 10.3 mg boron/kg/day reported by Allen et al. (1996) (EPA 
2004). Rather than using the default uncertainty factors of 10 for interspecies extrapolation and 10 for 
interindividual human variability, each uncertainty factor was further delineated into toxicokinetic and 
toxicodynamic components specific to boron. Since the critical effect (reduced fetal body weight in 
animals) and point of departure (BMDL05 of 10.3 mg/kg/day) for intermediate oral exposure to boron are 
the same as those for chronic oral exposures, as identified by EPA (2004), the chemical-specific 
uncertainty factors derived by U.S. EPA to derive a chronic RfD are appropriate for use in deriving the 
intermediate-duration MRL.
Briefly, each uncertainty factor of 10 for extrapolation from animals to humans and human variability was 
initially separated into default toxicokinetic and toxicodynamic adjustment factors of 3.16 (100 5 ) each to 
account for species differences in toxicokinetic disposition and toxicodymanic responses to orally- 
ingested boron. The same division was made for the uncertainty factor of 10 for human variability. Thus, 
the composite uncertainty factor (UFTOTAL) for the intermediate-duration oral MRL is defined as given by 
EPA (2004) as:
UFTOTAL = (AFAK x AFA D x AFHK x AFHD x UF)
where:
AFak = interspecies toxicokinetic adjustment factor
AFad = interspecies toxicodynamic adjustment factor
AFHK = interindividual toxicokinetic adjustment factor
AFHD = interindividual toxicodynamic adjustment factor
UF = other uncertainty factors (e.g., use of a LOAEL instead of a NOAEL)
Since no data were available to adequately describe the mode(s) or mechanism(s) of action for boron 
toxicity in animals or humans, the default toxicodynamic adjustment factor of 3.16 was used to account 
for inter- and intraspecies uncertainties in toxicodynamics.
The pregnant female is considered to be a sensitive population for boron exposure, as fetal effects in rats 
are the most sensitive end point identified for boron toxicity. Since boron exhibits near first-order 
toxicokinetics, distributing freely between total body water and tissues (except for bone, in which it 
accumulates to approximately 4-fold that of plasma [Chapin et al. 1997]), variability between maternal 
and fetal kinetics should be essentially equal. Thus, maternal boron plasma concentration is an 
appropriate surrogate for fetal plasma levels. No data are available to relate rat and human plasma boron 
concentration. However, boron is not metabolized, but almost completely eliminated in the urine, making 
renal clearance an appropriate kinetic factor for comparison of toxicokinetic differences between rats and 
humans. Given the known distribution of boron to total body water and bone, two-compartment
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pharmacokinetic models for boron in rats and humans can describe plasma concentration in terms of renal 
clearance. Boron’s toxicity is likely to be related to a continuous exposure over an extended portion of 
fetal development in which a steady state of circulating boron is achieved. Under the assumption of 
steady-state plasma boron levels, and assuming approximately complete clearance of born to urine, the 
two-compartment model can be simplified to the following expression:
Cs s  = (De x fa x BW) / Cl
where:
De = external dose of ingested boron (mg boron/kg body weight/day) 
fa = fraction of ingested boron absorbed from the gut 
BW = body weight (kg)
Cl = renal clearance (mL/minute)
Assuming that the ratio of 1 for internal, steady-state doses in rats and humans results in equivalent 
responses, the expressions for the plasma boron concentration in rats and humans can be expressed as the 
following ratio, which serves as the AFa k :
AFAK = (C1r  x fA H x BWh ) / (CIh  x fA R x BWr )
where the subscripts R and H represent rats and humans. Values for mean renal clearance of 1.0 and 
66.1 mL/minute in pregnant rats and humans, respectively, were derived from the studies of Vaziri et al. 
(2001), and Pahl et al. (2001), which also provided pregnant rat and human body weights of 0.303 and 
67.6 kg, respectively. Using gastrointestinal absorption fractions of 0.92 (Schou et al. 1984) and
0.95 (Vanderpool et al. 1994) for fA H and fA R, respectively, AFAK is derived as follows:
AFa k  = (1.00 x 0.92 x 67.6) / (66.1 x 0.95 x 0.303)
= 62.2 / 19.0
= 3.3
The assessment of human variability in boron toxicokinetics utilized glomerular filtration rate (GFR) as a 
surrogate for renal clearance. Pregnant women were considered the sensitive population, particularly 
those women with compromised renal function (3-5% preeclamptic women in the U.S. population).
Using a modification of Dourson et al. (1998), data from women with normal renal function were used to 
define an AFH K  as:
AFHK = GFRA VG / (GFRAVG -  (3 x SDGFR))
where GFRa v g  and SDGFR are mean and standard deviation of the GFR for healthy women. Three 
standard deviations below the mean GFR was chosen to account for the women with very low GFR.
From the studies of Dunlop (1981), Krutzen et al. (1992), and Sturgiss et al. (1996), a mean GFR of 
161.5 mL/minute and a mean GFR-3SDg f r  of 85.8 mL/minute resulted in an AFHK of 1.93. This number 
was rounded to 2.0 to account for uncertainties in human GFR.
Based on these analyses, the total uncertainty factor applied to the BMDL05 of 10.3 mg boron/kg is 
derived as:
UFTOTAL = (AFAK x AFAD x AFH K  x AFHD x UF)
= (3.3 x 3.16 x 2.0 x 3.16 x 1)
= 66
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If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: 
Not applicable.
Other additional studies or pertinent information that lend support to this MRL: Reproductive effects, 
including testicular atrophy and histopathology, sperm abnormalities, and reduced sperm production have 
been observed in mice, rats, and dogs after intermediate-duration ingestion of doses of 26 mg 
boron/kg/day (as boric acid or borax) and higher (Dixon et al. 1979; Fukuda et al. 2000; Harris et al.
1992; Ku et al. 1993a; Kudo et al. 2000; Seal and Weeth 1980; Treinen and Chapin 1991; Weir and 
Fisher 1972; Yoshizaki et al. 1999). Systemic effects have been observed in rats and dogs at higher 
doses. Hematological alterations (splenic extramedullary hematopoiesis and decreased hemoglobin 
levels) have been observed at 60.5 or 72 mg boron/kg/day (NTP 1987; Weir and Fisher 1972), 
desquamation of skin on paws and tail and inflamed eyes have been observed in rats exposed to 150 mg 
boron/kg/day (Weir and Fisher 1972), and hyperkeratosis and/or acanthosis of the stomach has been 
observed at 577 mg boron/kg/day (NTP 1987).
Agency Contacts (Chemical Managers): Malcolm Williams
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APPENDIX B. USER'S GUIDE
Chapter 1 
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release. If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight- 
of-evidence discussions for human health end points by addressing the following questions:
1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human 
data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). 
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer 
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
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MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. 
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure.
MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance. Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology. MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration. ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects. If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans). In 
deriving an MRL, these individual uncertainty factors are multiplied together. The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in 
conjunction with the text. All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures. Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends 




See Sample LSE Table 3-1 (page B-6)
(1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document. 
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures.
(2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15­
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. 
In this example, an inhalation study of intermediate exposure duration is reported. For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3) Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. 
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18).
(4) Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure. In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1).
(5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. 
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL.
(6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimens are provided in this column. This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981).
(7) System. This column further defines the systemic effects. These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems. In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 





(9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose. A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from 
Serious LOAELs.
(10) Reference. The complete reference citation is given in Chapter 9 of the profile.
(11) CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies. CELs are always considered serious effects. The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases.
(12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND 
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) Exposure Period. The same exposure periods appear as in the LSE table. In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log 
scale "y" axis. Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 
corresponds to the entry in the LSE table. The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17) CEL. Key number 38m is one of three studies for which CELs were derived. The diamond 




(18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper- 
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*).
(19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
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12 ^  a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX
BMDS Benchmark Dose Software
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
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DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code 
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram 
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F j first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization




Koc organic carbon partition coefficient
Kow  octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill




LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans--muconic acid





MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor




mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data Sys
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
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OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell





RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell




> greater than or equal to
= equal to
< less than








q i* cancer slope factor
- negative
+ positive
(+) weakly positive result
(-) weakly negative result
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adipose tissue.............................................................................................................................................. 95, 148
adrenals..................................................................................................................................................75, 90, 110
adsorbed............................................................................................................................................................. 140
adsorption................................................................................................................................  134, 140, 141, 152
ambient a ir ......................................................................................................................................................... 142
bioaccumulation.................................................................................................................................................153
bioconcentration factor.....................................................................................................................................141
biomarker......................................................................................................................... 100, 101, 115, 117, 156
blood cell count................................................................................................................................................... 36
body weight effects...................................................................................................................................... 21, 76
breast milk........................................................................................................................................ 147, 151, 154




cardiovascular................................................................................. 12, 17, 18, 19, 24, 35, 40, 84, 86, 100, 163
Cardiovascular Effects................................................................................................................................. 35, 40
chromosomal aberrations....................................................................................................................................87
clearance................................................................................................................................................91, 92, 115
death...................................................................................................... 5, 11, 17, 22, 23, 38, 39, 40, 78, 86, 170
deoxyribonucleic acid (see DNA)......................................................................................................................96
dermal effects............................................................................................................................20, 24, 75, 86, 103
developmental effects.................  12, 18, 20, 37, 82, 84, 85, 87, 96, 100, 107, 108, 110, 111, 113, 115, 116
DNA (see deoxyribonucleic acid)............................................................................................................. 96, 101
elimination ra te ................................................................................................................................................... 92
endocrine................................................................................................................................................. 75, 97, 98
endocrine effects................................................................................................................................................. 75
erythema...................................................................................................................................  17, 39, 75, 86, 115
fetus........................................................................................................................................ 12, 20, 98, 100, 114
follicle stimulating hormone (see FSH)............................................................................................................ 75
FSH (see follicle stimulating hormone)........................................................................................ 75, 80, 96, 98
gastrointestinal effects............................................................................................................  11, 17, 35, 40, 102
general population........................................................................................................................9, 148, 151, 170
genotoxic................................................................................................................................................. 22, 85, 87
genotoxicity.......................................................................................................................................................... 13
groundwater..................................................................................................3, 85, 130, 134, 139, 143, 159, 161
half-life.................................................................................................................... 11, 35, 91, 92, 100, 105, 140
hematological effects............................................................................................................................. 36, 73, 86





Kow...................................................................................................................................................  122, 123, 124
LD50................................................................................................................................................................ 39, 40
lymphoreticular................................................................................................................................................... 37
m ilk......................................................................................................................................................74, 144, 154
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neurological effects.................................................................................................37, 76, 77, 87, 102, 108, 114
neurophysiological............................................................................................................................................ 114
nuclear.................................................................................................................................................................... 9
ocular effects............................................................................................................... 24, 36, 40, 76, 86, 87, 107
pharmacodynamic.................................................................................................................................16, 92, 163
pharmacokinetic............................................................................................................................... 92, 93, 94, 99
renal effects................................................................................................................................ 24, 36, 74, 86, 96
reproductive effects...........................................................  12, 37, 77, 79, 80, 81, 82, 84, 87, 96, 97, 113, 117
respiratory effects.................................................................................................................................. 23, 24, 40
retention.......................................................................................................................................... 11, 16, 80, 109
systemic effects..........................................................................................................  12, 14, 21, 24, 40, 86, 101
thyroid..........................................................................................................................................................75, 109
toxicokinetic.................................................................................................................. 21, 22, 97, 115, 116, 163
tremors................................................................................................................................................................. 76
tum ors................................................................................................................................................................ 130
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